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Abstract
Autism Spectrum Disorder (ASD) is an invasive neurodevelopmental disorder characterized by impaired
social/communication functioning and restricted and repetitive behaviors. Prevalence estimates report that 1
in 45 children have been diagnosed with ASD. Investigations into the etiology of ASD have observed many,
often apparently disparate, neurobiological alterations. In response “biomarkers” (biologically based markers
that correlate to ASD-related behavioral phenotypes) have been proposed to aid with research, diagnoses,
stratification and future interventions. Indeed, as a result of their association with behavioral phenotypes,
biomarkers are somewhat capable of predicting diagnostic status. In addition, such biomarkers allow for the
direct study of analogous constructs across species. Auditory M100 latency delays and electrophysiological
gamma-band activity (GAMMA) alterations are exemplar biomarkers for ASD.
While studies have begun to uncover the biological bases of these biomarkers, several unresolved questions
prevent their full implementation. While both biomarkers have been repeatedly observed, the developmental
trajectories are unresolved. Furthermore, while recent studies have observed correlations in healthy adults
between cortical GAMMA and relative GABA levels in several systems, the analogous relationship within the
auditory system has not been demonstrated. Additionally, if such a correlation does indeed occur, its relation
in ASD remains unresolved.
This work characterizes M100 delays and GAMMA as ASD-related biomarkers through five projects. First, a
longitudinal MEG study examined the persistence of electrophysiological biomarker in ASD. Secondly a
multimodal study resolved the relationship of GAMMA and GABA concentrations in the auditory system in
both typically developing individuals (TD) and ASD. Furthermore, exploiting the translational potential of
GAMMA (Murine EEG) the analogous relationship was investigated preclinically. Additionally, a mouse
model that demonstrates increased sociability was investigated for electrophysiological alterations as a crucial
positive control for the use of GAMMA as a biomarker for decreased sociability in ASD. Lastly, this
hypersocial mouse model’s in-vitro electrophysiological functioning was characterized utilizing voltage
sensitive dye imaging.
This dissertation demonstrates that electrophysiological activity alterations are persistent biomarkers in ASD,
and moreover correlate to neurochemistry in TD. Such coupling is less clearly resolved in ASD. Moreover,
such a differential coupling phenomenon is recapitulated preclinically. Lastly, hypersocial mice exhibit
commensurate alterations to GAMMA.
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ABSTRACT 
 
Auditory Biomarkers in ASD; Multimodal Translational Investigations of the Underlying 
Neurobiological Mechanisms  
Russell G. Port 
Timothy P.L. Roberts, Ph.D. 
  
 Autism Spectrum Disorder (ASD) is an invasive neurodevelopmental disorder 
characterized by impaired social/communication functioning and restricted and repetitive 
behaviors. Prevalence estimates report that 1 in 45 children have been diagnosed with 
ASD. Investigations into the etiology of ASD have observed many, often apparently 
disparate, neurobiological alterations. In response “biomarkers” (biologically based 
markers that correlate to ASD-related behavioral phenotypes) have been proposed to aid 
with research, diagnoses, stratification and future interventions. Indeed, as a result of 
their association with behavioral phenotypes, biomarkers are somewhat capable of 
predicting diagnostic status. In addition, such biomarkers allow for the direct study of 
analogous constructs across species. Auditory M100 latency delays and 
electrophysiological gamma-band activity (GAMMA) alterations are exemplar 
biomarkers for ASD.  
 While studies have begun to uncover the biological bases of these biomarkers,  
several unresolved questions prevent their full implementation. While both biomarkers 
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have been repeatedly observed, the developmental trajectories are unresolved. 
Furthermore, while recent studies have observed correlations in healthy adults between 
cortical GAMMA and relative GABA levels in several systems, the analogous 
relationship within the auditory system has not been demonstrated. Additionally, if such a 
correlation does indeed occur, its relation in ASD remains unresolved. 
 This work characterizes M100 delays and GAMMA as ASD-related biomarkers  
through five projects. First, a longitudinal MEG study examined the persistence of 
electrophysiological biomarker in ASD.  Secondly a multimodal study resolved the 
relationship of GAMMA and GABA concentrations in the auditory system in both 
typically developing individuals (TD) and ASD. Furthermore, exploiting the translational 
potential of GAMMA (Murine EEG) the analogous relationship was investigated 
preclinically. Additionally, a mouse model that demonstrates increased sociability was 
investigated for electrophysiological alterations as a crucial positive control for the use of 
GAMMA as a biomarker for decreased sociability in ASD. Lastly, this hypersocial 
mouse model’s in-vitro electrophysiological functioning was characterized utilizing 
voltage sensitive dye imaging.  
 This dissertation demonstrates that electrophysiological activity alterations are 
persistent biomarkers in ASD, and moreover correlate to neurochemistry in TD. Such 
coupling is less clearly resolved in ASD. Moreover, such a differential coupling 
phenomenon is recapitulated preclinically. Lastly, hypersocial mice exhibit 
commensurate alterations to GAMMA. 
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CHAPTER 1 
Introduction 
 
 Autism spectrum disorder (ASD) is an array of neurodevelopmental syndromes 
characterized by restricted/stereotyped behaviors and social communication impairments 
(American Psychiatric Association 2013). Recent estimates suggest a prevalence of 1 in 
68 children, potentially reaching as high as 1 in 42 males (Developmental Disabilities 
Monitoring Network Surveillance Year 2010 Principal Investigators & Centers for 
Disease Control and Prevention (CDC) 2014). This estimate though is based on the 
previous version of Diagnostic and Statistical Manual of Mental Disorders (DSM IV-
TR); the effect of the reclassification of ASD by the DSM 5 on the prevalence rate has 
not been resolved. ASD not only affects the individuals themselves as well as direct 
caregivers and family members of individuals with ASD, but also society in general: 
estimates suggest that the United States of American spends at least $61 billion per year 
on caring for children with ASD (not including the cost of adult individuals with ASD) 
(Buescher et al. 2014). 
 The pathogenic underpinning of ASD, except in rare monogenic syndromic 
forms, is largely unknown and perhaps consequently, a fully effective treatment for ASD 
has yet to be uncovered. While there are several weak or rare genetic or environmental 
insults associated with ASD, these are often non-specific for ASD, and have yet to lead to 
a common neurobiological pathogenic mechanism. Based on concurrent studies 
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suggesting ASD was a polygenetic interaction of three genes, just under two decades ago 
Piven and colleagues hypothesized that a linkage analysis of 60 sibling pairs affected by 
ASD would reveal the genetic basis this disorder (Piven, Palmer, Landa, et al. 1997). 
Recently, a complex interplay of genetics (with over 200 susceptibility genes), 
pre/peri/post –natal environmental insults, and epigenetic interactions have been 
suggested for pathogenic mechanisms of ASD (Tordjman et al. 2014), demonstrating 
how the suspected range of etiologies of ASD has ballooned since 1997. Furthermore, 
several leading hypotheses for the neurobiological bases for ASD have been presented, 
ranging from imbalances of excitation and inhibition (E/I imbalance) within key neural 
systems (Rubenstein & Merzenich 2003), to divergent connectivity profiles for short and 
long range brain connectivity (Belmonte et al. 2004). Indeed, the range of 
neurobiological alterations in individuals with ASD includes oxidative stress, molecular 
pathways of cortical organization, neurotransmitter/neuromodulator system, cortical 
architecture and even whole brain connectivity (Santangelo & Tsatsanis 2005). As such, 
the variety of possible targets for intervention appears dauntingly broad dampening 
optimism for research to make immediate therapeutic advances. This may be largely due 
to ASD being defined completely by characteristic behaviors, for which the underlying 
neural bases are still unknown.  
 The use of several “biomarkers”, biologically based markers, for ASD has been 
suggested to improve the likelihood of success in uncovering such etiologies of, and 
common pathways in, ASD (Port et al. 2015). A biomarker is signal of normal, 
pathogenic or interventional biological processes, which can be both objectively 
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measured and evaluated (Biomarkers Definitions Working Group, 2001). For ASD such a 
biomarker would be a biologically based measure that correlates to an ASD-related 
behavioral phenotype, and as a result is capable of making diagnostic predictions at the 
subject level. Ideally such a biomarker would be both diagnostic and prognostic, scale 
with the disease/disorder severity, be able to stratify a heterogeneous study population 
based on underlying biology (e.g. for clinical trial enrichment), and signal early signs of 
the efficacy of an intervention ( Biomarkers Definitions Working Group, 2001). In 
addition, biomarkers should be minimally invasive, easy to implement, robust and 
ideally, biomarkers should have a direct, or at least plausible, biological underpinning 
(e.g. M100 latency and thalamocortical white matter integrity) suggesting both 
mechanistic relevance and, in principle, offering a therapeutic target. Cost minimization, 
although desirable, is embroiled in a discussion of “value” viz-a-viz the $61B national 
annual care costs, and lies beyond the scope of this thesis. Biomarkers do not just hold 
promise for clinical studies; translational preclinical studies benefit from biomarkers by 
allowing the measurement of analogous constructs across species/modalities. Indeed the 
recapitulation of a clinically observed biomarker in an animal model might well be 
construed as providing evidentiary support for the relevance of (and thus validity of) that 
particular construct. This is especially important for disorders such as ASD, where 
diagnoses are completely behaviorally defined. While there has been success modeling 
some of the social and behavioral perturbations of ASD (Silverman et al. 2010), no model 
fully captures the complex behavioral aspects of ASD. Furthermore how to validate (and 
the degree to which such validation should be expected) such models remain unknown 
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(Crawley 2007). This is not to imply that biomarkers are universally considered a core 
goal or “gold standard” of ASD-related research. Recently concerns have been raised 
about the relative effectiveness (and value) of these biomarkers versus standard 
behavioral testing, and furthermore the generalizability of said biomarkers to the 
population at large (e.g. studies take place in adult subjects with an equal split between 
individuals with ASD and typically developing controls) (Yerys & Pennington 2011). 
Yerys and Pennington do admit though that biomarkers will be especially useful when A) 
its biological basis is elucidated and subsequently B) when biomarkers can stratify those 
with ASD into biologically based sub-groups. As such, while biomarkers are currently 
still under developmental/validation, in future years (when the concerns raised by Yerys 
& Pennington are resolved) biomarkers may provide substantial and critical utility for the 
study and treatment of ASD. 
 Currently there exist many candidate biomarkers for ASD, ranging from blood-
based arrays (Anderson et al. 1990),  developmental patterns of eye tracking (Rice et al. 
2012), medical imaging including MRI and PET (Lange et al. 2010; C. Ecker et al. 2010; 
Christine Ecker et al. 2010; Chugani et al. 1999), and electrophysiological methodologies 
such EEG and MEG (Wilson et al. 2007; Gandal et al. 2010; Roberts et al. 2010; 
Maxwell, Villalobos, et al. 2013; Rojas & Wilson 2014), 
 Of these techniques magnetoencephalography (MEG) offers a unique position. 
MEG’s spatial resolution is in the range of millimeters for cortical activity, similar to that 
of functional magnetic resonance imaging (fMRI) (Leahy et al. 1998). Contrary to 
fMRI’s measurement of the hemodynamic response through (presumed) neurovascular 
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coupling (i.e. on the time scale of seconds), MEG allows greater resolution in the 
temporal dimension (milliseconds) as well as direct access to the neuronal electrical 
activity of interest rather than an indirect proxy. Furthermore, secondary to its high 
temporal sampling rate, MEG can accommodate spectral decomposition, such that 
activity within different frequency bands (e.g. alpha 8-12Hz, or gamma 30-100Hz) can be 
interrogated (either separately or in combination). As such, MEG allows for the 
investigation and characterization of the distribution, timing, synchrony, content and 
connectivity of actual neural activity directly.  
 Such temporal precision in not unique to MEG though, its electrical counterpart 
electroencephalography (EEG) also demonstrates such sensitivity to the temporal 
dimension. In addition, EEG is considerably less expensive to utilize, both in terms of the 
equipment, and secondary expenses (e.g. magnetically shielded rooms, helium). EEG 
though, does not have the precise spatial localization of MEG (though there is debate, see 
Barkley & Baumgartner 2003), due in part to the differences in electrical conductivity 
(whereas not magnetic permeability) of different tissue compartments (grey matter/white 
matter/CSF/calvarium/scalp), which leads to spatial smearing in EEG, but not MEG 
(Hämäläinen et al. 1993). In addition, the rate of decay with distance of electric potentials 
versus magnetic fields, often allows less confounding interference from other neural 
generators using MEG. This can be overcome in EEG, through the use of high density 
electrode configurations, exact subject specific models of tissue compartments, Laplacian 
transforms (similar to taking the second derivate of the electrical current), and advanced 
source modeling (Gevins et al. 1995); though the manipulation of data with such analyses 
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provides many opportunities for errors to occur, and are sometimes nonetheless limited 
by the spatial orientation of the underlying generators (this may also be true for MEG 
which exhibits a different, arguably complementary, orientation preference to EEG). 
MEG by comparison can tolerate simplistic spherical (single compartment) head models, 
and basic localization techniques (e.g. equivalent current dipoles) and still have excellent 
accuracy (~3mm) (Yamamoto et al. 1988).  Lastly as alluded to above, and of specific 
relevance for studies of primary auditory cortex – the focus of this thesis, MEG has 
sensitivity to sources primarily tangential orientated to the cortex (as compared to radial 
sources), which is consistent with the orientation of primary and secondary neurons in 
auditory cortex, and so allows for the direct and independent study of left and right 
hemisphere auditory cortices.  
 MEG is also less cumbersome than EEG, with no need to touch the participant’s 
head repeatedly or apply gel when placing the recording electrodes. This is especially 
relevant in studies of ASD, due to the high sensitivity of individuals with ASD to direct 
touching (Dawson et al. 2000). For MEG machines, the magnetometers are housed in a 
dewar, with participants seated under or supine with their head’s contained ensuring 
adequate head coverage. See Figure 1.1.  
 Moreover, the non-invasive nature of MEG, combined with short passive 
paradigms and the recording of early obligate responses, defends against attention, 
performance and movement confounds, issues especially relevant in this traditionally 
non-compliant study population (individuals with ASD). 
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 Several MEG-derived biomarkers have been suggested for ASD and the specific 
functional domains associated with impairment in ASD, (auditory M50/M100 latency 
prolongation, mismatch field/negativity latency delay, gamma-band activity [30-100Hz] 
deficits), measures which are robustly derived, sensitive to ASD, and tend to scale with at 
least aspects of symptomatology (Port et al. 2015). Where these biomarkers may differ is 
their specificity to ASD, responsiveness to treatment, predictiveness and their link to a 
biological basis.  
 Auditory magnetic middle latency responses (M50/M100) are characteristic 
neuroelectrophysiological event related field (ERF) components that can be detected by 
MEG sensors over auditory cortex ~ 50 and 100 milliseconds (respectively) after the 
presentation of a sound. These are the magnetic “cousins” to the familiar P50 and N100 
commonly encountered in auditory event related potentials (ERP) studies. Such middle 
latency responses are not stationary across individuals and paradigms, and are modulated 
by stimulus properties such as intensity (Stufflebeam et al. 1998), frequency (Roberts & 
Poeppel 1996) and other physical and perceptual features (Roberts et al. 2000). Right 
hemisphere middle latency response (M50/100) delay has been repeatedly shown in ASD 
(Port et al. 2015). In ASD, both the right hemisphere M100 latency response to simple 
sinusoidal tones is delayed (Gage, Siegel & Roberts 2003), and also the developmental 
trajectory of such responses are also perturbed (Gage, Siegel, Callen, et al. 2003). Of 
potential note, while the developmental trajectory of M100 latency maturation may be 
perturbed in ASD, studies with larger populations suggest a similar slope, though 
differential intercept to the linear regression of middle latency responses and age for 
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ASD as compared to typically developing controls (Roberts et al. 2013). As such, a 
persistent delay or prolongation of latency exists in ASD, which despite similar rate of 
maturation, results in an atypical developmental trajectory versus typically developing 
controls (Port et al. 2015). In addition to delayed M100 latencies and altered 
developmental trajectories of these latencies, further abnormalities exist. As stated above, 
M100 latencies are sensitive to stimulus properties including frequency (high frequency 
tones have shorter latencies). The frequency encoding of different tones as signaled by 
the M100 may also be perturbed in ASD with a reduced dynamic range of the latencies 
(Gage, Siegel, Callen, et al. 2003).  
 Auditory M100 alterations were not without controversy though, concurrent 
studies demonstrated no M100 delays (Tecchio et al. 2003). As suggested in (Port et al. 
2015), the discordant results may be due to the choice of stimuli, as well as the 
methodology for selecting the M100 latency. In short, Tecchio and colleagues defined the 
M100 as the “first power maximum following the 50-msec latency”, which due to the age 
(Oram Cardy et al. 2004) and/or ASD diagnostic status (Roberts et al. 2013) of a subject 
may actually be a prolonged M50 response. Fortunately topographic representations of 
surface magnetic fields can aid in the separation of the two responses (Oram Cardy et al. 
2004). Another potential confound to studies of M100 latency delays in ASD is that 
M100 latencies are observed more often in typically developing children than children 
with ASD at a young age (6–10 years old) (Edgar et al. 2014). 
 Findings of M100 latency prolongation in ASD have since been observed in 
larger studies (Roberts et al. 2010; Edgar et al. 2014). In addition, these larger studies 
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have allowed for the determination that while M100 latencies are not related to general 
cognitive ability, though have not resolved its association with language ability (Oram 
Cardy et al. 2008; Edgar et al. 2014; Roberts et al. 2010). While M100 latencies may or 
may not relate to language ability, it appears M100 latency delays are specific to ASD as 
opposed to general language impairments (Roberts et al. 2012). Further studies of the 
specificity of M100 latency delays with respect to other diagnoses are underway. 
Furthermore, partial support for the use of ERP/Fs as specific biomarkers for ASD also 
comes from a recent clinical study where behavioral interventions led to behavioral 
improvements and a concurrent normalization of the latency of visual ERPs (Dawson et 
al. 2012). This effect of behavioral interventions on ERP timings has also been 
demonstrate for auditory middle latency responses (Russo et al. 2010), though care 
should be taken due to the small sample of these studies. 
 In addition, larger studies have also allowed for the detection of bilateral M50 
deficits in ASD (Edgar et al. 2014; Roberts et al. 2013). It may be that larger cohorts are 
required to detect such an effect in this earlier component, because both M100 (Roberts 
et al. 2010) and M50 latency (Roberts et al. 2013) delays in ASD are approximately 10% 
of typically developing control latencies (i.e. ~10ms vs. ~5ms, respectively), and thus 
given similar measurement precision, M50 delays require more statistical power to be 
resolved (Port et al. 2015).  
 Middle latency response delays may have plausible biological bases that form 
working mechanistic hypotheses, and that may in fact be sole or combined explanatory 
factors (leading to a form of biologically-based stratification). Either poor signal 
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transduction (i.e. synaptic dysfunction) (Harada et al. 2011; Rojas et al. 2014; Gaetz et al. 
2014; Banerjee et al. 2013; C T Engineer et al. 2014) or perturbed signal conduction 
(Stufflebeam et al. 2008; Roberts et al. 2009; Dockstader et al. 2012; Roberts et al. 2013) 
or their combination could cause altered ERPs and  ERFs. As a specific example of the 
value of multimodal imaging approaches, the use of diffusion tensor imaging (DTI) has 
allowed insights to these hypotheses. DTI is a variant of magnetic resonance imaging 
(MRI) scan that shows sensitivity to the organization and directional preference of tissue 
water diffusion (Basser et al. 1994; Mori & Barker 1999), and by common inference to 
qualities of the microstructure of white matter in the brain. Typically developing children 
demonstrate a linear relationship between fractional anisotropy (FA; a quantitative metric 
of properties of the white matter microstructure) and both age and M100 latency (Roberts 
et al. 2009). As age or FA increases, M100 latency shortens. An analogous relationship 
exists between M50, age and FA in typically developing children, whereas the FA to 
M50 latency coupling appears absent in ASD (Roberts et al. 2013). Additionally in 
support of white matter alterations causing M100 latency delays, recent studies have 
shown both M100 latency alterations (Jenkins et al. 2014) and white matter perturbations 
(Owen et al. 2014) in individuals with 16p11.2 deletions, a genetic anomaly that may 
exists with or without typical ASD phenotypic signs.  
 The use of M100 latency prolongation as a biomarker of ASD also holds promise 
in preclinical rodent models that recapitulate key aspects of ASD. Mice exposed 
prenatally to valproic acid (VPA) exhibited a delayed N40 (the 40ms EEG-derived rodent 
analog of the MEG-derived human M100) (Gandal et al. 2010). Similar murine N40 
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delays in other animal models that are relevant to ASD have since been shown to scale 
with sociability (Saunders et al. 2013; Billingslea et al. 2014). Since the initial murine 
description of delay middle response latency, cortical (i.e. middle latency) evoked 
response delays have been demonstrated for rat-based models that recapitulate key 
aspects of ASD including prenatal VPA insults (Engineer et al. 2014) and a genetic 
model of Rett syndrome (Engineer et al. 2015). Of potential note, the rat-based VPA 
model exhibits shortening of the delay cortical evoked responses with behavioral training 
(Engineer et al. 2014), similar to the aforementioned clinical trials. One of the advantages 
of the utilization of such preclinical models, in general, is that more precise anatomic 
delineation is available; indeed in Engineer et al., delayed N1 generator contributors were 
specifically localized to auditory association cortex (AAC) areas and not primary 
auditory cortex (AI), a resolution currently unachievable in humans. 
 Recent work has suggested another biomarker for the study of ASD, neural 
gamma-band oscillatory activity (Grice et al. 2001). Gamma-band activity (sometimes, 
“GBA”) is thought to play critical roles in sensory integration (Başar-Eroglu et al. 1996) 
and many higher level cognitive processes (for review see Herrmann et al. 2010; Tallon-
Baudry & Bertrand 1999). Indeed, at the local cortical circuit level, gamma-band activity 
has been linked to both increasing signal to noise (Sohal et al. 2009), and gating the 
amplitude (Cardin et al. 2009) of the evoked responses. While gamma-band alterations 
with regards to ASD were originally identified in response to a face inversion task (Grice 
et al. 2001), alterations have since been identified in other visual tasks (Sun et al. 2012), 
for other sensory systems (Wilson et al. 2007), and at rest (Orekhova et al. 2007; Cornew 
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et al. 2012). In general, as with all oscillations, deficits may be manifest in three 
categories: alterations in frequency (Gaetz et al. 2012), phase (Rojas et al. 2008) or 
amplitude (Wilson et al. 2007). While not specific to ASD (Maharajh et al. 2007; Brenner 
et al. 2009), gamma-band deficits may relate to core domains of functioning (e.g. as 
proposed by the Research Domain Criteria [RDoCs] recently presented by the NIMH), 
for which the exact domain affected is dependent on the time of critical dysfunction or 
anatomic region involved (Port et al. 2014). Supporting the notion of particular gamma-
band metrics being distinct in ASD though, a recent study found that gamma-band 
perturbed resting-state hemispheric laterality is related to severity of social impairment 
(Maxwell, Villalobos, et al. 2013). In addition, recovery of normal gamma-band 
hemispheric asymmetry is related to the behavioral improvements (reduced SRS scores) 
produced by a behavioral intervention (Van Hecke et al. 2013), suggesting a role for 
quantitative gamma-band activity as an objective marker of response to targeted therapy.  
 Within the auditory system, phase-locked gamma-band oscillatory responses to 
both simple tones (Gandal et al. 2010; Edgar et al. 2015) and gamma-band auditory 
steady state response (ASSRs) (Wilson et al. 2007; Rojas et al. 2008) have been 
repeatedly shown to be decreased. For transient gamma-band responses, the decreased 
phase-locked activity was concurrent to increased non-phase-locked (induced power) 
activity (Rojas et al. 2008), though this has not been consistently replicated (Gandal et al. 
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2010). Similar to increases observed in resting state gamma-band activity1 (Orekhova et 
al. 2007; Cornew et al. 2012), a recent study demonstrated increased pre-stimulus power 
for an simple tone based auditory task in children with ASD (Edgar et al. 2015), though 
the exact interpretation of such findings are unclear due the nature of pre-stimulus 
activity (rest versus refractory period versus resonant activity versus distracted activity) 
being unmeasured. Such increases in pre-stimulus gamma-band activity are associated 
with language abilities (Edgar et al. 2015) according to the CELF-4 core language index, 
with increased pre-stimulus power (perhaps interpreted as background “noise” in the 
brain) being associated with lower core language index scores (weaker performance). 
Some have referred to this concept as the “noisy brain” hypothesis (Pérez Velázquez & 
Galán 2013). 
 Interestingly auditory gamma-band activity may be an endophenotype for ASD2. 
First degree relatives of individuals with ASD have been consistently shown to have 
altered auditory gamma-band activity (Rojas et al. 2008; Rojas et al. 2011; McFadden et 
al. 2012). Separately such relatives have been shown to exhibit higher rates of the broad 
autism phenotype (BAP), a subclinical expression of ASD behaviors (Piven, Palmer, 																																								 																					1 Though such findings of increased resting-state gamma-band activity are disputed 
(Sheikhani et al. 2012; Maxwell, Villalobos, et al. 2013), and may be related to 
behavioral, equipment or analysis differences between the studies(Rojas & Wilson 2014). 
2 An interesting definition property of an endophenotype as opposed to a biomarker in 
general is that an endophenotype must also exhibit the property of heritability, often 
untested in biomarker research.	
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Jacobi, et al. 1997). Additionally there is an association between the severity of the BAP 
in relatives of individuals with ASD and the ASD symptom severity exhibited by the 
proband (Maxwell, Parish-Morris, et al. 2013). Such social impairments seen in relatives 
of individuals with ASD are also correlated to the relative’s gamma-band activity 
observed in responses to an auditory gamma-band steady-state tone (Rojas et al. 2011). 
Therefore current clinical dialogistic resolution may have less resolution/sensitivity than 
auditory gamma-band alterations to detecting ASD-related phenotypes. Along that line, 
several recent studies have demonstrated the ability to distinguish between low and high 
risk for ASD using gamma-band metrics (Tierney et al. 2012; Elsabbagh et al. 2009).  
This may not be specific for ASD, as other studies have observed the ability of gamma-
band activity to relate to current (Benasich et al. 2008) and predict future (Gou et al. 
2011) cognitive and language abilities. An alternative view of the first-degree relative 
data could be that despite gamma-band deficits similar to their affected siblings, their 
relative lack of behavioral impairment might be associated with some compensatory 
mechanism (either spontaneous or secondary to environmental differences). As such 
further study of the un-, or less-affected siblings might shed light on some effective 
pathways for symptom amelioration or even remediation. 
 Gamma-band oscillatory activity also has a plausible biological basis, and may be 
a convergence point (common pathway/mechanism) of several of the described 
neurobiological alterations seen in ASD (Port et al. 2014). While dependent on several 
core constituents (e.g. membrane time constants of pyramidal cells), gamma-band 
activity is hypothesized to arise from local circuit interactions (frequently modeled 
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through simple interneuron–interneuron or pyramidal–interneuron models, also known as 
interneuron gamma (ING) and pyramidal-interneuron gamma (PING) mechanisms 
respectively; Figure 1.2), with key roles for excitation and inhibition kinetics (Buzsáki & 
Wang 2012).  
 Indeed, a repeated finding is that γ-aminobutyric acid (GABA) receptor activity is 
necessary for ~ 40Hz activity (Whittington et al. 2000). In both of the aforementioned 
models for gamma-band activity generation, inhibitory feedback onto specific cells 
causes a temporary cessation in population firing, with the GABAA receptor time 
constant (25ms) playing a driving role in frequency determination (Traub et al. 1996). 
Moreover, specifically parvalbumin (PV) positive fast spiking basket cells are thought to 
be critically involved due to their perisomatically targeted synapses, due to their nature of 
forming interconnected networks and the observation of narrow spikes due to KV3.1/3.2 
channels, among other evidence (Buzsáki & Wang 2012).  
 The role of GABAergic cells in the generation of gamma band activity was 
confirmed by expressing the photoactivated Cl− pump halorhodopsin in parvalbumin 
(PV) fast spiking cells in-vivo and then effectively temporally removing them local 
circuit functioning. When this inhibition of PV fast spiking cells occurred, gamma-band 
activity was suppressed (Sohal et al. 2009). In addition, optogenetically driving PV fast 
spiking neurons in a naturalistic manner (Sohal et al. 2009), or even with randomly 
patterned light (Cardin et al. 2009), subsequently increases gamma-band activity in local 
field potentials (LFPs). Such is not true for analogous stimulation of pyramidal cells by 
light (Cardin et al. 2009). As such, it appears that resonant circuit properties generate 
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gamma-band activity in LFPs, not simply the firing rate of PV fast spiking cells. In 
support of this, the frequency of enhancement in the LFPs is not modulated by the 
stimulus intensity used, instead the amplitude of the LFP enhancement is (Cardin et al. 
2009). Support for this link between GABAergic processes and gamma-band activity has 
been observed in the human and animal literature, where either in-vivo relative cortical 
GABA concentrations (in humans) (Balz et al. 2015; Muthukumaraswamy et al. 2009; 
Gaetz et al. 2011) or PV immunodensity (mice) (Nakamura et al. 2015) is related to 
stimulus evoked gamma-gamma metrics. Furthermore, recently it was also demonstrated 
that primary visual cortex GABAA receptor density correlates with gamma-band activity 
during a visually based response task (non-target stimuli during a N-Back memory task) 
(Kujala et al. 2015).  This is not to imply that only GABA is associated with gamma-band 
activity, any alterations to inhibitory or excitatory drive will alter gamma-band activity 
(Lally et al. 2014; Yamawaki et al. 2008; Mann & Mody 2010; Traub et al. 1996; 
Thomases et al. 2013; Carlén et al. 2012). 
 Alterations to the balance of excitation and inhibitory have been repeatedly shown 
in ASD, the majority of which can be related to gamma-band activity dysfunction (Port et 
al. 2014). Proteins responsible for the synthesis (GAD65/GAD67) of both GABA itself 
and GABA (GABAA/GABAB) receptors are decreased in post-mortem samples of ASD 
neuronal tissue (Fatemi et al. 2002; Fatemi et al. 2014; Fatemi et al. 2009). While the 
exact meaning of this is unclear due to possible homeostatic changes (i.e. excessive 
concentrations of GABA may lead to receptor density decreases) or changes resulting 
from death, concurrent in-vivo studies have demonstrated regionally specific decreased 
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cortical relative GABA concentrations in ASD (Harada et al. 2011; Rojas et al. 2014; 
Gaetz et al. 2014). In addition, genetic alterations to the 15q11-13 locus, which encodes 
many GABA related proteins, is found in as may as 3% of the idiopathic ASD (Meguro-
Horike et al. 2011). This locus includes the Gabrb3 gene, for which polymorphisms have 
been associated with ASD (Buxbaum et al. 2002). Further supporting this hypothesis of 
GABAergic dysfunction, post mortem analyses of the hippocampus of individuals with 
ASD (compared to typically developing age-matched controls) demonstrates interneuron 
sub-type specific alterations (Lawrence et al. 2010). In both humans and mouse models 
that recapitulate key aspects of ASD, reductions in cortical density of PV interneurons 
have been demonstrated (Zikopoulos & Barbas 2013; Gogolla et al. 2009; Nakamura et 
al. 2015), with reductions in PV (via genetic deletion) leading to ASD-like behavioral 
phenotypes in mice (Wöhr et al. 2015).  
 Separately, excitatory drive in ASD has been shown to be perturbed. Glutamate 
based neurotransmission related messenger RNAs (mRNAs) and proteins have been 
shown to be altered in post mortem brains of individuals with ASD (Purcell et al. 2001), 
along with enzymes that regulate glutamate production (as part of the tricarboxylic acid 
(TCA) cycle) (Shimmura et al. 2013). Again, the exact interpretation of these alterations 
are unclear, with in-vivo measurements of Glx (a proxy for glutamate; glutamate and 
glutamine combined) demonstrating both increased and decreased concentrations in the 
brain of individuals with ASD, with a possible age dependence for the exact finding 
(Rojas et al. 2015). Interestingly a recent study that examined glutamate by itself using 
MRS, found increased cortical concentrations in individuals with ASD (Brown et al. 
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2013). It should be noted that the volume of tissue examined by typical in-vivo MRS 
studies (>1cc and up to 27cc in humans) renders interpretations of at the tissue, or cellular 
level, challenging. Separately, the kainate receptor subunit, GluR6 is strongly linked to 
ASD (Jamain et al. 2002; Shuang et al. 2004; Strutz-Seebohm et al. 2006). Blood-based 
genotyping studies also have linked ASD to specific metabotropic glutamate receptor 7; 
again supporting the hypothesis of glutamate’s involvement in ASD (Yang & Pan 2013). 
When combined, with the aforementioned decreases in GABAergic inhibition, this 
finding of altered glutamatergic tone may explain the concurrent findings of high co-
morbidity of seizures in ASD (with a prevalence of co-morbid epilepsy as high as 38%) 
(Danielsson et al. 2005). 
 Based on the observations of glutamate and GABA and, especially, the 
prevalence of comorbid seizure disorders in ASD (attributed to excess glutamate), 
Rubenstein and Merzenich in 2003 put forward a hypothesis suggesting that the 
biological basis of ASD might lie in an imbalance of excitatory and inhibitory activity. 
Much of the above two paragraphs lends support to this theory, specifically in the 
abundance of key excitatory and inhibitory neurotransmitters and their receptors. It seems 
that with the above interpretation of gamma-band activity, this hypothesis is open to in-
vivo testing with MEG to stratify patients across the autism continuum, to evaluate 
impact of regional variation in neurotransmitters, and to assess specificity for ASD by 
comparison with other clinical control groups. 
 It is not only neurotransmitters that are dysregulated in ASD, neuromodulatory 
systems have been known to be perturbed for over 15 years (Boullin et al. 1970; Modahl 
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et al. 1998). Not only do these neuromodulator affect current neurotransmission, they 
may also play key roles in the development of neuronal tissue (Whitaker-Azmitia 2001). 
Indeed, rodents prenatally treated with a serotonin receptor agonist demonstrate 
alterations to key brain regions involved in social activity, as well as a ASD-like 
behavioral phenotype (McNamara et al. 2008). In addition to prenatal roles for serotonin, 
serotonin synthesis demonstrates an altered developmental trajectory in children with 
ASD (Chugani et al. 1999), and depletions of it’s precursor can exacerbated symptoms in 
individuals with ASD (McDougle et al. 1996). Conversely serotonin system modulating 
pharmaceutical interventions are often prescribed in ASD. 
 Dopamine has also been implicated in ASD, with its role in mediating repetitive 
and stereotyped behaviors shown in both humans (Staal 2014) and mice (Chartoff et al. 
2001). Separately multiple dopamine related genes have been related to ASD (Nguyen et 
al. 2014), and several studies have observed dopamine increase in cortex of individuals 
with ASD (Chugani 2012). Dopamine’s link to repetitive and stereotyped behaviors is not 
unique; Acetylcholine has also been link to such behaviors (Karvat & Kimchi 2014), and 
shown to be dysregulated in ASD (Deutsch et al. 2010). 
 Neuropeptides may also be involved in ASD, with oxytocin decreased in the 
blood plasma of patients with ASD (Modahl et al. 1998). Both differences in processing 
of oxytocin (Green et al. 2001) and an association with the gene encoding the oxytocin 
receptor has been reported (Wu et al. 2005) in ASD, though the later may depend on the 
exact study population (Tansey et al. 2010). Furthermore oxytocin has a known role in 
social behavior and bonding (Lieberwirth & Wang 2014), including that the murine 
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oxytocin receptor is expressed in regions know to be involved in social behaviors 
(Ferguson et al. 2000). In further support of this hypothesis, interventions involving 
oxytocin are effective in both humans and mice models that recapitulate key aspects of 
ASD at recovering social-related neural functioning (Gordon et al. 2013; Tyzio et al. 
2014 respectively).  While oxytocin’s role is not immediately apparent in excitatory and 
inhibitory balance, recent work has shown the role of oxytocin in reducing baseline noise 
(i.e. spontaneous firing), and increase the stimulus-related fidelity of firing (Owen et al. 
2013). As such these alterations to neuromodulatory and neuropeptide systems can act 
both synaptically or on the firing properties of a cell (e.g. kinetics and firing probability 
of cells). 
 While serotonin, dopamine and oxytocin represent classes of neurochemical with 
hypothetical involvement in ASD, the present work focuses on the most prevalent E/I 
imbalance hypothesis, drawing together tools that are sensitive to neurotransmitters (e.g. 
MRS estimates of GABA) and to the consequence of local circuitry function (MEG 
measures of gamma band activity). 
 Architectural alterations have also been seen in ASD that relate to E/I balance. In 
support of the hypothesis of differentially altered long versus short range connectivity 
(Belmonte et al. 2004),  magnetic resonance imaging suggests that short range 
connectivity is increased in ASD (Herbert et al. 2004), along with long range 
connectivity decreases (Jou et al. 2011). As mentioned above, gamma-band activity is 
thought to related to local circuit function (Sohal et al. 2009; Cardin et al. 2009), and so 
possible increases in local connectivity may result in increased local activity at rest (as 
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observed in ASD; see above). Recent reports though suggest that this sort range hyper-
connectivity, may not exist functionally (Khan et al. 2013). Additional architectural 
alterations have been observed at the local circuit level in individuals with ASD with 
cortical minicolumns are containing less peripheral neuropil space (thought to be 
important in inhibitory signaling), while minicolumns concurrently are more densely 
packed (Casanova et al. 2002). 
 As such, the repeated findings of gamma-band activity alterations in ASD, its 
potential role as an endophenotype, and the known biological basis of gamma-band 
activity (for which relevant disruptions have been found in ASD) suggest gamma-band 
activity being a potential biomarker for ASD. Furthermore, decreased auditory related 
gamma-band activity are a conserved phenotype in several animal models of ASD 
regardless of the nature of the insult utilized (Gandal et al. 2010; Gandal, Sisti, et al. 
2012; Gandal, Anderson, et al. 2012; Saunders, Gandal, Roberts, et al. 2012; Tatard-
Leitman et al. 2014). Such decreases in phase-locked post-stimulus gamma-band 
responses have since been independently replicated (Nakamura et al. 2015). Additionally, 
as in clinical ASD, increased pre-stimulus and baseline activity have been observed in 
murine models relevant to ASD (Saunders, Gandal & Siegel 2012; Gandal, Sisti, et al. 
2012; Tatard-Leitman et al. 2014; Billingslea et al. 2014), though several of these studies 
are focused on animal models that recreate key suspected genetic etiologies of 
schizophrenia. However, these mice demonstrate social impairments akin to ASD 
(Tatard-Leitman et al. 2014; Billingslea et al. 2014), and at least one has been also 
presented as a model of ASD (Saunders et al. 2013). Furthermore, there is considerable 
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overlap of symptomatology, comorbid schizophrenia/psychosis and suggestions that 
neurobiological underpinnings are related (de Lacy & King 2013). Of potential note, 
baseline power increases in animal models that recapitulate key aspects of ASD have also 
been observed by independent laboratories (Zhong et al. 2009). Furthermore, a treatment 
that recovers proper social functioning also recovers baseline gamma-band activity 
(Tyzio et al. 2014) in animal models that recapitulate key aspects of ASD.  
 These gamma-band alterations seen in murine models that recapitulate key 
aspects of ASD have been shown to be associated with several behavioral/biological 
metrics. Pre-stimulus/baseline gamma-band activity has been shown to correlated to 
sociability (Gandal, Sisti, et al. 2012) and  working memory (Gandal, Sisti, et al. 2012; 
Billingslea et al. 2014). Moreover, directly increasing baseline excitatory drive in medial 
prefrontal cortex (via optogenetics) reduces sociability in mice, which can be recovered 
by supplemental increases to inhibitory drive (Yizhar et al. 2011). These works have 
since directly spawned analogous analyses in human-based studies, where pre-stimulus 
gamma-band power predicts language functioning in children (Edgar et al. 2015). 
Importantly, pre-clinical work has also demonstrate that while related baseline gamma-
power and gamma-band evoked power responses are related, they are not redundant 
measures; only about 27% of variance is explained when directly comparing these 
metrics (Billingslea et al. 2014). Correlates of gamma-band activity are not restricted to 
only behavioral or electrophysiological phenotypes in animal models relevant to ASD, 
stimulus evoked gamma-band responses have been shown to correlate to underlying 
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synaptic protein levels (Gandal et al. 2010), and PV positive cell density (Nakamura et al. 
2015). 
 Gamma-band alterations have also been investigated in mouse models of 
monogenetic syndromes that have considerable overlap with ASD. For instance Rett 
syndrome, a genetic syndrome, results from mutations in the MeCP2 gene (Amir et al. 
1999), is marked by ASD-like behavioral alterations, among other perturbations 
(Chahrour & Zoghbi 2007). Mice with alterations to their MeCP2 genetic load (i.e. either 
heterozygous females or site-specific alteration of amino acids) demonstrate altered 
gamma-band activity both at rest (Goffin et al. 2012), during exploratory activity (Lang 
et al. 2014) and in response to auditory stimuli (Goffin et al. 2012; Liao et al. 2012). The 
exact nature of the auditory stimulus produced gamma-band alterations is unclear as 
studies have found opposing effects (Goffin et al. 2012; Liao et al. 2012), possibly due to 
the differing genetic insults used. 
 Though much is known about ASD, E/I balance and MEG-derived auditory 
biomarkers, there are still several unresolved questions. For instance the developmental 
trajectories of these biomarkers are still unresolved, and so it is unknown if the auditory 
MEG biomarkers for ASD are persistent, or resolve with time. Furthermore, while there 
is mounting evidence that gamma-band activity is reliant on, and furthermore coupled to, 
underlying GABAergic tone (see above) in healthy adults for both motor and visual 
systems, whether this coupling holds true for the auditory system remains unknown. 
Moreover, the effect of ASD with regards to such coupling is also undetermined. Lastly, 
while gamma-band activity alterations are hypothesized to represent a biomarker for 
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ASD (Rojas & Wilson 2014), the relation of gamma-band activity to increased 
sociability remains unknown.  
 To resolve such questions, this dissertation undertakes the following experiments: 
1) The first longitudinal characterization of auditory MEG biomarkers from childhood 
into adolescence 2) A multimodal study examining the coupling between gamma-band 
activity (utilizing MEG) and relative cortical GABA levels (utilizing MRS) in the 
auditory system for both typically developing controls as well as individuals with ASD 3) 
The characterization of the in-vivo electrophysiological activity and ex-vivo amino acid 
concentrations, in a murine model recapitulating a key genetic insult in familial ASD 4) 
An in-vivo investigation of spectral activity in a mouse model that demonstrate increased 
(rather than decreased) sociability due to a mutation in the µ-opioid receptor 5) An in-
vitro investigation of the functional consequence of the aforementioned µ-opioid receptor 
mutation. For the organizational flow of this dissertation, and the feedback of each 
chapter with regards to previous chapter see Figure 1.3. 
 
Figure Legends: 
Figure 1.1 A participant in a MEG machine, and a subset of potential subsequent 
analyses. A child seated in an MEG machine, with their head positioned under the 
dewar (left top). Note the screen in front of the child is at a comfortable viewing 
distance for both presentations of stimuli and movies (to minimize fatigue). Analyses 
can follow two major routes, sensor-space (top) or source-space (bottom). For sensor-
space analyses, evoked responses to stimuli (such as auditory tones) can be averaged 
25	
over trials to produce event related fields (ERFs) for all channels separately (middle 
top). Within these multicomponent ERFs, specific responses can be observed such as 
the M100 (dashed vertical line), with additional use of topographic plots (right top) to 
verify correct magnetic field orientation. For source-space analyses (bottom), head 
models (either standard or subject-specific) can be generated for source localization 
(left bottom). Source-space locations (such as Heschl’s Gyrus; 2nd left bottom) can be 
interrogated within the head model via the use of source localization techniques (e.g. 
equivalent current dipoles and beamformers). Virtual sensor time courses can then be 
produced for said location, and source space ERFs produced (3rd left bottom). Such 
ERFs, derived from either source or sensor space, can be further decomposed into 
their spectral sub-components to examine otherwise obscured frequency specific 
alterations (right bottom). 
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Figure 1.2 Hypothesized mechanisms of gamma-band activity generation in both 
interneuron-interneuron & pyramidal cell-interneuron networks. (A) Interneuron-
Interneuron (I-I) networks (also known as interneuron gamma (ING) mechanism) 
involves two reciprocally connected perisomatically synapsing parvalbumin positive 
(PV) basket cell interneurons (green) releasing GABA (pink circles) to rhythmically 
inhibit one another. After an external drive is applied to the network, the interneurons 
fire in phase with one another at gamma-band frequency. After cell 1 fires an action 
potential (first vertical dashed line), it releases GABA onto both itself and other 
interneurons (represented here by cell 2). With the activation of GABAA receptors, 
chloride channels open causing an inhibitory post-synaptic current (IPSC). This 
current hyperpolarizes (via a inhibitory post-synaptic potential (IPSP)) cells 1 and 2 
to prevent additional action potentials (purple = membrane potential; blue = 
intracellular current). After the chloride channels close (~25ms), both cell 1 and 2 are 
permitted to fire once more in response to the continued external drive (second 
vertical dashed line). If either cell 1 or 2 does not fire within the timeframe between 
chloride channels closing and its counterpart’s GABA release, the cell’s action 
potential will be postponed (due to the chloride mediate ISPC) until the chloride 
channels close (cell 2 third/forth vertical dashed line). External excitatory cells in this 
model (cell 3; blue cells) also fire action potentials when the chloride conductance is 
at a minimum. While a single excitatory cell may not have complete firing fidelity to 
the gamma-band oscillation (cell 3, vertical line 4), fidelity is kept across the 
population of excitatory cells (cell 3 dashed resting potential/intracellular current). 
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The recorded local field potential (LFP; green) will be sensitive to the post-synaptic 
potentials of the excitatory cells, but not the interneurons, due to the cellular 
morphology of each class of cell. (B) Excitatory-Inhibitory (E-I) (also known as 
pyramidal-interneuron gamma (PING) mechanism) networks for gamma generation 
involves reciprocally connected excitatory pyramidal cells (cell 1; blue), and 
perisomatically synapsing PV basket cell interneurons (cell 2; green). External drive 
causes the excitatory cell to fire an action potential and release glutamate (red circle). 
This in turn excites the inhibitory cell to fire an action potential and release GABA 
back onto the excitatory cell (feedback inhibition). Similar to the I-I network, the 
excitatory cell is now prevented from firing due to increased chloride conductance. 
After ~ 25ms the chloride channels close and cell 1 becomes depolarized due to 
external excitatory drive and fires an action potential, repeating the cycle. Note in 
both models the prominent role for perisomatically targeting PV interneurons, GABA 
release, and the GABAA receptor time constant. In addition, in both models, the 
GABAA receptor time constant leads to firing at 40Hz (i.e. 1/25ms; gamma-band 
activity). Figure based on (Whittington et al. 2000; Tiesinga & Sejnowski 2009; 
Gonzalez-Burgos & Lewis 2008). 
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Figure 1.3 Organizational flow of dissertation with the feedback of later chapters on 
original questions. Circles = major question; Arrow/Square = Chapters with specific 
findings with respective to the previous question; Dashed line = Feedback between 
chapters 
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Figures: 
Figure 1. 1 
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Figure 1. 2 
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Figure 1. 3 	
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Abstract:  
Background:  
  Individuals with autism spectrum disorder (ASD) show atypical brain activity, 
perhaps due to delayed maturation. Previous studies examining the maturation of auditory 
electrophysiological activity have been limited due to the use of a cross-sectional design. 
The present study took a first step in examining magnetoencephalography (MEG) 
evidence of abnormal auditory response maturation in ASD via the use of a longitudinal 
design.  
 
Methods:  
Initially recruited for a previous study, 27 children with ASD and nine typically 
developing (TD) children, aged 6- to 11-years-old, were re-recruited two to five years 
later. At both timepoints, MEG data were obtained while participants passively listened 
to sinusoidal pure-tones. Bilateral primary/secondary auditory cortex time domain 
(100ms evoked response latency (M100)) and spectrotemporal measures (gamma-band 
power and inter-trial coherence (ITC)) were examined. 
 
Results: 
M100 latencies were delayed in ASD versus TD at the initial exam (~19 ms) and 
at follow-up (~18 ms). At both exams, M100 latencies were associated with clinical ASD 
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severity. In addition, gamma-band evoked power and ITC were reduced in ASD versus 
TD. M100 and gamma-band maturation rates did not differ between ASD and TD. MEG 
measures were also qualitatively examined for five children who exhibited “optimal 
outcome”, initially on spectrum, but no longer meeting diagnostic criteria at follow-up. 
These data, presented to motivate future studies, showed M100 latency and gamma-band 
mean values in this cohort in-between TD and ASD at both time points.  
 
Conclusions 
 Children with ASD showed perturbed auditory cortex neural activity, as 
evidenced by M100 latency delays as well as reduced transient gamma-band activity. 
Despite evidence for maturation of these responses in ASD, the neural abnormalities in 
ASD persisted across time. Of note, five children initially diagnosed on spectrum and no 
longer meeting ASD diagnostic criteria at follow-up qualitatively showed more ‘normal’ 
brain auditory responses. Further investigation with larger cohorts is needed to determine 
if the above auditory response phenotypes have prognostic utility, predictive of clinical 
outcome. 
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1. Introduction: 
 Autism spectrum disorder (ASD) describes a group of disorders characterized by 
social/communication impairments and restricted/repetitive behaviors (American 
Psychiatric Association 2013). Recent prevalence estimates report that 1 in 68 children 
have ASD (Developmental Disabilities Monitoring Network Surveillance Year 2010 
Principal Investigators & Centers for Disease Control and Prevention (CDC) 2014). 
Given that interventions for ASD show variable success (Erickson et al. 2014; Van Hecke 
et al. 2013; Dawson et al. 2010), and given that treatment outcome is difficult to predict 
at treatment onset, there is a need for early response indicators. Pre-clinical (animal) 
studies of novel treatments are also hampered by the lack of directly translatable metrics. 
“Biomarkers” offer a biological target for therapeutics, a bridge between preclinical and 
clinical studies, and may also serve as early response indictors of treatment 
success/failure (Port et al. 2015; Port et al. 2014).  
 Two prospective brain biomarkers, Superior Temporal Gyrus (STG) M100 
auditory latency (Gage, Siegel & Roberts 2003; Roberts et al. 2010; Edgar, Lanza, et al. 
2014) and STG post-stimulus auditory gamma-band activity (Wilson et al. 2007; Gandal 
et al. 2010; J Christopher Edgar et al. 2015; Edgar et al. 2016), have been identified as 
abnormal in ASD as well as in animal models that recapitulate key aspects of ASD 
(Gandal et al. 2010; C T Engineer et al. 2014). Auditory M100 responses, and their 
electrical counterpart the N1, are characteristic electrophysiological responses seen in the 
auditory event related fields/potentials (ERF/P) (Hari et al. 1980). M100 responses 
become stronger and are observed at earlier latencies as a function of typical 
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development (Paetau et al. 1995; Edgar, Lanza, et al. 2014) First described by Gage and 
colleagues in our group (Gage, Siegel, Callen, et al. 2003), right-hemisphere auditory 
M100 latencies were observed to be prolonged by ~10% in children with ASD versus 
age-matched typically developing controls (TD). This ~10 ms right hemisphere M100 
latency prolongation in children with ASD was observed in later studies, with group 
differences in M100 latency remaining even after co-varying cognitive and language 
ability (Roberts et al. 2010; J Christopher Edgar et al. 2015; Edgar, Lanza, et al. 2014). 
These later studies, with moderately large samples (also including (Edgar, Lanza, et al. 
2014)), also allowed for the observation that M100 group differences existed even in the 
presence of a seemingly normal M100 latency maturation rate in ASD, suggesting that 
the persistent delay in auditory M100 latencies in children as well as adolescents with 
ASD was due to an early initial M100 latency ‘offset’. 
 In addition to M100 latency, STG auditory post-stimulus gamma-band (typically 
> 30Hz) activity has received considerable attention as a biomarker for ASD. Though not 
specific to ASD (Maharajh et al. 2007; Krishnan et al. 2009; Edgar, Chen, et al. 2014), 
altered post-stimulus gamma-band activity has been repeatedly demonstrated in ASD in 
different sensory systems, stimulus complexity, and in children and adults with ASD 
(Grice et al. 2001; Wilson et al. 2007; Rojas et al. 2008; Gandal et al. 2010; Sun et al. 
2012). Within the auditory system, post-stimulus phase-locked gamma-band measures 
(evoked power as well as inter-trial coherence) have been found to be reduced in ASD 
(Wilson et al. 2007; Rojas et al. 2008; Gandal et al. 2010; J Christopher Edgar et al. 
2015; Edgar et al. 2016). Auditory gamma-band alterations may represent 
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endophenotypes, observed in first degree relatives of individuals with ASD (Rojas et al. 
2008; Rojas et al. 2011; McFadden et al. 2012), with some evidence that gamma-band 
activity in relatives is associated with their social functioning (Rojas et al. 2011). 
Although the existence of post-stimulus gamma-band alterations in first-degree relatives 
may call into question the appropriateness of this measure as a diagnostic or response 
biomarker, subclinical expression of social impairment (Broad Autism Phenotype) is 
thought to exist in the relatives of individuals with ASD (Piven, Palmer, Landa, et al. 
1997). As such, gamma-band biomarkers may support a basis for a clinical discrimination 
(Port et al. 2015). Along this line, several recent studies have demonstrated the ability to 
distinguish between infants at low and high risk for ASD (typically the risk being 
conferred by the presence of an older sibling with ASD) via gamma-band metrics 
(Tierney et al. 2012; Elsabbagh et al. 2009). Such findings, however, may not be specific 
to ASD, as other studies have shown that gamma-band activity relates to current 
(Benasich et al. 2008) as well as future (Gou et al. 2011) cognitive and language abilities. 
 The aforementioned cross-sectional studies of M100 latency prolongation and 
post-stimulus gamma-band alterations in ASD, although informative, have limitations.  In 
addition to the limits inherent to cross-sectional studies (e.g., inter-subject “biological” 
variability), cross-sectional designs do not allow for developmental changes over time, a 
particular limitation as some children initially diagnosed with ASD may show significant 
improvement over time (known as “optimal outcome”) (Zappella 2002; Mukaddes et al. 
2014; Helt et al. 2008; Granpeesheh et al. 2009). Though much remains to be known 
about “optimal outcome”, research suggests a small cohort of individuals originally 
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diagnosed with ASD no longer meet diagnostic criteria at later follow-up.  Indeed domain 
specific measures suggest they may later function well within normal ranges with respect 
to cognitive and social abilities (Helt et al. 2008). The role, impact, and specificity of 
interventions associated with “optimal outcome” are currently unknown. Although it has 
been suggested that such individuals demonstrate better social skills and higher 
intelligence, certain clinical measures (i.e., higher IQ) are not strongly predictive of 
“optimal outcome”. In addition, initial autism severity is not associated with “optimal 
outcome” (Helt et al. 2008). Of note, individuals showing “optimal outcome” do 
demonstrate subtle residual impairments even after “losing” their ASD diagnosis (Kelley 
et al. 2006). With regard to the above, an objective prognostic biomarker and/or real-time 
monitor of intervention efficacy would be of use. 
  In an attempt to address the aforementioned limitations of cross-sectional studies 
(inter-subject variability and the insensitivity to developmental improvement), the present 
study utilized a longitudinal design to examine auditory M100 latencies, auditory 
gamma-band responses, and their maturation in TD children and children with ASD. The 
present study tested the hypotheses that children with ASD would demonstrate prolonged 
auditory M100 latencies as well as reduced post stimulus phase-locked gamma-band 
metrics. Furthermore, cross-sectional analyses allowed direct assessment of whether 
M100 latencies in ASD show evidence of abnormal maturation. Given longitudinal 
findings showing similar rates of M100 latency maturation in TD and ASD, it was 
hypothesized that the children with ASD would demonstrate a persistent prolongation in 
M100 latency delay given a similar rate of maturation in TD and ASD (i.e., maturation 
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rates not faster than TD and thus the M100 latency in older individuals with ASD does 
not ‘catch up’ with older TD M100 latencies). In addition, the use of a longitudinal 
design allowed for examination of associations between MEG measures and both current 
and future clinical/behavioral status.  It was hypothesized that M100 latencies would be 
associated with current autism severity, but not language ability (Roberts et al. 2010), 
and that gamma-band metrics would be associated with follow-up language ability, but 
not autism severity (Gou et al. 2011). 
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2. Materials and Methods: 
2.1 Participants 
 Initial time point 1 data were obtained from previous magnetoencephalography 
(MEG) studies (10;20). A subsample of participants (TD = 9, ASD = 27) were re-
recruited two to five years later (mean age = 12.1years). The longitudinal cohort was 
smaller than our previously published studies because of a restricted intake age-range (to 
allow for subsequent follow-up during the adolescent period) as well as difficulties re-
contacting and re-recruiting participants over a long time interval, and additional 
exclusion criteria that arose (such as dental work in the intervening period, or contra-
indicating medication use).  
 Of note, a subset of the re-recruited children with ASD (N = 5) showed 
considerable improvement at follow-up (i.e., sub-threshold for a diagnosis of ASD). 
These individuals are referred to here as “had ASD”. All 36 participants (9 TD [3 males], 
22 ASD [22 males], 5 “had ASD” [4 males]) had evaluable M100 data. Table 2.1 reports 
diagnostic scores and demographics for the three groups (TD, ASD, “had ASD”). Due to 
gamma-band activity analyses (which relied on individual MRI) being more sensitive to 
artifacts (e.g. motion) than M100 latency measures, measures that are also extracted from 
raw sensor data, eight children (1 TD, 7 ASD) were excluded from gamma-band activity 
analyses. This left 28 participants (8 TD [3 male], 15 ASD [15 male], 5 “had ASD” [4 
male]) for the gamma-band activity analyses. Table 2.2 reports population diagnostic 
scores and demographics for the three groups (TD, ASD, “had ASD”) included in 
gamma-band activity analyses. Due to the requirements of parametric statistics (i.e. linear 
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mixed effect model (LMM) due to missing responses) and the small sample size of the 
“had ASD” group, the cohort of “had ASD” individuals were not included in the 
statistical analyses and the data from this group were instead only descriptively reported.  
 
2.2 Recruitment and Inclusion/Exclusion Criteria 
 Akin to procedures described in Edgar et al. 2015, subjects with ASD were 
originally recruited from the Regional Autism Center of The Children’s Hospital of 
Philadelphia (CHOP), the Neuropsychiatry program of the Department of Psychiatry of 
the University of Pennsylvania School of Medicine, and from local and regional parent 
support groups such as ASCEND (Asperger Syndrome Information Alliance for 
Southeastern Pennsylvania)  and local chapters of Autism Speaks. All children screened 
for inclusion in the ASD sample had a prior ASD diagnosis made by an expert clinician, 
typically a developmental pediatrician in the Regional Autism Center at the Children’s 
Hospital of Philadelphia. The original diagnosis was made after an extensive clinical 
interview, documentation of DSM-IV criteria for ASD, and use of various ASD 
diagnostic tools, such as the Childhood Autism Rating Scale and, in many cases, the 
ADOS. Subjects with typical development (TD) were recruited through local newspaper 
advertisements and from pediatric practices of the CHOP primary care network.  
 Research participants made two visits to CHOP. During the first visit (2–3 weeks 
prior to the MEG exam), clinical and diagnostic testing was performed to confirm the 
referral ASD diagnosis, to administer neuropsychological tests, and to ensure that the TD 
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children met study inclusion/exclusion criteria. Assessments were performed by licensed 
child psychologists with expertise in autism (L.B., E.S.K.). Given the extensive clinical 
evaluations upon which original ASD diagnosis was made, an abbreviated diagnostic 
battery was used to confirm the original diagnosis. Specifically, the ASD diagnosis was 
confirmed with standard diagnostic tools, including direct observation with the Autism 
Diagnostic Observation Schedule (ADOS; Lord et al. 2000)) and parent report on the 
Social Communication Questionnaire (SCQ; Rutter et al. 2003). Dimensional symptom 
severity ratings were also obtained by parent report on the Social Responsiveness Scale 
(SRS; Constantino & Gruber 2012). The Autism Diagnostic Interview-Revised (ADI-R), 
a parent interview about current and prior ASD symptoms, was utilized to resolve 
diagnostic discordances between the ADOS and parent rating scales in the rare instances 
in which such discordances occurred. At the time of their original study visit, children 
were required to exceed established cut-offs on both the ADOS and SCQ, or, in the event 
of a discordance between those measures, on both the ADOS and ADI-R. Children 1 
point below ADOS cut-offs were included if they also exceeded cut-offs on at least two 
parent questionnaires or on the ADI-R. For children for whom original diagnosis was not 
made by an expert clinician according to DSM criteria (e.g., diagnoses made by a 
school), more rigorous standards were applied, and the child was required to exceed cut-
offs on both the ADOS and ADI-R for inclusion in the ASD group. For final inclusion in 
the ASD group, children had to meet the above criteria at the time of their original study 
participation and also had to exceed diagnostic cut-offs on the ADOS at their two to five -
year follow-up (parent rating scale corroboration was not required at follow-up). To rule 
42	
out global cognitive delay, all subjects were required to score at or above the 2nd 
percentile (SS>70) on the Perceptual Reasoning Index (PRI) of the Wechsler Intelligence 
Scale for Children-IV (WISC-IV; Wechsler 2003). In all subjects, the WISC-IV Verbal 
Comprehension Index (VCI) was also obtained. 
 Inclusion criteria for the TD children included scoring below the cut-off for ASD 
on all domains of the ADOS as well as parent questionnaires, and performance above the 
16th percentile on the Clinical Evaluation of Language Fundamentals—4th edition 
(CELF-4;  Semel & Wiig 2003). In addition to the above inclusion/exclusion criteria, all 
subjects and families were native English speakers and had no known genetic syndromes 
or neurological (e.g., cerebral palsy, epilepsy), or sensory (hearing, visual) impairments. 
The study was approved by the CHOP Institutional Review Board and all participants’ 
families gave written informed consent. As indicated by institutional policy, where 
competent to do so, children over the age of seven additionally gave verbal assent.  
 TD children were free of medications at both exams, except for one participant 
who was prescribed Naltrexone at follow-up. In the children with ASD, 12 were 
prescribed medications/took dietary supplements at the first scan. At follow-up, 14 took 
medications/supplements. The “had ASD” cohort did not report taking medications at the 
initial exam. At follow-up 3 “had ASD” participants were taking medication. 
Supplemental Table 1 provides medication information. 
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2.3 Electrophysiological Data Collection 
 MEG data were obtained using a whole-cortex 275-channel system (VSM 
MedTech Inc., Coquitlam, BC) in a magnetically shielded room. Prior to data acquisition, 
three head-position indicator coils were attached to the participant’s scalp at the nasion 
and left- and right-preauricular points. These head coils provided continuous 
specification of head position and orientation in relation to the MEG sensors. To 
minimize fatigue, during the task, participants viewed (but did not listen to) a movie 
projected onto a screen positioned at a comfortable viewing distance. Electrodes were 
attached to the left and right clavicles for electrocardiogram recordings (ECG) and to the 
bipolar oblique (upper and lower left sites) for electrooculogram recordings (EOG). A 
band-pass filter (0.03–300 Hz) was applied to the EOG, ECG, and MEG signals, with 
signals digitized at 1200 Hz, and with third-order gradiometer environmental noise 
reduction of the MEG data.  
 After the MEG session, structural magnetic resonance imaging (sMRI) provided 
T1-weighted, 3D MP-RAGE anatomical images for source localization acquired on a 3T 
Siemens Verio™ scanner (Siemens Healthcare, Erlangen, Germany) with voxel size 0.8 x 
0.8 x 0.9 mm3.  
 
2.4 Stimuli 
 Stimuli consisted of sinusoidal tones presented using Eprime v1.1. Tones were 
presented via a sound pressure transducer and sound conduction tubing to the 
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participant’s peripheral auditory canal via ear-tip inserts (ER3A, Etymotic Research, IL). 
Prior to data acquisition, 1000Hz tones (300 ms duration, 10 ms rise time) were presented 
binaurally and loudness incrementally decreased until reaching auditory threshold for 
each ear. Stimulus tones were then presented at 45dB sensation level above threshold. 
During the task participants passively listened to binaurally presented interleaved 200, 
300, 500 and 1000 Hz sinusoidal tones (tones 300 ms duration; 10 ms ramps) with a 1000 
ms (±100) inter-trial interval. Participants heard a total of 130 tones/frequency. 
 
2.5 Data preprocessing 
 MEG responses were analyzed using the MatLab (Mathworks, Natick, MA) open-
source toolbox Fieldtrip (Oostenveld et al. 2011). Using the continuous data and the 
procedures outlined in Fieldtrip (FieldtripWiki, 2015), ICA identified heartbeat and eye 
artifacts (blinks and saccades), and then these artifact components were removed from 
the epoched data (+/- 500 ms around trigger). Trials with jump and muscle artifact were 
also rejected (using Fieldtrip’s Z-score based artifact rejection). Lastly, to account for 
differences in head motion during the MEG scan, if any fiducial moved more than 10 mm 
from the average head position during a trial that trial was rejected. 
 
2.6 M100 Data Analysis  
 For each group, over 92% of trials remained after motion and artifact rejection 
(TD = 95.3±1.29%, ASD = 92.7±0.82%). A LMM (random intercept and random slope 
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of Timepoint) showed a trend towards a main effect of Diagnosis (F(1,29.02)=3.02, p 
<0.10), and a marginally significant main effect of Timepoint (F(1,28.9) = 4.01 initial = 
95.3±0.98, follow-up = 92.7±1.00, p = 0.052). The interaction of Diagnosis X Timepoint 
was not significant, nor was any term involving stimulus frequency. Although a group 
difference in number of evaluable trials was suggested, rejection rates across groups were 
considered low, and given generally similar mean trial values between the groups, this 
difference was deemed unlikely to affect any group difference M100 latency finding. 
 Determination of the latency of M100 sources in the left and right Heschl’s Gyrus 
was accomplished using the data from the above analyses pipeline. In addition, a 3 – 40 
Hz band-pass filter was applied to the multi-channel (all ipsilateral channels) waveforms. 
In each participant, the left and right M100 peaks were then identified as the largest point 
in the M100 scoring window (90–190 ms) using the sensor butterfly plot of the band-
passed ERF. To confirm that the M100 was accurately identified, magnetic field 
topographic plots over all ipsilateral sensors at the selected latency were examined to 
ensure a topography reflecting a M100 dipolar source.  
 Given a M100 latency dependence on stimulus frequency (Roberts & Poeppel 
1996), and given that M100 responses are occasionally missing/unidentifiable for 
individual stimulus tone frequencies, M100 analyses were performed using LMM (with 
both random intercepts and a random slope for timepoint), with pairwise comparisons on 
the marginal means for Diagnosis, Timepoint, Hemisphere, Condition, as well as the 
Diagnosis X Hemisphere and Diagnosis X Timepoint, and Diagnosis X Timepoint X 
Hemisphere interactions. To investigate M100 latency maturation, LMMs were used to 
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create a tone-frequency independent “effective” M100 latency for each hemisphere. The 
effective M100 latencies were then used to compute a rate of maturation: (follow-up 
M100 effective latency – initial M100 effective latency)/change in years. A LMM (with 
random intercept) investigated statistical differences in rate of maturation, with pairwise 
comparison for Diagnosis, Hemisphere and Diagnosis X Hemisphere. 
 
2.7 Gamma-band Data Analysis  
 For each group, over 93% of trials remained (TD = 95.2±0.83%, ASD = 
93.1±0.61%). A LMM (analogous to used for testing of group differences in M100 trials 
remaining) showed a marginally significant main effect of Diagnosis (p = 0.052), and a 
main effect of Timepoint (F(1,21)=5.28; initial = 95.0±0.62, follow-up = 93.3±0.64, p < 
0.05). The interaction of Diagnosis X Timepoint was not significant, although ASD but 
not TD demonstrated a change (gain) in the amount of remaining trials between initial 
and follow-up. Although group differences in the number of evaluable trials were 
suggested, rejection rates across groups were considered low, and given generally similar 
mean trial values between the groups, this difference was deemed unlikely to affect any 
group difference gamma-band finding. 
 Subject-specific single-shell head models were created from each participant’s 
MP-RAGE MRI. To coregister MEG and sMRI data, three anatomical landmarks (nasion 
and right and left preauriculars points) as well as an additional 200+ points on the scalp 
and face were digitized for each participant using the Probe Position Identification (PPI) 
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System (Polhemus, Colchester, VT), and a transformation matrix that involved 
rotation/translation between the MEG and sMRI coordinate systems was obtained via a 
least-squares match of the PPI points to the surface of the scalp and face. This head 
model was then fitted to the mean head position (in MEG coordinate space) as 
determined by the fiducials (Figure 2.1A). Separately, the participant’s MRI was 
normalized to an age-matched average brain template (Fonov et al. 2011) using non-
linear warping. A left and right Heschl’s Gyrus location was identified and then reverse 
transformed to subject space. A linearly-constrained minimum variance (LCMV) 
beamformer was computed for each participant’s left and right Heschl’s Gyrus, 
discarding the contralateral hemisphere’s sensors to reduce inter-hemispheric signal 
cancelation due to correlated activity (Herdman et al. 2003). Heschl’s Gyrus virtual 
electrodes (VE) were then computed using a dipole orientation optimized for post-
stimulus gamma-band activity (i.e. orientation determined via principal component 
analysis on the 0-270 ms post-stimulus window filtered 30-58 Hz). 
 Broadband resultant VE time courses were time-frequency transformed (Hilbert 
transform) using in-house MatLab scripts. For each participant, evoked power, total 
power (evoked and induced power) and inter-trial coherence (ITC) were calculated. Mean 
power/coherence was then derived for the spectrotemporal regions containing a gamma-
band response. To avoid erroneously quantifying gamma-band activity by either a) not 
correctly accounted for gamma-band response maturation, or b) including low-level non-
stimulus related signal (noise), gamma-band responses were quantified based on a time-
frequency region containing both TD and ASD group-level activity (initial scan – evoked 
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power: 10-180 ms, 30-100 Hz, ITC: 10-170 ms 30-65 Hz, total power: 20-180 ms, 30-58 
Hz; follow-up scan – evoked power: 10-170 ms, 30-100 Hz, ITC: 10-150 ms, 30-75 Hz, 
total power: 20-160 ms, 30-57 Hz). Gamma-band activity analyses were performed using 
LMMs, with pairwise comparisons on Diagnosis, Hemisphere, Timepoint, Diagnosis X 
Hemisphere, Diagnosis X Timepoint, and Diagnosis X Timepoint X Hemisphere. To test 
maturation group differences, a gamma-band activity maturation measure was computed: 
(follow-up gamma-band activity metric – initial gamma-band activity metric)/change in 
years.  
 
2.8 Correlations with behavioral metrics 
 To test hypotheses regarding clinical measures as well as to examine the 
specificity of such associations, LMM (random intercept) analyses examined associations 
between MEG measures and scores on the Social Responsiveness Scale (SRS; a measure 
of ASD symptom severity, (Constantino et al. 2003)), CELF-4 core language index (CLI; 
a measure of language functioning), WISC-IV GAI (a measure of global cognitive 
function), and WISC-IV VCI (a measure of verbal comprehension). Each LMM had fixed 
effects of Timepoint, Age and behavioral metric, and were co-varied for Age and 
behavioral metric. Hierarchical regressions tested the hypothesis that initial gamma-band 
activity explained additional variance in the follow-up behavioral metrics (SRS, CELF-4 
CLI, WISC-IV GAI & VCI) beyond the variance accounted for by initial behavioral 
measure and age (Dependent Variable = Behavioral Metric at follow-up; block 1 = Age 
and Behavioral Metric at initial exam, Block 2 = MEG measure).  
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3. Results: 
 As shown in Table 2.1, TD versus ASD did not differ on age at initial exam or at 
follow-up. As expected, children with ASD had higher SRS and ADOS Calibrated 
Severity Scores (CSS) (Gotham et al. 2009; Hus & Lord 2014) than TD at both exams. 
No group differences were observed in global functioning (WISC-IV GAI) at either time 
point. Group differences in verbal functioning (WISC-IV VCI) were present at the initial 
exam but not at follow-up. Children with ASD scored significantly lower on the CELF-4 
Core Language Index than TD at both exams.  The population included in gamma-band 
activity analyses exhibited a similar demographic profile: ASD exhibited higher scores 
on autism metrics (SRS and ADOS CSS), and decreased CELF-4 Core Language Indices 
at both exams. At the initial exam, ASD demonstrated significantly lower WISC-IV VCI 
than TD, though not so at follow-up. Lastly, in the gamma-band activity analyses 
participants, group differences in age or general functioning (WISC-IV GAI) were not 
observed. 
 
3.1 M100 latency 
 A main effect of Condition (stimulus tone), F(3,114.62) = 17.53 p < 0.001, 
showed the expected earlier M100 latencies to higher versus lower frequency tones 
(Roberts & Poeppel 1996); a main effect of Hemisphere, F(1,154.53) = 111.76, p < 
0.001, showed the expected earlier right than left M100 latencies (Roberts et al. 2000); 
and a main effect of Timepoint, F(1,21.77) = 8.52, p < 0.01, showed the excepted 
maturational change with earlier latencies at follow-up versus initial exam. The main 
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effect of Diagnosis (ASD versus TD) was significant, F(1,23.27) = 7.43, p < 0.05, 
confirming the a priori hypothesis of delayed M100 latencies in ASD versus TD (TD = 
122±6.0 ms; ASD = 141±4.0 ms). Simple effect analyses of a significant Diagnosis X 
Hemisphere X Timepoint interaction, F(2,152.94) = 3.30, p < 0.05, showed significantly 
earlier M100 latencies at follow-up versus the initial exam in both groups and both 
hemispheres except for no significant right-hemisphere changes in TD. This interaction 
though is potentially confounded due to inter-subject (despite no group difference) 
differences in follow-up interval. None of the other interaction terms involving Diagnosis 
were significant. M100 latency values for all groups at both exams (marginal means after 
collapsing across condition) are shown in Figure 2.2.  
 Additional analyses examined group differences in the M100 latency maturation 
rate measure (i.e., (follow-up M100 effective latency – initial M100 effective 
latency)/change in years). Both TD and ASD demonstrated the characteristic ~3-5 
ms/year M100 latency maturation, with no significant differences for Diagnosis, 
Hemisphere or their interaction (p > 0.05). Thus both TD and ASD showed maturational 
shortening in M100 latency with no resolvable difference in maturation rate between 
groups, despite the above persistent and significant absolute latency difference between 
groups. 
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3.2 Gamma-band activity 
 To increase signal-to noise, responses were averaged across condition (shown 
effective in (Gandal et al. 2010)). As shown in Figure 2.3, at both exams, gamma-band 
activity was visible in the grand average time-frequency response for each group.  
 An LMM (with subject as a random effect) tested for group differences in total 
power. Gamma-band total power did not differ between TD and ASD at either exam 
(data not shown). For evoked power (tested via LMM with random intercepts), a main 
effect of Diagnosis, F(1,41.6) = 8.68,  p < 0.01, confirmed the a priori hypotheses of 
reduced gamma-band evoked activity in ASD (38.4±4.7% change from baseline) versus 
TD (61.5±6.4% change from baseline; Figure 2.4A). The main effect of Timepoint was 
also significant, F(1,43.07) =8 .04, p < 0.01, demonstrating maturation of evoked 
response power over time (initial = 41.1±3.1 % change from baseline, follow-up = 
58.8±6.4 % change from baseline). Of note, although Figure 2.4A suggests greater 
gamma-band evoked group differences at follow-up (33.1±12.8 % change difference 
between TD and ASD; p = 0.013) versus initial exam (13.2±6.2 % change difference 
between TD and ASD; p = 0.046), the interaction term was not significant. Finally, 
analyses examined group differences in evoked gamma-band maturation rates (LMM 
with random intercepts). Although showing a four-fold faster maturation rate, the rate of 
change in evoked gamma-band activity for TD (7.7±3.0 % change from baseline /year) 
was not significantly different from ASD (2.1±2.2 % change from baseline /year; Figure 
2.4).  
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 For gamma-band ITC (tested via LMM with random intercept and Timepoint as a 
random slope), a main effect of Diagnosis, F(1,22.24) = 6.30, p <0.05, indicated greater 
ITC in TD versus ASD (ASD = 0.040±0.003 ITC, TD = 0.053±0.004 ITC). Although the 
interaction was not significant, ASD exhibited only a qualitative decrease in ITC versus 
TD at initial exam (ASD = 0.040±0.003, TD = 0.050±0.005, TD–ASD= 0.010±0.007, p = 
0.116), which became significant at follow-up exam (TD-ASD = 0.016±0.006, p < 0.05). 
As shown in Figure 2.4, analyses examining ITC maturation (LMM with random 
intercept) showed no significant group differences. 
 
3.3 Correlation of MEG Auditory Biomarkers and Behavioral Metrics 
 Data from all participants (including “had ASD”) were included in the 
correlational analyses. To ensure specificity of any associations and to provide negative 
controls, all comparisons between behavioral metrics and MEG-derived measures 
(excluding rates of maturation) were examined. Of note, the behavioral measures (SRS, 
CELF-4 CLI, WISC-IV GAI, WISC-IV VCI) shared considerable variance, especially 
the CELF-4 CLI, WISC-IV GAI and WISC-IV VCI, with up to 80% variance shared (see 
Supplemental Table 2.2 for bivariate correlations among behavioral measures). 
Examining all participants at both timepoints, both left and right hemisphere M100 
latencies were associated with SRS after removing variance associated with Age and 
Time (LH: SRS F(1,54.30) = 6.48 p < 0.05, estimate = 0.2 ms/SRS point, RH: SRS 
F(1,62.38) = 15.20 p < 0.001, estimate = 0.2 ms/SRS point; Figure 2.5). No associations 
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were observed for CELF-4 Core Language Index or WISC-IV metrics (GAI/VCI) in 
either hemisphere (p > 0.1), or for any gamma-band metric.  
 Although M100 latency did not correlate with current language scores, right-
hemisphere initial M100 latency predicted additional variance in the follow-up CELF-4 
Core Language Index metric (R2 change = 0.03, p < 0.05). In addition, a trend was 
observed for an association between initial evoked gamma-band power and follow-up 
WISC-IV VCI (R2 change = 0.033, p < 0.1). Furthermore, initial gamma-band ITC 
predicted additional variance in follow-up WISC-IV VCI after removing the effect of age 
and initial WISC-IV VCI score (R2 change = 0.05, p < 0.05). Thus, these MEG measure 
may offer a prognostic indication of language outcome (perhaps signifying “capacity for 
improvement”). 
 
3.4 Preliminary results for “had ASD” 
 As previously mentioned, a third group of participants emerged over the course of 
the study - the “had ASD” group. Although too small for statistical assessment, data from 
these participants are included as descriptive preliminary findings. These participants 
showed a diagnostic profile similar to the primary ASD group at the initial exam (Table 
2.1 & 2.2, SRS = 75.0, ADOS CSS =7.8). At follow-up, however, these participants had 
intermediate SRS and ADOS scores (Table 2.1 & 2.2, SRS = 54.4 ADOS CSS = 2.5). 
Such “optimal outcome” has been demonstrated before, with such children tending to 
have initial language/communication scores that predict outcome (Helt et al. 2008). Not 
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inconsistent with this, these five children scored between TD and ASD on the WISC-IV 
VCI at both time points (initial = 104.2, follow-up = 109.6).  
 With regard to M100 latencies, as shown in Figure 2.2A, M100 latencies in the 
“had ASD” group at the initial exam were either similar to TD (left hemisphere) or in-
between TD and ASD (right hemisphere). As shown in 2B and 2C, this profile was also 
observed at follow-up as well as for the M100 latency maturation rate measure. In 
addition, “had ASD” showed gamma-band evoked power and ITC values between TD 
and ASD at the initial and follow-up exams. Follow-up studies are needed to confirm if 
this represents an electrophysiological signature of “capacity for improvement”. 
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4. Discussion: 
 M100 latencies and phase-locked gamma-band evoked power matured from 
initial to follow-up exam. This finding supports findings from cross-sectional studies 
(Paetau et al. 1995; Rojas et al. 2006). In addition, similar to previous studies (Gage, 
Siegel & Roberts 2003; Roberts et al. 2010; Roberts et al. 2013; Wilson et al. 2007; J 
Christopher Edgar et al. 2015; J. Christopher Edgar et al. 2015; Edgar et al. 2016), 
delayed right hemisphere M100 latencies and reduced gamma-band evoked power and 
ITC were observed in ASD versus TD. Of note, different from previous studies, left-
hemisphere M100 group differences were also observed in ASD, with bilateral M100 
latency findings in the present study perhaps associated with greater power in 
longitudinal studies. Interestingly, M100 latency delays were greater than those reported 
in previous studies (Gage, Siegel & Roberts 2003; Roberts et al. 2010; Roberts et al. 
2013; J Christopher Edgar et al. 2015), an effect perhaps due to the use of cross-sectional 
designs in previous studies. In particular, whereas cross-sectional studies likely include 
some children that later exhibit “optimal outcome”, in the present study such information 
was available and these ASD subjects (“had ASD”) were excluded from primary 
analyses. Indeed, reanalysis of the data for timepoint 1 that included the “had ASD” 
individuals in the ASD group, while still showing significant group differences, 
decreased the effect size by several milliseconds.  
 Maturation rates for M100 latency as well as the gamma-band metrics did not 
differ between TD and ASD, a finding that confirms previous cross-sectional maturation 
rate estimates (Roberts et al. 2013; Edgar, Lanza, et al. 2014)  As such, present findings 
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support findings from previous studies suggesting a perturbed developmental trajectory 
(despite similar maturation rate) of M100 latency in ASD, due to a persistent latency 
offset.  
 Analyses examined the relationship of the two auditory biomarkers to current and 
future behavior. Four separate (though related) behavioral metrics were tested in order to 
examine the specificity of associations. Right- and left- hemisphere M100 latencies were 
associated with greater clinical impairment (higher SRS scores). To the authors’ 
knowledge, this is the first time such associations have been demonstrated.   
 Although analogous relationships were not observed for gamma-band metrics, 
initial gamma-band ITC predicted variance in follow-up WISC-IV VCI scores. Gamma-
band evoked power exhibited a similar, though non-significant relationship, with WISC-
IV VCI scores. Somewhat unexpectedly, right M100 latencies also predicted CELF-4 
Core scores. Although in previous studies gamma-band metrics predicted future cognitive 
and language abilities (Gou et al. 2011), such associations have not been previously 
reported for M100 latencies. Although the current right-hemisphere M100 associations 
with CELF-4 Core score may appear contradictory (no association at the current exam, 
but an association scores at the later exam), a potential explanation for such a result may 
be that language-related issues arising from M100 latency prolongations are cumulative. 
As such, the later the language-related measure taken, the greater the observed language 
deficit for that subject. Over a population, this would allow for a greater range of 
language ability, making an association with M100 latencies easier to detect. Thus, it is 
hypothesized that a M100 latency delay relates to diminished capacity for language 
57	
improvement (and as well that an earlier M100 latency predicts the availability of 
capacity for improvement). Given “capacity” for improvement, the degree of 
improvement will likely depend on interventions in the follow-up interval, and thus the 
M100 latency measure is suggested as a prognostic/predictive biomarker for future 
intervention studies. Previous (cross-sectional) studies examining the association of 
M100 latencies and general language ability are inconsistent (Oram Cardy et al. 2008; 
Roberts et al. 2010; Roberts et al. 2013), perhaps due to the prevalence (as well as 
variety) of language impairments in ASD or the language measure taken concurrently to 
the M100 measurement. Of note, the M100 latency delay in children appears to be 
specific to ASD, at least in comparison to children with specific language impairment 
(SLI) (Roberts et al. 2012).  
 A few study limitations are of note. First, a potential confound is the gender bias 
(more females in the control group). In a separate analysis, previously collected and 
published datasets were investigated for gender effects for M100 latency and gamma-
band evoked power and ITC (Roberts et al. 2010; J Christopher Edgar et al. 2015). The 
main effect of Gender was not significant for any analysis. Gender therefore likely does 
not confound present findings.  
 A second limitation is that children were only scanned twice (two to five year 
inter-scan interval). To determine if the findings here extend to other developmental 
periods (i.e. before or after the age range sampled here), multiple time points are 
required. Longer follow-up periods would also provide resolution of statistical tendencies 
in maturation rates that did not reach significance in the present study. Multiple 
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timepoints and an extended study age-range would also permit the consideration of non-
linear dependencies of observed variables on age. 
 Finally, given the small sample, statistical analyses could not be performed on the 
“has ASD” cohort. In these children, M100 latency and gamma-band findings were 
qualitatively observed to be in-between TD and the remaining ASD group, suggesting 
that these auditory neural measures may serve as prognostic biomarkers. These findings 
are only suggestive though, and a larger cohort is needed to confirm and establish the 
precision/sensitivity of the above observations. As noted in the Introduction, the 
endogenous, environmental or therapeutic factors that contribute to clinical change are 
currently generally unknown. The literature on “optimal outcomes”, however, does 
indicate that in children who exhibit “optimal outcome” subtle impairments are still 
observed (Orinstein et al. 2015), a finding supported in the present study via the 
observation in “had ASD” of auditory neural measures at follow-up with values between 
TD and ASD. In future studies with larger samples, quantitative assessments of the 
intervention/treatments the children with ASD receive are needed to help identify the 
basis and/or mechanism for improvement. 
 To conclude, the present study demonstrated altered auditory M100 and gamma-
band neural activity in children with ASD. Electrophysiological measures correlated 
with, and predicted subsequent change in behavioral measures. The children with ASD 
who showed clinical improvement appeared to have somewhat more normal 
electrophysiological responses at the first and follow-up exams. As such, present findings 
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may suggest that the auditory neural measures investigated in this study may serve as 
prognostic biomarkers, with further study needed to validate such findings. 
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Tables Legends: 
Table 2.1 Demographics of M100 study population. No significant differences in age (4th 
block from left) or Wechsler Intelligence Scale for Children-IV General Ability Index 
(WISC-IV GAI) (5th block from left) were observed between TD (top), and ASD 
(middle). Children with ASD exhibited significantly higher Social Responsiveness 
Scale (SRS) and Autism Diagnostic Observation Schedule Calibrated Severity Scores 
(ADOS CSS) at both initial and follow-up exams (1st and 2nd block from the right). 
Wechsler Intelligence Scale for Children-IV Verbal Comprehension Index (WISC-IV 
VCI) scores were significantly lower in children with ASD (middle right) at initial 
exam. ASD children also demonstrated significantly lower scores on the Clinical 
Evaluation of Language Fundamentals – fourth edition (CELF-4 Core Language 
Index). A subgroup of children who had an initial diagnosis of ASD no longer met 
diagnosis criteria at the follow-up exam (“had ASD” (bottom)). These children 
exhibited SRS and ADOS CSS scores similar to children with ASD at the initial 
exam, and then intermediate corresponding scores at follow-up. These children had 
similar age and GAI to children with ASD, though intermediate WISC-IV VCI 
scores. Values are counts or mean (standard deviation). 
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Table 2.2 Demographics of gamma-band study population. Identical to the M100 study 
population: No significant differences in age (4th  block from left) or Wechsler 
Intelligence Scale for Children-IV General Ability Index (WISC-IV GAI) (5th block 
from left) were observed between TD (top) , and ASD (middle). Children with ASD 
exhibited significantly higher Social Responsiveness Scale (SRS) and Autism 
Diagnostic Observation Schedule Calibrated Severity Scores (ADOS CSS) at both 
initial and follow-up exams (1st and 2nd block from the right). Wechsler Intelligence 
Scale for Children-IV Verbal Comprehension Index  (WISC-IV VCI) scores were 
significantly lower in children with ASD (middle right) at initial exam. ASD children 
also demonstrated significantly lower scores on the Clinical Evaluation of Language 
Fundamentals – fourth edition (CELF-4) Core Language Index. A subgroup of 
children who had an initial diagnosis of ASD no longer met diagnosis criteria at the 
follow-up exam (“had ASD” (bottom)). These children exhibited SRS and ADOS 
CSS scores similar to children with ASD at the initial exam, and then intermediate 
corresponding scores at follow-up. These children had similar age and GAI to 
children with ASD, though intermediate Wechsler Intelligence Scale for Children-IV 
Verbal Comprehension Index WISC-IV VCI scores. Values are counts or mean 
(standard deviation). 
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Supplemental Table  2.1 Medications and supplements. Subjects, listed by Diagnosis 
(Dx) and subject number, and showing medications and supplements at initial exam 
(2nd column) and follow-up exam (right column). General health medications are in 
blue, while medications for comorbid psychiatric disorders are in black. 
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Supplemental Table 2.2 Correlation between behavioral measures. Bivariate Pearson’s 
correlations between the four behavioral measures used in this study. Social 
Responsiveness Scale (SRS); Wechsler Intelligence Scale for Children-IV General 
Ability Index  (WISCV-IV GAI); Clinical Evaluation of Language Fundamentals – 
fourth edition (CELF-4) Language Core Index; Wechsler Intelligence Scale for 
Children-IV Verbal Comprehension Index  (WISC-IV VCI). * p <0.05, ** p <0.01 
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Figure Legends: 
Figure 2.1 Gamma-band activity analyses. (A) Head models were generated from each 
subject’s structural MRIs and centered at the average head position. Trials where any 
fiducial moved in any direction >10mm from this average position were rejected (B) 
After normalizing individual MRIs to an age-matched template, Heschl’s Gyrus was 
non-linear reverse source interpolated. (C) A LCMV beamformer (with only 
ipsilateral sensors included) at subject space Heschl’s Gyrus was used to generate 
virtual electrode time courses  (D) Left and right STG time courses were used to 
obtain time frequency measures (evoked, total power, ITC) using in-house scripts. 
Arrow points to gamma-band activity response. 
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Figure 2.2 M100 latencies predict diagnosis. (A) T-tests showed that children with ASD 
versus TD had prolonged left and right-hemisphere M100 latencies at the initial 
exam. (B) At the follow-up exam, children with ASD again showed prolonged M100 
latencies. The “had ASD” exhibited non-significant intermediate M100 latencies at 
both timepoints. (C) No group differences between TD and ASD were present for 
maturation rates. Intermediate M100 latency maturation (as compared to TD and 
ASD) rates are exhibited by the “had ASD” cohort. Although analyses were 
conducted for only ASD and TD, mean and SE values are also shown for “the had” 
ASD group. # p <0.10, * p <0.05 
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Figure 2.3 Children with ASD exhibit reduced gamma-band evoked power. (A) Group 
average evoked power plots for TD children  (left) at initial exam (upper, A) and 
follow-up exam (lower, C) show the auditory gamma-band post-stimulus response. At 
both time points, children with ASD (right) showed reduced gamma-band responses 
(initial exam– upper, B; follow-up exam – lower, D). Dashed box show gamma-band 
ROI used. 
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Figure 2.4 Children with ASD exhibit reduced gamma-band evoked power and inter-trial 
coherence. Evoked power (top row) responses were reduced in children with ASD at 
both initial (A) and follow-up exam (B). The “had ASD” group exhibited 
qualitatively intermediate responses at both timepoints. Maturation of the evoked 
gamma-band response (upper C) was reduced four-fold in ASD versus TD. ITC 
(bottom row) demonstrated a similar pattern, though not significant at initial exam. # 
p < 0.10,  * p <0.05 
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Figure 2.5 M100 latencies and SRS scores. Effective right-hemisphere M100 latencies 
(removing effect of condition) were associated with social responsiveness scores 
across the study population. *** p < 0.001 
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Supplemental Table 2. 1 
  Medications 
Dx #  Original Visit  Follow-up Visit 
TD 1 None  Naltrexone 
TD 2 None  None  
TD 3 None  None 
TD 4 None None 
TD 5 None None 
TD 6 None None  
TD 7 None   None 
TD 8 None None 
TD 9 None None  
ASD 1 None  None  
ASD 2 None  None 
ASD 3 
Ritalin, Daytrana,  
Risperidone, Vistaril, 
Melatonin 
Ritalin, Daytrana, Celexa, Catapres, 
Risperidone, 
ASD 4 None None 
ASD 5 None None  
ASD 6 
Adderall, Trileptal, Abilify, 
Paxil CR, Desmopressin Lamictal, Xanax, Zyprexa 
ASD 7 None  None  
ASD 8 None  None 
ASD 9 None  Abilify 
ASD 10 None Vyvanse  
ASD 11 None  None 
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ASD 12 Vyvanse Vyvanse  
ASD 13 Strattera Strattera, Zoloft 
ASD 14 
Metadate, Claritin, Vitamin 
B12 injections 
Metadate, Ritalin, Claritin, Vitamin 
B12 injections  
ASD 15 Vitamins Melatonin  
ASD 16 Intuniv  Metadate, Abilify 
ASD 17 Ritalin, Melatonin  
Ritalin, Melatonin, Fish Oil, 
Vitamins 
ASD 18 Focalin Focalin  
ASD 19 Vyvanse  Strattera, Fluoxetine  
ASD 20 Flovent Flovent, Albuterol 
ASD 21 None  None  
ASD 22 Vitamins Vitamins 
“had 
ASD” 1 None Fluoxetine  
“had 
ASD” 2 None Intuniv  
“had 
ASD” 3 None  None  
“had 
ASD” 4 None  Concerta, Nasonex (seasonal) 
“had 
ASD” 5 None None  
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Supplemental Table 2. 2 
 
 SRS 
WISC-IV 
GAI 
CELF-4 
CLI 
WISC-IV 
VCI 
SRS  Pearson 
Correlation 
1 -.223 -.300* -.291* 
Sig. (2-tailed)  .081 .016 .020 
N 64 62 64 64 
WISC-IV 
GAI 
Pearson 
Correlation 
-.223 1 .733** .894** 
Sig. (2-tailed) .081  .000 .000 
N 62 64 64 64 
CELF-4 
CLI 
Pearson 
Correlation 
-.300* .733** 1 .304* 
Sig. (2-tailed) .016 .000  .012 
N 64 64 67 67 
WISC-IV 
VCI 
Pearson 
Correlation 
-.291* .894** .304* 1 
Sig. (2-tailed) .020 .000 .012  
N 64 64 67 67 
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Figures: 
Figure 2. 1 
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Figure 2. 2 
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Figure 2. 3
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Figure 2. 4
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Figure 2. 5 
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Abstract: 
 Autism spectrum disorder (ASD) is hypothesized to arise from imbalances 
between excitatory and inhibitory neurotransmission (E/I imbalance). Recent studies have 
demonstrated E/I imbalance in both individuals with ASD as well as in corresponding 
rodent models. One process thought to be reliant on E/I balance is gamma-band activity 
(Gamma), with support arising from observed correlations between motor, as well as 
visual, Gamma and underlying GABA concentrations in healthy adults. In accordance 
with these correlations, perturbed Gamma has also been observed in ASD individuals and 
in relevant animal models, though the relationship between Gamma and related GABA 
concentrations in ASD remains unexplored. This study combined 
magnetoencephalography (MEG) and edited magnetic resonance spectroscopy (MRS) in 
17 typically developing individuals (TD) and 31 individuals with ASD. Auditory cortex 
localized phase-locked Gamma was compared to resting Superior Temporal Gyrus 
relative cortical GABA concentrations. Replicating previous studies both gamma-band 
inter-trial coherence (ITC) and GABA+/Cr were decreased in ASD versus TD. For all 
subjects independent of diagnosis, Gamma metrics (coherence/power) were significantly 
correlated to relative cortical GABA concentrations. For TD ITC and to a lesser extent 
evoked power were correlated to relative GABA concentrations. Individuals with ASD 
demonstrated a non-significant trend between gamma-band ITC and relative GABA 
concentrations, and no correlation between evoked power and GABA concentrations. 
Additionally, linear regression slopes were not significantly different between groups for 
ITC-based coupling. This suggests that a “functional to neurochemical coupling” or 
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“GABA efficiency” metric may provide early indication for treatment stratification with 
regards to interventions that recover E/I balance. 
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1. Introduction: 
Autism spectrum disorder (ASD) is a neurodevelopmental disorders characterized 
by pervasive invasive social/communication impairments and restricted/repetitive 
behaviors (American Psychiatric Association, 2013). Current prevalence estimates 
suggest that 1 in 68 children is diagnosed with ASD (Developmental Disabilities 
Monitoring Network Surveillance Year 2010 Principal Investigators & Centers for 
Disease Control and Prevention (CDC), 2014). For over a decade an imbalance in neural 
excitation/inhibition (E/I imbalance) has been explored as a pathogenic mechanism of 
ASD (Rubenstein & Merzenich, 2003), with support coming from both clinical in-vivo 
imaging (Brown, Singel, Hepburn, & Rojas, 2013; Gaetz et al., 2014; Harada et al., 2011; 
Rojas, Singel, Steinmetz, Hepburn, & Brown, 2014) and post-mortem (Casanova et al., 
2006; Fatemi, Folsom, Reutiman, & Thuras, 2009; Fatemi, Reutiman, Folsom, & Thuras, 
2009; Fatemi et al., 2002; Zikopoulos & Barbas, 2013) studies. Furthermore, such E/I 
imbalance phenotypes have been recapitulated in animal models that recreate key aspects 
of ASD (Calfa, Li, Rutherford, & Pozzo-Miller, 2015; M J Gandal, Anderson, et al., 
2012; Gogolla et al., 2009; Liao, Gandal, Ehrlichman, Siegel, & Carlson, 2012; Lin, 
Gean, Wang, Chan, & Chen, 2013; Saunders, Gandal, Roberts, & Siegel, 2012). 
 Recently E/I imbalance has been investigated in ASD via the use of magnetic 
resonance spectroscopy (MRS), a technique that allows in-vivo measurement of resting 
neurochemical concentrations.  Such experiments have observed alterations to both 
relative cortical inhibitory (γ-Aminobutyric acid (GABA)) as well as excitatory 
(glutamate) neurotransmitters in individuals with ASD (for review see (Rojas, Becker, & 
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Wilson, 2015)). While these studies have found ASD-related alterations to in vivo 
concentrations, these findings should be carefully considered because the direct link by 
which these group level differences explain phenotypic (i.e., clinical/behavioral) 
symptoms is far from conclusive. 
 Excitatory and inhibitory neurotransmitters are thought to form the basis for 
neural communication in the brain. Numerous studies suggest that the gamma-band 
response (30-80 Hz) is critically dependent on E/I signaling (Cardin et al., 2009; Sohal, 
Zhang, Yizhar, & Deisseroth, 2009; Whittington, Traub, Kopell, Ermentrout, & Buhl, 
2000; Yizhar et al., 2011), and known to be important for basic sensory (e.g. visual 
system and auditory system) functions (Başar-Eroglu, Strüber, Schürmann, Stadler, & 
Başar, 1996; Gray, König, Engel, & Singer, 1989) as well as higher order cognitive 
processes (Herrmann, Fründ, & Lenz, 2010). The gamma-band response is also clearly 
perturbed in multiple systems (i.e. visual, auditory and rest) in ASD (Grice et al., 2001; 
Orekhova et al., 2007; Wilson, Rojas, Reite, Teale, & Rogers, 2007). Furthermore this 
neurophysiological ASD-related phenotype is conserved in animal models that recreate 
key aspects of ASD, while not reliant on the nature of the specific insult (i.e. 
environmental insult versus genetic insult) (M J Gandal, Anderson, et al., 2012; Michael 
J Gandal et al., 2010; Saunders et al., 2012). 
 Although in-vivo relative cortical GABA has been shown to be decreased in ASD 
(Gaetz et al., 2014; Harada et al., 2011; Rojas et al., 2014), further replication is 
warranted. Furthermore, whereas gamma-band neurophysiological correlates of GABA 
concentrations have been observed in the visual and motor system of healthy adults 
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(Gaetz, Edgar, Wang, & Roberts, 2011; Muthukumaraswamy, Edden, Jones, 
Swettenham, & Singh, 2009), there has been some controversy (Cousijn et al., 2014). A 
recent EEG study in adults showed a positive correlation between GABA level and 
gamma-band power (Balz et al., 2015). However, no such correlation has been observed 
in the auditory system for either typically developing (TD) individuals or individuals with 
ASD. 
As such this study tests the following three hypotheses; 1) Replicating previous 
studies, relative GABA concentrations in Superior Temporal Gyrus (STG) (Gaetz et al., 
2014; Rojas et al., 2014), as well as phase-locked gamma-band responses (Edgar et al., 
2015; Michael J Gandal et al., 2010; Rojas, Maharajh, Teale, & Rogers, 2008; Wilson et 
al., 2007) will be decreased in ASD. 2) In line with previous studies involving 
multimodal sensory integration (Balz et al., 2015) in-vivo relative cortical GABA 
concentrations will positively correlate to phase-locked gamma-band activity in the 
auditory system for TD individuals. 3) Since previous studies suggest decreases in both 
relative cortical GABA levels as well as phase-locked gamma-band activity (see above), 
individuals with ASD will also exhibit a direct linear relationship between relative 
cortical GABA concentrations and phase-locked gamma-band activity. 
These hypothesized relationships between relative cortical GABA levels and 
gamma-band dysfunction are novel and have yet to be demonstrated explicitly within the 
same subjects. As such, the following three competing, but not mutually exclusive, 
outcomes may occur.  1) altered E/I balance and gamma-band dysfunction are not 
correlated in an overall ASD population, or are at least not resolvable due to separate sub-
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populations of ASD individuals, some of whom demonstrate GABA+/gamma-band 
activity correlation, and some of whom do not;  2) altered E/I balance (GABA+) and 
gamma-band dysfunction are present in ASD, yet with altered coupling (regression slope) 
as compared to typically developing individuals, or 3) altered E/I balance and gamma-
band dysfunction exist in ASD with the same regression slope as in TD, and though the 
coupling is similar, both measures are concomitantly decreased. 
This study aims to determine the extent to which in-vivo relative GABA 
concentration (via spectrally edited Magnetic Resonance Spectroscopy (MRS)) predicts 
gamma-band activity (recorded by magnetoencephalography (MEG)) in both typically 
developing participants and especially in participants with ASD. If the neurochemical-
neurophysiological relationship is conserved in ASD, such observations provide key 
interpretational value for diminished gamma-band activity as a “biomarker” (a 
biologically based marker) of ASD (Rojas & Wilson, 2014), with anomalous GABA 
levels providing the etiological basis for this coupling. Moreover this observation would 
suggest a possible mechanism of treatment: restoring E/I balance may recover neuronal 
functioning. This is especially relevant because several GABA-related pharmacological 
interventions have recently been tested for, and are emerging for, treatment of ASD 
(Berry-Kravis et al., 2012; Erickson et al., 2014; Lemonnier et al., 2012). In addition, 
these interventions have been shown effective in murine models of ASD to effectively 
normalize behavioral phenotypes (e.g. enhance sociability) (Silverman et al., 2015; Tyzio 
et al., 2014) and restore neural functioning (M J Gandal, Sisti, et al., 2012; Tyzio et al., 
2014) .   
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2. Materials and Methods: 
2.1 Participants 
Sixty-two participants (21 TD, 41 ASD), ranging from 6 to 29 years old (mean 
age = 16.3±6.1 (mean ± standard deviation)), were recruited into the current study and 
completed both MEG and MRS scans. While the age range of the recruited population 
was comparatively large, such a range allowed for the opportunity to detect possible age-
specific alterations both within and across diagnostic groups (i.e. developmental 
trajectories). In addition such a large age range ensured that resultant observations were 
indeed a persistent phenotype across ages, and not an epiphenomenon of study 
recruitment criteria. Final study population demographics are summarized in Table 1, and 
additional sample characteristics are shown in Supplemental Table 1. Of these 
participants, 24 participants’ MEG data had previously been reported for gamma-band 
alterations, with these studies demonstrating decreased phase-locked gamma-band 
activity in ASD versus TD (Edgar et al., 2015; Port et al., 2016). These studies examined 
neither GABA alterations, nor the relation between GABA and gamma-band activity 
measures. One TD subject was prescribed medication (though non-psychotropic). 
Fourteen individuals with ASD were prescribed medications/took dietary supplements. 
Table 2 provides medication information.  Tailored recruitment and evaluation strategies 
were used for children vs. adult participants: 
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2.2 Child and Adolescent Recruitment and Inclusion/Exclusion Criteria 
 Following procedures described in Edgar et al. 2015, subjects with ASD were 
recruited from the Regional Autism Center of The Children’s Hospital of Philadelphia 
(CHOP), from the Neuropsychiatry program of the Department of Psychiatry of the 
University of Pennsylvania School of Medicine, from local and regional parent support 
groups such as ASCEND (Asperger Syndrome Information Alliance for Southeastern 
Pennsylvania)  and local chapters of Autism Society of America. All children screened 
for inclusion in the ASD sample had a prior ASD diagnosis made by an expert clinician, 
typically a developmental pediatrician in the Regional Autism Center at the Children’s 
Hospital of Philadelphia. The original diagnosis was made after an extensive clinical 
interview, documentation of DSM-IV criteria for ASD, and use of various ASD 
diagnostic tools, such as the Childhood Autism Rating Scale and, in many cases, the 
Autism Diagnostic Observation Schedule (ADOS;  Lord et al. 2000). Subjects with 
typical development (TD) were recruited through local newspaper advertisements and 
from pediatric practices of the CHOP primary care network.   
 Research participants made two visits to CHOP. During the first visit (2–3 weeks 
prior to the MEG exam), clinical and diagnostic testing was performed to confirm the 
referral ASD diagnosis, to administer neuropsychological tests, and to ensure that the TD 
children met study inclusion/exclusion criteria. Assessments were performed by licensed 
child psychologists with expertise in autism (L.B., E.S.K.). Given the extensive clinical 
evaluations upon which original ASD diagnosis was made, an abbreviated diagnostic 
battery was used to confirm the original diagnosis. Specifically, the ASD diagnosis was 
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confirmed with standard diagnostic tools, including direct observation with the ADOS 
and parent report on the Social Communication Questionnaire (SCQ; Rutter et al. 2003). 
Dimensional symptom severity ratings were also obtained by parent report on the Social 
Responsiveness Scale (SRS; Constantino & Gruber 2012). The Autism Diagnostic 
Interview-Revised (ADI-R), a parent interview about current and prior ASD symptoms, 
was utilized to resolve diagnostic discordances between the ADOS and parent rating 
scales in the rare instances in which such discordances occurred. For final inclusion in the 
ASD group, children were required to exceed established cut-offs on both the ADOS and 
SCQ, or, in the event of a discordance between those measures, on both the ADOS and 
ADI-R. Children 1 point below ADOS cut-offs were included if they exceeded cut-offs 
on at least two parent questionnaires or the ADI-R. For children for whom original 
diagnosis was not made by an expert clinician according to DSM criteria (e.g., diagnoses 
made by a school), more rigorous standards were applied, and the child was required to 
exceed cut-offs on both the ADOS and ADI-R for inclusion in the ASD group. A subset 
of children included in this sample were part of a three-year longitudinal study.  This 
subset of children met all described inclusion criteria at the time of their original study 
participation.  At three-year follow-up, they continued to be included in the ASD group if 
they exceeded diagnostic cut-offs on the ADOS; parent rating scale corroboration was not 
required. Only 1 of these participants provided imaging data at both their initial and 
longitudinal follow-up visit.  To rule out global cognitive delay, all subjects were 
required to score at or above the 2nd percentile (SS>70) on the Perceptual Reasoning 
Index (PRI) of the Wechsler Intelligence Scale for Children-IV (WISC-IV; Wechsler 
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2003). In all subjects, the WISC-IV Verbal Comprehension Index (VCI) was also 
obtained. 
 Inclusion criteria for the TD children included scoring below the cut-off for ASD 
on all domains of the ADOS as well on parent questionnaires, and demonstrating 
performance above the 16th percentile on the Clinical Evaluation of Language 
Fundamentals—4th edition (CELF-4; Semel & Wiig 2003). In addition to the above 
inclusion/exclusion criteria, all subjects and families were native English speakers and 
had no known genetic syndromes or neurological (e.g., cerebral palsy, epilepsy), or 
sensory (hearing, visual) impairments. The study was approved by the CHOP 
Institutional Review Board and all participants’ families gave written informed consent. 
As indicated by institutional policy, where competent to do so, children over the age of 
seven additionally gave verbal assent. 
 
2.3 Adult Recruitment and Inclusion/Exclusion Criteria 
 This sample included 23 young adults between the ages of 18 and 29.  Adult 
participants with ASD (N=13; 20.8±2.2 years old (mean age ± standard deviation)) were 
recruited from the Adult Autism Spectrum Program in the Department of Psychiatry at 
the Hospital of the University of Pennsylvania, as well as from cohorts of participants 
participating in prior MEG studies by the current investigators and prior studies at the 
Center for Autism Research at the Children’s Hospital of Philadelphia.   TD participants 
(N=10, 25.0±3.3 years old (mean age ± standard deviation)) were recruited through local 
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newspaper advertisements and from participation in prior studies. Diagnostic procedures 
were similar to those described for the child cohort but were modified to meet the 
constraints of an adult sample.  All adults were required to have a prior diagnosis of 
ASD, made by an expert clinician according to DSM criteria. At the time of study 
participation, they had to exceed established cut-offs on the ADOS-2 as well as either the 
SCQ (Lifetime) or SRS-2 Adult-Informant Report (Constantino & Gruber, 2012).   
Individuals for whom informant report was not available were included in the ASD group 
if they had a documented prior diagnosis of ASD and exceeded established cut-offs on 
the ADOS-2 as well as on both the SRS-2 Adult-Self Report and Broad Autism 
Phenotype Questionnaire (BAPQ; Hurley et al. 2007). Individuals 1 point below 
diagnostic cut-offs on the ADOS-2 were included if they exceeded cut-offs on two 
informant report questionnaires or on the ADI-R.  To rule out global cognitive delay, all 
subjects were required to score at or above the 2nd percentile (SS>70) on the Perceptual 
Reasoning Index (PRI) of the Wechsler Abbreviated Intelligence Scale-II (WASI-II; 
Wechsler 2011) For all subjects, the WASI-II Verbal Comprehension Index (VCI) was 
also obtained. 
Inclusion criteria for the TD adults included scoring below the cut-off for ASD on 
all domains of the ADOS-2 and below cut-offs on informant and self-report 
questionnaires, along with performance above the 16th percentile on the CELF-4 (if 
within age-range for this measure (Semel & Wiig, 2003)), WASI-II Verbal 
Comprehension Index, and average of the Peabody Picture Vocabulary Test-4 (PPVT-4; 
Dunn & Dunn 2007) and Expressive Vocabulary Test-2 (EVT-2; Williams 2007).  TD 
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adults also had no history of current psychiatric illness, as documented during initial 
screening and by subsequent self and informant ratings on the Adult Behavior Checklist 
(ABCL; Achenbach & Rescorla 2003), and they were taking no psychotropic 
medications.  As with the child sample, all adult participants were native English 
speakers, had no known genetic syndromes or neurological (e.g., cerebral palsy, 
epilepsy), or sensory (hearing, visual) impairments, and had a negative drug and alcohol 
screen administered prior to both study visits.   
 
Electrophysiological Data Collection 
Magnetoencephalography data were obtained using a 275-channel system (VSM 
MedTech Inc., Coquitlam, BC) in a magnetically shielded room. Prior to data acquisition, 
three head-position indicator coils were attached to the subject’s scalp at the nasion, left 
and right-preauricular points, which provided continuous measurement of head position 
in relation to the MEG sensors. To minimize fatigue, during the task participants viewed 
(but did not listen to) a movie projected onto a screen positioned at a comfortable 
viewing distance.  
Electrodes were attached to the left and right clavicles for electrocardiogram 
(ECG) recordings and to the bipolar oblique (upper and lower left sites) for 
electrooculogram recordings (EOG). A band-pass filter (0.03–300 Hz) was applied to the 
EOG, ECG, and MEG signals, and signals were digitized at 1200 Hz with third order 
gradiometer environmental noise reduction applied to the MEG data.  
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2.4 Electrophysiological Data Collection 
Magnetoencephalography data were obtained using a 275-channel system (VSM 
MedTech Inc., Coquitlam, BC) in a magnetically shielded room. Prior to data acquisition, 
three head-position indicator coils were attached to the subject’s scalp at the nasion, left 
and right-preauricular points, which provided continuous measurement of head position 
in relation to the MEG sensors. To minimize fatigue, during the task participants viewed 
(but did not listen to) a movie projected onto a screen positioned at a comfortable 
viewing distance.  
Electrodes were attached to the left and right clavicles for electrocardiogram 
(ECG) recordings and to the bipolar oblique (upper and lower left sites) for 
electrooculogram recordings (EOG). A band-pass filter (0.03–300 Hz) was applied to the 
EOG, ECG, and MEG signals, and signals were digitized at 1200 Hz with third order 
gradiometer environmental noise reduction applied to the MEG data.  
 
2.5 Stimuli 
 Stimuli consisted of 200, 300 500 and 1000 Hz sinusoidal tones presented using 
Eprime v1.1 (Psychology Software Tools Inc., Pittsburgh, USA). Tones were presented 
via a sound pressure transducer and sound conduction tubing to the participant’s 
peripheral auditory canal via ear-tip inserts (ER3A, Etymotic Research, IL, USA). Prior 
to data acquisition, 1000 Hz tones (300 ms duration, 10 ms rise time) were presented 
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binaurally and incrementally until reaching auditory threshold for each ear. Stimulus 
tones were presented at 45 dB sensation level above threshold. Each trial consisted of 
participants passively listened to binaurally presented random 200, 300, 500 & 1000 Hz 
sinusoidal tones (130 tones/frequency; 300 ms duration; 10 ms ramps) plus a 1000 ms 
(±100ms) inter-trial interval.  In total, this experimental protocol took approximately 12 
minutes.    
 
2.6 Structural MRI and MRS methods  
After MEG, structural MRI and MRS data were acquired on a 3T Siemens 
Verio™ scanner using a 32-channel receive only head RF coil. First an axial orientated 
3D MP-RAGE anatomic scan was obtained for each subject (field of view = 256 × 256 × 
192 mm and matrix = 256 × 256 × 192 to yield 1 mm isotropic voxel resolution (TR/TE 
= 1900/2.87 ms; inversion time = 1100 ms; flip angle = 9°)). Then the MEGA-PRESS 
spectral editing sequence (Mescher, Merkle, Kirsch, Garwood, & Gruetter, 1998), with 
TE = 68 ms, TR = 1500 ms and 128 pairs of interleaved spectra (acquisition time ~7 
minutes) was utilized to obtain single voxel (4 cm x 3 cm x 2 cm) GABA MRS. Pilot 
observations and recent published studies (Gaetz et al., 2014) indicated that this approach 
provided a reasonable compromise between SNR vs. exposure to degradation over 
acquisition time due to motion and potential static field drift. The MRS voxel was first 
aligned to the left mid-temporal lobe with the long aspect (4 cm) of the cuboid positioned 
such that the top of the voxel contained the Superior Temporal Gyrus. Medial–lateral 
adjustments were then made to abut (but not include) the left lateral ventricle. 
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2.7 MRS analysis and quantification 
GABA measurements using the conventional MEGA-PRESS sequence are known 
to contain some contribution from co-edited macromolecules. Thus, our “GABA plus” 
macromolecule measurements are reported using the conventional GABA+ notation. A 5 
Hz Lorentzian line-broadening filter was applied prior to jMRUI fitting. Then for the un-
edited runs, Hankel Lanczos Singular Value Decomposition (HLSVD) was used to 
quantify creatine (Cr) and N-acetylaspartate (NAA), with the amplitude of each 
component being recorded. HLSVD fits used up to 15 components to minimize residual 
signal in the 1-4ppm region. For the subtraction-edited spectra, GABA+ was modeled 
using an identical technique (up to 15 components, one component modeling the entire 
GABA+ signal at 3ppm, with no other component overlapping the GABA component 
region).   
 
2.8 Tissue Segmentation and Quantification 
 To account for possible confounding effects of tissue composition on any MRS 
result, all subjects had the tissue composition (i.e. gray matter, white matter, and cerebral 
spinal fluid) of their MRS voxel calculated, using the subject’s MP-RAGE. The 
automated tissue segmentation tool, FAST (Zhang et al., 2001) was utilized to yield three 
partial volume images, each describing the fraction of tissue type present in the imaging 
voxels. The relative contribution of each tissue fraction to the MRS voxels were then 
95	
computed by summing their respective number of imaging voxels located within the 
prescribed MRS voxel. Tissue composition fraction was included as a covariate, or 
additional regressor in analyses (see below). 
 
2.9 Gamma-band Data Analysis  
Gamma-band responses were analyzed using the MatLab (Mathworks, Natick, 
MA) open-source toolbox Fieldtrip (Oostenveld, Fries, Maris, & Schoffelen, 2011), using 
identical procedures as (Port et al., 2016). Using the continuous data and using the 
procedures outlined in Fieldtrip (FieldtripWiki, 2015a, 2015b), independent component 
analysis (ICA) identified heartbeat and eye artifacts (blinks and saccades), and then these 
artifact components were removed from the stimulus-epoched data (+/- 500 ms around 
trigger). Trials with jump and muscle artifact were then rejected using Fieldtrip’s Z-score 
based artifact rejection method. Lastly, to account for differences in head motion during 
the MEG scan, if any fiducial moved more than 10mm from the average head position 
during a trial, the trial was rejected. For each group, over 93% (483 trials) of trials 
remained (TD = 96±0.3%, ASD = 94±0.7%; p < 0.01), far exceeding the required amount 
of trials to give a stable response. Thus slight group differences were considered 
mitigated. 
Subject-specific single-shell head models were created from individual 
participant’s MP-RAGE MRI scans. To coregister MEG and sMRI data, three anatomical 
landmarks (nasion and right and left preauricular) as well as an additional 200+ points on 
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the scalp and face were digitized for each participant using the Probe Position 
Identification (PPI) System (Polhemus, Colchester, VT), and a transformation matrix that 
involved rotation/translation between the MEG and sMRI coordinate systems was 
obtained via a least-squares match of the PPI points to the surface of the scalp and face. 
This head model was then fitted to the mean head position (in MEG coordinate space) as 
determined by the fiducials. Separately, the participant’s MRI was normalized to an age-
matched average brain template (children - (Fonov et al., 2011); adults - ICBM152 
average brain) using non-linear warping. A left and right Heschl’s Gyrus location was 
identified and then reverse non-linear transformed to subject space.  
A linearly-constrained minimum variance (LCMV) beamformer was computed for each 
participant’s left and right Heschl’s Gyrus, discarding the contralateral hemisphere’s 
sensors to reduce inter-hemispheric signal cancelation due to correlated activity 
(Herdman et al., 2003). Heschl’s Gyrus virtual electrodes (VE) were then computed using 
an orientation optimized for post-stimulus gamma-band activity (i.e. orientation 
calculated by using principal component analysis on the 0-270ms post-stimulus window 
with filtering 30-58Hz). Broadband resultant VE time courses were then time-frequency 
transformed (Morlet Wavelets; 3 – 100 Hz; cycles ranging from 3 (low) to 6 (high); both 
with 100 linearly spaced bins). For each participant, baseline corrected evoked power 
(relative change) and inter-trial coherence (ITC) were calculated. Fieldtrip’s permutation 
testing was then utilized to choose a spectrotemporal ROI for which to quantify gamma-
band activity (Monte-Carlo permutation test with cluster correction for multiple 
comparison correction). The post-stimulus region containing the gamma-band response 
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(0 to 200 ms) was compared to the pre-stimulus (-300 to -100 ms) for all participants, and 
the regions of statistical difference calculated between the two. This resultant statistical 
map (Figure 1) was used to mask individual subject’s time-frequency plots (with only 
regions that were both p < 0.05 and above 30 Hz included), for which then the average 
evoked-power and ITC was calculated on a subject-wise basis. 
 
2.10 Statistical analyses 
 To assess significance for group differences ANOVAs were utilized. For 
GABA+/Cr analyses, covariates of Gray Matter contribution and Age were applied to 
GABA+/Cr measures, with the fixed effects of Diagnosis, Age and Gray Matter (co-
varied for age). For gamma-band measures (evoked power and ITC), ANOVAs with a 
fixed effect of Diagnosis were applied. 
 To determine if gray matter contributed differences to GABA+/Cr difference, a 
hierarchical linear regression was utilized, with Diagnosis and Age entered into the first 
block, and then Gray Matter in the second. Linear regression analyses were also 
performed for each gamma-band metrics and its relation to relative GABA+ 
concentrations. These relative cortical GABA+ to gamma-band activity regressions were 
performed for both diagnoses separately, and after collapsing across diagnosis. 
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3. Results: 
3.1 Demographics 
 Sixty-two participants were recruited into the study and completed both MEG and 
MRS experiments. Of these, 15 participants were removed due to poor MEG/MRS scan 
quality (4 - TD, 10 - ASD). As such, forty-eight participants remained in the final data 
analyses (17 TD, 31 ASD), of whom 6 were females (5 TD, 1 ASD). A Chi-squared test 
demonstrated that groups did not differ on gender (p > 0.05). In addition groups did not 
significantly differ on age (TD = 19.31±1.82 years old, ASD = 15.57±0.88 years old, 
mean ± SEM, p > 0.05). Note there is a non-significant tendency for elevated age in the 
TD group. See Table 1 as well as Supplemental Table 1 for more information. Similar 
effects are observed if the TD sample is selectively subjected to a-posteriori decimation 
to reduce TD average age (at the expense of sample count). 
 
3.2 ASD participants demonstrate reduced phase-locked activity 
 Gamma-band responses were visible at the diagnostic group level for both TD and 
ASD cohorts (Figure 1A & 1B). A significant main effect of Diagnosis, F(1,46) = 4.25, p 
< 0.05,  demonstrated gamma-band coherence (ITC) was significantly decreased in 
participants with ASD as compared to TD (TD = 0.071±0.004 ITC, ASD = 0.060±0.003 
ITC, mean ± SEM, Figure 2B). A similar, though non-significant, main effect of 
Diagnosis (F(1,46) = 2.53, p = 0.119)  demonstrated decreased gamma-band evoked 
power in ASD versus TD (TD = 2.89±0.58 relative change from baseline, ASD = 
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1.75±0.43 relative change from baseline, mean ± SEM, Figure 2C). Thus, gamma-band 
ITC was observed to be more sensitive to group differences than gamma-band evoked 
power, largely attributable to its lower measurement variance.  
 
3.3 ASD participants demonstrate decreased GABA+ 
 A main effect of Age, F(1,44) = 4.94, p < 0.05, revealed a decrease of GABA+/Cr 
with maturation (standardize beta coefficient from hierarchical regression = -0.32) . In 
addition, a significant main effect of Diagnosis was observed, F(1,44) = 4.85, p < 0.05, 
demonstrating that ASD group exhibited less relative cortical GABA concentrations than 
the TD group (TD = 0.311±0.011 GABA+/Cr, ASD = 0.280±0.008 GABA+/Cr, mean ± 
SEM, Figure 2A). Notably, a significant main effect of voxel Gray Matter Fraction was 
not observed, F(1,44) = 1.14, p > 0.1) between groups, and furthermore Gray Matter 
Fraction did not account for significant variance above that accounted for by Age and 
Diagnosis (R2 change = 0.021, p > 0.10). 
 
3.4 The relation of relative cortical GABA to phase-locked gamma-band activity is less 
apparent in ASD 
 Across the study population, gamma-band ITC was significant correlated with 
relative cortical GABA+ (R2 = 0.188, p < 0.01; Figure 3). This relationship was also 
significant in the TD group (R2 = 0.238, p < 0.05; Figure 3), though only trended towards 
significance for the ASD cohort (R2 = 0.089, p = 0.110; Figure 3). An ANCOVA 
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(dependent variable = gamma-band ITC, fixed effects = Diagnosis, GABA+/Cr and their 
interaction, covariate = GABA+/Cr), demonstrated no significant differences in the 
slopes of the regression between TD and ASD (Diagnosis X GABA+/Cr interaction, p > 
0.1). 
 The GABA+ coupling to gamma-band evoked power was weaker than for ITC in 
all groups. Relative cortical GABA significantly correlated to stimulus evoked gamma-
band power across the study population (R2 = 0.108, p<0.05, Figure 4). Within diagnostic 
groups (TD and ASD) though, this relationship was trending towards significance in TD, 
and not significant in ASD (TD R2 = 0.173, p < 0.1.0; ASD R2 = 0.021 p > 0.1; Figure 4).  
An ANCOVA (same structure as used for ITC) demonstrated no difference in the slope 
of the regression lines (Diagnosis X GABA+/Cr interaction, p > 0.1). 
  
101	
4. Discussion: 
  The brain is thought to communicate using excitatory and inhibitory 
neurotransmission, and numerous studies have suggested that in particular the brain’s 
gamma-band response is critically reliant on such E/I balance (Cardin et al., 2009; Sohal 
et al., 2009; Whittington et al., 2000; Yizhar et al., 2011). This gamma-band activity is 
thought be involved with numerous brain functions ranging from basic sensory (e.g. 
visual system and auditory system) (Başar-Eroglu et al., 1996; Gray et al., 1989) 
functions to higher order cognitive processes (Herrmann et al., 2010). Of relevance to this 
study the gamma-band response has been repeatedly observed to be perturbed in ASD 
(Grice et al., 2001; Orekhova et al., 2007; Wilson et al., 2007). Supporting the notion of 
gamma-band activity being reliant on E/I balance, several independent studies have 
demonstrated decreased in-vivo relative cortical GABA in ASD (Gaetz et al., 2014; 
Harada et al., 2011; Rojas et al., 2014). Moreover, gamma-band neurophysiological 
activity has been shown to correlate to corresponding GABA concentrations in both the 
visual and motor system of healthy adults (Gaetz et al., 2011; Muthukumaraswamy et al., 
2009), though this is not fully resolved (Cousijn et al., 2014). In addition, Balz and 
colleagues (2015) recently observed a correlation between gamma-band power and 
GABA levels for visual-audio sensory integration in the human brain. However, the 
analogous correlation had yet to be observed for the auditory system for either typically 
developing (TD) children or individuals with ASD. 
This study examined both the gamma-band response to simple auditory tones as 
well as also the corresponding STG GABA levels in individuals with ASD and age 
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matched TD controls.  The ASD cohort demonstrated both reduced relative GABA+ 
concentration and gamma-band ITC deficits compared to TD.  Across diagnoses, a 
significant correlation was observed between the concentrations of relative cortical 
GABA and gamma-band coherence. However, this association only reached statistical 
significance in the TD group, though trended towards significance in individuals with 
ASD. In addition, statistical testing of the slopes of the two linear regressions showed no 
significant effect of diagnostic group.  
 The lack of a significant correlation of gamma-band activity to GABA+ in ASD 
could be interpreted in at least 3 ways: 1) the correlation is not resolvable because it is 
confounded by inter-subject biological differences in the heterogeneous ASD population, 
which manifests as increased measurement variance, precluding statistical resolution, 2) 
the ASD population in fact consists of two (or more) stratified sub-populations, some of 
whom demonstrate a gamma-band coherence to GABA+/Cr correlation and some of 
whom do not, 3) the relationship between gamma-band coherence and GABA+/Cr 
observed in typically developing individuals and interpreted as reflecting intact neuronal 
local circuitry is simply disrupted in ASD and may reflect an impairment in the function 
of that local circuitry.  
In agreement with previous studies, both gamma-band ITC (Edgar et al., 2015; 
Michael J Gandal et al., 2010; Rojas et al., 2008) and relative cortical GABA (Gaetz et 
al., 2014; Rojas et al., 2014)  were significantly reduced in ASD, as compared to TD. 
However, auditory gamma-band evoked power deficits in ASD (as compared to TD) 
failed to reach significance. Of note, this lack of significance does not negate the three 
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aforementioned hypotheses, as this lack of finding of significance may likely arise from 
the elevated variance associated with the ASD population. While the differential 
significance (ITC significant, evoked power not significant) for the group differences in 
phase-locked gamma-band activity metrics is contrary to previous studies (Edgar et al., 
2015; Rojas et al., 2008), non-significant trends in reduced ASD evoked power have also 
been reported previously (Michael J Gandal et al., 2010). This non-significant decrease in 
evoked power may be due to the use of a larger age range in the current study or other 
undetermined population effects. In addition, previous studies have averaged over 
hemispheres to increase signal to noise (Michael J Gandal et al., 2010; Port et al., 2016), 
whereas the current study only reported the left hemisphere responses to compare directly 
with in-vivo left auditory cortex MRS GABA. 
 While relative cortical GABA is significantly reduced in ASD as compared to TD 
in support of previous findings (Gaetz et al., 2014; Rojas et al., 2014), the relative 
consequence of such a specific GABA deficiency is also unknown. Additionally, a 
limitation of this study (and several previous studies) is the relative inaccessibility of a 
simultaneous measure of the neurotransmitter glutamate. This arises partly from technical 
resolution challenges (often leading to a proxy measure of Glx, comprising both 
glutamate and glutamine (Rojas et al., 2015)) but more importantly from the existence of 
glutamate in the brain in both a neurotransmission and metabolic role. Glutamate is 
known to be involved in both synaptic transmission and metabolic processing, shuttling 
between neurons and astrocytes as part of the Glutamate – Glutamine cycle (for review 
see Hertz 2013). Of note though, a recent study that specifically examined glutamate 
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concentrations in ASD (without glutamine) demonstrated that glutamate is increased 
(Brown et al., 2013), also consistent with increased excitation to inhibition ratio in ASD.  
 GABA, with its function as the main inhibitory neurotransmitter, also has a role in 
the TCA cycle. The exact role of GABA is hypothesized to be dependent on the isoform 
of glutamate decarboxylase (GAD) that produced the molecule  (GAD65 = 
neurotransmission, GAD67 = GABA shunt) (Martin & Rimvall, 1993). This clear 
separation of GAD65/67 derived GABA in neurotransmission has been called into 
question though (Soghomonian & Martin, 1998). Nevertheless, current MRS methods are 
not able to resolve the metabolite versus neurotransmitter pools of either glutamate or 
GABA, because the voxel size required to achieve adequate signal in reasonable time 
encompasses all neuronal compartments (e.g. synaptic, white matter & somatic 
compartments) and in addition glial cells. This concern should temper interpretations. 
Nonetheless establishing any association between GABA and gamma-band activity 
would support the hypothesis of gamma-band activity representing a proxy index of the 
relevant neurotransmitter functioning GABA. 
The present data support the hypothesis that decreases in relative cortical GABA+ 
is of functional consequence. Consistent with previous studies, a significant relationship 
of relative cortical GABA to gamma-band activity was determined in TD controls (Balz 
et al., 2015; Gaetz et al., 2011; Muthukumaraswamy et al., 2009). As such, these and 
previous findings, support the hypothesis that relative cortical GABA concentrations 
derived from MRS may relate to the E/I balance within TD participants. Furthermore, in 
a disorder marked by alterations to the neural excitatory and inhibitory systems (see 
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introduction), this coupling of MRS-derived GABA and MEG-derived gamma-band 
activity seems to be perturbed. Of note, this is the first study report such an association 
for the auditory system, and also the first to demonstrate the association between GABA 
and gamma-band coherence. In addition, this is only the second to observe this 
relationship for gamma-band power. Lastly, this is also the first study to examine the 
relationship in individuals with ASD.   
Both across the study population, and for TD controls, ITC was significantly 
related to relative cortical GABA concentration. For individuals with ASD this 
association was trending towards significance (p = 0.110), possibly limited by ASD 
heterogeneity. The correlation of evoked power (as opposed to ITC) to relative GABA+ 
was less prominent. Indeed, TD demonstrated only trending significance for the coupling 
of evoked power to relative GABA+, and ASD demonstrated no relationship. This 
weaker coupling of relative GABA+ to evoked power may arise from the constituents of 
the evoked power signal. An oscillation has three core characteristics, phase, frequency 
and amplitude. Evoked power consists of both phase and amplitude information, whereas 
ITC is solely based on phase. As such, this stronger coupling for ITC (to GABA) may be 
a result of small alterations in relative cortical GABA concentrations affecting the 
synchrony/reliability of oscillatory activity (i.e. exact timing of neuronal firing across 
trials) more than the amount of neurons firing across trials. If so, then when relative 
cortical GABA is reduced both ITC and evoked-power would be reduced in turn, though 
the ITC signal’s reduction would be more prominent due to the evoked power signal still 
having the same amplitude (amount of neurons firing) though reduced phase. 
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Evoked power responses demonstrated considerable increased variance as 
compared to ITC in the present study. The sources of such variance cannot be determined 
as either biologically based or relating to methodological procedures (i.e. less effective 
measuring of the evoked power signal). It may be that ITC is more reliable since it is only 
sensitive to phase, as opposed to phase and amplitude. Such a case could occur when the 
underlying neurons contributing to the responses fire at the same phase (from trial to 
trial), though the amount (which affects the amplitude of the oscillatory activity) of 
neurons firing alters between trials. 
Interestingly, relative to TD, the ASD group showed uniformly weaker coupling 
(lower R2) between gamma-band activity and relative cortical GABA. However, 
ANCOVAs demonstrated no significant differences (p > 0.10) between diagnostic groups 
for the coupling (i.e. slope of the regression). These ANCOVA findings are difficult to 
interpret due to the lack of a significant association for evoked power in ASD. As such, 
further (and ideally with larger populations) studies are needed to determine if this 
weaker, though similar, coupling is due to the increase variance associated with ASD.  
Additionally, the coherence to GABA coupling may only occur within a sub-population 
of ASD.  Thus, the current findings may ultimately yield a class of stratification 
biomarkers markers for ASD treatment. For example, when considering a metric based 
on relative cortical GABA and gamma-band coherence (Figure 5), an individual ASD 
score that falls within range of the corresponding TD derived relationship (i.e. within the 
95% confidence interval of age-matched controls; Figure 3) may be aided by therapies 
that increase GABAergic signaling. In such a situation, both the GABA+/Cr and gamma-
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band coherence are concomitantly decreased, and so “rescuing” GABAergic activity may 
recover gamma-band activity. The clinical trials of arbaclofen (Berry-Kravis et al., 2012), 
and other GABA-related treatments have not been effective in a broad study population, 
but identifying such a sub-population might allow such clinical trial populations to be 
enriched. As such, speculation lends support to the hypothesis that GABAergic 
treatments may be efficacious in a sub-population of those with ASD. What remains 
unknown is the neuroelectrophysiological characteristics (i.e. gamma-band activity 
profile) of both responders and non-responders in these clinical trials. While highly 
speculative, it may be the case that for those who improve clinically in response to 
GABAergic modulation, gamma-band activity may also be normalized. Such an 
observation would allow gamma-band activity to be used a treatment marker, reflecting 
at least drug sensitivity (target engagement). It still remains to be established if 
diminished gamma-band activity is causal for the behavioral alterations in ASD, or a 
closely linked proxy for relevant neural bases. Further studies are needed to confirm both 
the use of these measures as biomarkers appropriate for stratification for treatment, and 
their causal relationship to behavioral symptomatology.  
Alternatively, Figure 5 may also be interpreted as measure of “GABAergic 
efficiency”. While in a typically developing population GABA has a certain efficiency at 
creating gamma-band activity, in ASD the efficiency is reduced in most cases. Hence 
such an interpretation places a key causal link between GABA and gamma-band activity. 
In cases those with low “GABAergic efficiency” supplementing GABA, or it relative 
action, might again be expected to aid in the normalization of electrophysiological 
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activity (e.g. gamma-band activity), although perhaps less efficiently. Although highly 
related, there are subtle differences between a coupling (“functional to neurochemical 
coupling”) and efficiency (“GABAergic efficiency”) arguments (e.g. causality, and 
whether the underlying relationship is intact). Both hypotheses though promote the use of 
GABA-related interventions in individuals with ASD who demonstrate coupling between 
gamma-band activity and GABA+/Cr levels.  
While a significant relationship between gamma-band coherence and relative 
cortical GABA was observed when collapsing across diagnostic group, these measures 
are not redundant. For both gamma-band evoked power and ITC, relative cortical GABA 
explained around 10-20 % of the variance. As such, there was still significant variance 
unaccounted for. Previous work has demonstrated the efficacy of combining both 
functional and structural data when available for creating quantifiable markers of ASD 
(Ingalhalikar, Parker, Bloy, Roberts, & Verma, 2014). It maybe that a multi-modal 
biomarker that includes both information from gamma-band activity and relative cortical 
GABA, as well as other factors (e.g. M100 latency, DTI measures of thalamocortical 
microstructure) will prove to be optimal.  
The current study focused solely on the auditory system, however previous 
findings have demonstrated relative cortical GABA to be differentially altered depending 
on which cortical/subcortical structure was examined (Gaetz et al., 2014; Harada et al., 
2011). What remains undetermined is if the relationship between underlying 
neurochemistry and oscillatory activity remains and is of the same magnitude in other 
brain systems. 
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 To conclude, this study observed correlations between MEG measures of 
gamma-band oscillatory activity and regionally co-localized estimates of GABA 
concentrations within the auditory system in TD individuals. However, for individuals 
with ASD weaker coupling between relative cortical GABA+ and gamma-band 
coherence was observed. Further work is needed to test the hypothesis that a “functional 
to neurochemical coupling” metric may be of use for the stratification of the 
heterogeneous ASD population into treatment/clinical trial enrichment cohorts based on 
the underlying biological pathology.  
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Table Legends: 
Table 3.1 Demographics of study population. No significant difference exists in age 
between TD and ASD individuals. A chi-squared test revealed no significant effect of 
gender distribution between groups (p>0.3). Values are counts or mean (standard 
deviation). 
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Table 3.2 Medications and supplements taken by participants. Subjects listed by 
Diagnosis (Dx) with corresponding supplements/medications. 
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Supplemental Table 3.1 Age characteristics of study population. TD (top) versus ASD 
(bottom) counts for age ranges of study participants. Participants younger than 18 are 
shown in the middle column, and those 18 and over are shown in the right column.  
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Figure Legends: 
Figure 3.1 Both TD and ASD individuals demonstrated robust and quantifiable results. 
Group average evoked power (A) and ITC (B) in response to auditory stimuli 
demonstrate quantifiable results for both TD (left) and ASD (right). Individuals with 
ASD exhibit less phase-locked gamma-band activity in response to the auditory 
stimuli. Outline is the permutation test derived region of significant post-stimulus 
gamma-band activity (C ) Exemplar MRS spectra for TD (left) and ASD (right) show 
clear and defined GABA+ peaks (gray bar overlay). 
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Figure 3.2 Individuals with ASD exhibit less gamma-band coherence and relative 
cortical GABA in auditory cortex. (A) Relative cortical GABA+ in auditory cortex is 
reduced in ASD (red) as compared to TD (blue). (B) A significant decrease in 
gamma-band coherence in response to auditory stimuli is observed for ASD 
compared to TD (C) A similar, though only qualitative decrease is observed for 
gamma-band evoked power in ASD as compared to TD. * p=<0.05.  
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Figure 3.3 Auditory gamma-band coherence and relative cortical GABA in auditory 
cortex are associated across the study population, and within TD (though suggested 
for ASD as well). The linear regression of TD (blue) and all individuals pooled 
(black) together is significant, and positively correlated. Blue boundary lines are the 
95% confident interval of the TD mean. ASD (red) trend towards a similar 
relationship. Slopes of the TD and ASD linear fits are not significantly different 
(p>0.1).  # p = 0.11; * p < 0.05; ** p < 0.01 
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Figure 3.4 Auditory gamma-band evoked power and relative cortical GABA in auditory 
cortex are associated across the study population. The study population (black) 
exhibits a positive relationship between relative cortical GABA and gamma-band 
coherence. A trend towards a similar relationship is seen in TD (blue). ASD (red) 
demonstrate no coupling. Blue boundary lines are the 95% confident interval of the 
TD mean.  #  p < 0.10; * p < 0.05 
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Figure 3.5 Functional to neurochemical coupling may serve as a potential biomarker for 
ASD sub-population stratification. TD (blue) and ASD (red) relative functional 
(evoked power = left; ITC = right) to neurochemical (relative cortical GABA+) 
coupling may allow for identification of those individuals amenable to GABA-related 
interventions to increase gamma-band activity. Error bars are the 95% confident 
interval. 
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Tables: 
Table 3. 1 
  N Female Age 
Control 17 5 19.31 (7.51) 
ASD 31 1 15.57 (4.88) 
p >0.3 >0.05 
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Table 3. 2 
DX # Medications 
ASD 1 Abilify 
ASD 2 Buproion HCL, Concerta ER, Clonidine HCL 
ASD 3 Concerta, Metadate, Focalin 
ASD 4 Concerta, Doxycycline hyclate 
ASD 5 Flovent, Albuterol 
ASD 6 Focalin  
ASD 7 Focalin,  Prozac,  Melatonin  
ASD 8 Lamictal, Xanax, Zyprexa 
ASD 9 Metadate, Abilify 
ASD 10 Metadate, Claritin, Vitamin B12 injections, Ritalin 
ASD 11 None 
ASD 12 None 
ASD 13 None 
ASD 14 None 
ASD 15 None 
ASD 16 None 
ASD 17 None 
ASD 18 None 
ASD 19 None 
ASD 20 None 
ASD 21 None  
ASD 22 None  
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ASD 23 None  
ASD 24 Strattera, Fluoxetine  
ASD 25 Tenex, Focalin, Strattera, Abilify 
ASD 26 Zoloft 
ASD 27 None 
ASD 28 Intuniv 
ASD 29 Concerta, Wellbutrin 
ASD 30 None 
ASD 31 Zoloft 
TD 1 None  
TD 2 None  
TD 3 None  
TD 4 None  
TD 5 None  
TD 6 None  
TD 7 None  
TD 8 None  
TD 9 None  
TD 10 None  
TD 11 None  
TD 12 None  
TD 13 None  
TD 14 None  
TD 15 None  
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TD 16 None  
TD 17 Omeprazole, Ketoconazole (topical cream) 
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Supplemental Table 3. 1 
 
Count 
  >18 18 and over 
TD 7 10 
ASD 18 13 
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Figures: 
Figure 3. 1 
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Figure 3. 2 
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Figure 3. 3 
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Figure 3. 4 
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Figure 3. 5 
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CHAPTER 4 
In-vivo electrophysiological and ex-vivo neurochemical characterization 
of Pcdh10+/- mice 
 
Russell G. Porta, Christopher Gawjewskia, Elizabeth Krizmanb,c, Michael B. 
Robinsonb,c,d, Gregory C. Carlsona, Steven J. Siegela 
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Abstract: 	 Autism Spectrum Disorder currently affects 1 in 45 children, causing 
characteristic social/communication impairments as well as restricted and repetitive 
behaviors. Recent studies have linked a subset of familial ASD to mutations in the 
Protocadherin 10 (Pcdh10) gene. Subsequently mice heterozygous for Pcdh10 (Pcdh10+/) 
have began to be investigated in an effort to understand the neurobiology of ASD. 
Pcdh10+/- mice demonstrate face validity by exhibiting specific alterations to social 
behavior, and moreover, such social deficits are sex-specific (affecting only male mice). 
As such this mouse model recapitulates the gender bias observed in ASD. Furthermore, 
these male Pcdh10+/- mice demonstrate precise alterations to high frequency responses in 
in-vitro slice preparations. The in-vivo ramifications of such decreased high frequency 
responses observed in-vitro are unknown. Therefore, to further characterize the effect of 
PCDH10 loss, Pcdh10+/- mice and their wild-type littermates underwent in-vivo depth 
electroencephalography (EEG) as well as ex-vivo amino acid concentration 
quantification using High Performance Liquid Chromatography (HPLC).  Male Pcdh10+/- 
mice demonstrated select reductions to gamma-band (30-100 Hz), but not lower 
frequency, auditory steady state responses versus their wild-type littermates. In addition, 
the signal to noise ratio for high gamma-band (60-100 Hz) activity was decreased in male 
Pcdh10+/- mice versus their wild-type counterparts, concurrent to low gamma-band (30-
60 Hz) resting-state power increases. Pcdh10+/- mice also demonstrated increases in 
multiple amino acids including GABA. Of note, whilst WT mice demonstrated coupling 
between underlying GABA concentrations and auditory gamma-band activity, Pcdh10+/- 
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mice did not. As such, this study provides crucial insight into the hypothesis of E/I 
imbalance in ASD and its functional consequences. 
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1. Introduction: 
 Autism Spectrum Disorder (ASD) is characterized by marked impairments to 
social/communication functioning, and the appearance of restricted/stereotyped behaviors 
(American Psychiatric Association, 2013). Recent estimates suggest that 1 in 45 children 
between the ages of 3 and 17 are diagnosed with ASD, with three quarters of these being 
male (Zablotsky et al., 2015). Many biological alterations have been identified in ASD, 
including those affecting neuronal synapses (for review see Port et al., 2014). One such 
set of alterations involves the cell adhesion molecules encoded by the 
cadherin/Protocadherin superfamily of genes (Kim et al., 2011; Morrow et al., 2008; 
O’Roak et al., 2012), including Protocadherin 10 (Pcdh10) (Bucan et al., 2009; Morrow 
et al., 2008).  
 PCDH10 has been linked directly to cell migration (Nakao et al., 2008) and 
indirectly to spinogenesis (Pilpel and Segal, 2005). As such, the protein seems to have an 
important role in neuronal circuit formation. Moreover, PCDH10 is involved in synapse 
elimination through linking ubiquitinated PSD-95 to the proteasome (Tsai et al., 2012). 
Of note, Tsai and colleagues (2012) also demonstrated that Pcdh10 translation is 
suppressed by Fragile X mental retardation protein (FMRP). This is of particular 
relevance because transcriptional silencing of the Fmr1 gene that encodes FMRP causes 
Fragile X Syndrome, a syndromic form of ASD (O’Donnell and Warren, 2002). 
Recently, male mice heterozygous for Pcdh10 (Pcdh10+/-) were shown to demonstrate 
perturbed behavioral (reduced sociability) and neuroanatomical (abnormal dendritic spine 
density and morphology) phenotypes (Schoch et al., 2016). Of particular note, the 
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reduced sociability was not demonstrated in female Pcdh10+/- mice, perhaps consistent 
with the gender bias of ASD (see above). As such, this murine model recapitulates several 
key aspects of ASD. Furthermore, these male Pcdh10+/- mice also demonstrated specific 
alterations to in-vitro amygdala electrophysiological responses for high-frequency, but 
not single, stimulation (Schoch et al., 2016). The purpose of such high-frequency 
stimulation within in-vitro preparations is to induce high-frequency activity, in an effort 
to mimic the analogous activity seen within in-vivo systems (Contreras and Llinas, 2001). 
Such higher frequency activity (in particular gamma-band activity) is thought to play key 
roles in local circuit functions (Cardin et al., 2009; Sohal et al., 2009) and is correlated to 
many cognitive/behavioral functions (for review see Herrmann et al., 2010). 
 Deficits in gamma-band (30-100 Hz) electrophysiological activity have been 
hypothesized as a biomarker for ASD (Rojas and Wilson, 2014). Gamma-band activity 
alterations have been repeatedly observed in ASD (Grice et al., 2001; Maxwell et al., 
2013; Orekhova et al., 2007; Wilson et al., 2007). In addition, gamma-band perturbations 
in ASD correlate to social functioning (Maxwell et al., 2013) and show normalization 
with clinically effective behavioral intervention (Van Hecke et al., 2013). Alterations to 
gamma-band activity are also observed in first degree relatives of individuals with ASD, 
and as such may constitute an endophenotype (Rojas et al., 2008). Moreover, within these 
first degree relatives gamma-band activity is associated with sociability (Rojas et al., 
2011). Such perturbations to gamma-band activity appear to represent a conserved 
phenotype in multiple murine models recapitulating key aspects of ASD, regardless of 
the nature of the specific insult (Gandal et al., 2012a, 2010; Saunders et al., 2012). 
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Furthermore, the normalization of in-vivo preclinical gamma-band activity is concurrent 
with behavioral improvements (Gandal et al., 2012b; Yizhar et al., 2011). Of note, 
gamma-band alterations seen in such murine models are correlated with underlying 
neurobiology such as specific cell densities (Nakamura et al., 2015) as well as synaptic 
protein levels (Gandal et al., 2010).  
 An additional potential clinical biomarker for ASD is auditory M100 latency 
prolongations (for review see (Port et al., 2015)). Using magnetoencephalography (MEG) 
Gage and colleagues (Gage et al., 2003) first identified a ~10 ms delay in children with 
ASD for the neuromagnetic response that occurs ~100 ms post auditory stimuli (M100). 
Since this initial description, subsequent larger studies have recapitulated this M100 
delay and also demonstrated that such findings cannot be accounted for by cognitive or 
language abilities (Edgar et al., 2015, 2014; Roberts et al., 2010).  Analogous delays to 
middle latency responses (e.g. the electroencephalographic murine counterpart to the 
M100, the N40) have been observed in preclinical models which recapitulate key aspects 
of ASD (Billingslea et al., 2014; Engineer et al., 2015, 2014; Gandal et al., 2012a, 2010; 
Saunders et al., 2013, 2012a). Such latency prolongations are associated with sociability 
in these murine models (Billingslea et al., 2014; Saunders et al., 2013).  
 In fulfillment of their biomarker statuses, both gamma-band activity and auditory 
M100 latencies have plausible biological bases. In both cases perturbed signal 
transduction (synaptic transmission) may cause the observed alterations in ASD (Port et 
al., 2015).  Moreover, γ-Aminobutyric acid (GABA) may play a crucial role for the two 
aforementioned biomarkers of ASD, with excitatory/inhibitory (E/I) imbalance being 
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posited as a potential underlying pathogenic mechanism for ASD (Rubenstein and 
Merzenich, 2003). GABA-related alterations in individuals with ASD are well 
documented both in post-mortem (Casanova et al., 2006; Fatemi et al., 2014, 2009a, 
2009b, 2002) and in-vivo (Gaetz et al., 2014; Harada et al., 2011; Rojas et al., 2014) 
clinical studies. Further support for GABAergic dysfunction in ASD comes from 
preclinical models, where alterations to GABAergic expression (Gandal et al., 2012b; 
Gogolla et al., 2014, 2009; Zhang et al., 2014) or function (Banerjee et al., 2013; Cellot 
and Cherubini, 2014; Han et al., 2012) have frequently been observed. Direct 
measurements of neural GABA concentrations in rodent models recapitulating key 
aspects of ASD and other related disorders are less consistent, with decreases 
(Bitanihirwe et al., 2010; Groves et al., 2013; Ide et al., 2005), increases (Ali and Elgoly, 
2013; Gruss and Braun, 2004, 2001) and no change (Fatemi et al., 2008) in GABA 
concentrations being observed. Such observations are confounded by concurrent and 
inconsistent alterations to glutamate (Ali and Elgoly, 2013; Bitanihirwe et al., 2010; 
Gruss and Braun, 2004, 2001; Ide et al., 2005). Alterations to GABA, glutamate and/or 
their relative concentrations, are further complicated by sex, regional and age 
dependencies (Gruss and Braun, 2004, 2001).  
 As such, several questions remain unresolved: 1) If Pcdh10+/- mice demonstrate 
altered auditory electrophysiological responses akin to clinical ASD (e.g. delayed N40 
latencies and reduced gamma-band activity), 2) If Pcdh10+/- mice demonstrate altered 
underlying E/I balance, 3) how do such electrophysiological and neurochemical profiles 
relate to one another, and 4) what is the role of sex in these aforementioned questions as 
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only male Pcdh10+/- mice display social deficits. As such, Pcdh10+/- (heterozygous for 
Pcdh10) mice underwent electrophysiological characterization. To do so, depth 
electroencephalography (EEG) was recorded in these mice and their wild-type 
littermates. In addition, High Performance Liquid Chromatography (HPLC) was utilized 
to quantify ex-vivo amino acid concentrations in these WT and Pcdh10+/- mice. 
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2. Materials and methods: 
2.1 Animals 
Adult (3 - 4 months of age; males and females) Pcdh10+/- mice and their wild-type (WT) 
littermates were used in this study. Originally created by Lexicon Pharmaceuticals Inc. 
(USA) using a LacZ-neo selection cassette replacement of the first exon of Pcdh10; for 
this study Male Pcdh10+/- mice were crossed with female C57BL/6J mice (see Schoch et 
al., 2016 for additional details). This produced both Pcdh10+/- and WT (Pcdh10+/+) 
littermates for subsequent examination. Mice were group-housed (2-4 per cage) with ad 
libitum food and water access and maintained on a 12-hour light/dark cycle. The final 
sample size for each group (Sex by Genotype) was 11 male WT, 9 female WT, 9 male 
Pcdh10+/-, and 8 female Pcdh10+/-. All experiments were conducted in accordance and 
with approval with the University of Pennsylvania’s Institutional Animal Care and Use 
Committee (IACUC) and the National Institutes of Health guidelines. 
 
2.2 Surgery for EEG recordings 
All mice had intracranial electrodes (tri-polar stainless steel electrodes, 200 µm diameter, 
Plastics One, Roanoke VA) implanted (AP -2.7 mm, ML +4.0 mm, DV -2.8 mm; targeted 
to primary auditory cortex) via stereotactic surgery. Mice were anesthetized with 
isoflurane (with confirmation of sedateness) and their scalps cleaned with betadine. Then 
the skull was exposed (bregma to lambdoid sutures) and electrodes secured in the 
aforementioned coordinates with dental cement. These tri-polar electrodes were low 
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impedance (<5kΩ, 1000 Hz) (Gandal et al., 2010). Similar electrode configurations 
(though targeted to hippocampus) demonstrate the ability to detect auditory brain stem 
responses, as well as later subcortical and cortical responses (P1, N40, P2, P3A) 
(Connolly et al., 2003; Siegel et al., 2003), analogous to human Cz electrode recordings 
(Siegel et al., 2003). In addition, such hippocampal targeted configurations have 
demonstrated face and predictive validity for genetic, developmental and pharmacologic 
manipulations in mice (Gandal et al., 2012a, 2010; Saunders et al., 2012). 
 
2.3 Recording of EEG activity 
All mice received a minimum of one-week recovery following surgery. EEG recordings 
were collected in home cages, which were placed within a Faraday cage. Modified 
(heightened) cage tops were used to accommodate stimulus speakers and electrode 
cables. Electrode cables were connected to a high-impedance differential AC amplifier 
(A-M Systems, Carlsborg, Washington, USA). Mice were acclimatized to the testing 
apparatus for 30 minutes before testing to ensure habituation to the environment. 
Habituation and recordings took place in the presence of 55 dB background white noise. 
During testing stimuli consisted of either 100 white-noise clicks (10 ms duration, 85 dB, 
8 second inter-trial interval) or an amplitude-modulated white-noise stimulus at 20, 40, 
50, 60, and 80 Hz frequencies (100 trials per frequency, 1 second train duration, 85 dB, 1 
second inter-stimulus interval). In addition, the white-noise click paradigm also included 
a 60 second stimulus-free period at the beginning of the paradigm to allow for the 
collection of “resting-state” data. Stimuli were generated by Micro1401 hardware and 
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Spike 6 software (Cambridge Electronic Design, Cambridge, England) and delivered by 
speakers atop each cage. Signals were continuously sampled at 1667 Hz and an online 
bandpass filter (1–500 Hz) was applied to all EEG signals. 
 
2.4 EEG data analysis 
White-noise click paradigm analysis 
EEG signals were analyzed using the Fieldtrip (Oostenveld et al., 2011) toolbox for 
MatLab (Mathworks, Natick, USA). Single trials epochs (± 1 second relative to auditory 
stimulus onset) were extracted from continuous data. Artifact-containing epochs (e.g. 
movement) were then rejected using Fieldtrip’s Z-score based artifact detection routine 
with experimenter input adjusting the threshold for artifact determination. This produced 
between 89 and 93 trials remaining on average per sex by genotype group (e.g. male 
WT). A 2 X 2 ANOVA with the main effects of Sex, Genotype and their interaction 
demonstrated a significant main effect of Genotype, with the Pcdh10+/- group having 
more trials remaining than their WT littermates (WT trials remaining = 89.6 ± 0.8; 
Pcdh10+/- trials remaining = 92.3 ± 0.9, p < 0.05). Even with this difference in remaining 
trials between genotypes (less than 3%), the number of trials remaining was considered 
sufficient for all analyses and unlikely to cause group-wise significant differences. Trials 
were then baseline-corrected (baseline = -400 to -100 ms relative to stimulus onset) and 
subsequently averaged together to produce event related potentials (ERP). Latency and 
amplitude changes in the components of such ERPs are associated with psychiatric 
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disorders (Roberts et al., 2010; Rojas et al., 2007; Turetsky et al., 2007). As such, these 
components were quantified in all mice. The current electrode configuration targeted at 
auditory cortex recorded a multicomponent ERP which demonstrated two noticeable 
negative deflections occurring at ~20 ms and ~40 ms (Figure 4.1A), and are denoted 
throughout as AN20 (AuditoryN20) and AN40 (AuditoryN40). The amplitudes and 
latencies for both of these responses were determined by the time of the deflection peak 
(visual examination by RGP), defined by the negative vertex in the corresponding time 
window (AN20: 8-25 ms; AN40: 30-45 ms). Thus similar to equivalent electrode 
configurations targeted to hippocampus, these components have corresponding latencies 
(though at 40%) to analogous human evoked components (Siegel et al., 2003). 
To further characterize the Pcdh10+/- mice’s auditory electrophysiological responses, 
recordings were spectrally decomposed (Morlet wavelets; 100 linearly spaced frequency 
bins between 3 and 100 Hz; wavelet cycles increasing from 3 (at low frequencies) to 6 (at 
high frequencies)) as previously published (Gandal et al., 2010). Multiple forms of 
spectral activity can be calculated, each of which has a particular sensitivity profile to the 
underlying oscillatory activity. Phase locked metrics (evoked power and inter-trial 
coherence (ITC)) quantify the brain’s ability to align oscillatory activity over multiple 
trials. As such, they are often considered a measure of reliability of the brain’s oscillatory 
activity. Non-phase locked activity, also known as induced power, is oscillatory activity 
in response to a stimuli which is not aligned with respect to phase over trials. The 
combination of both evoked power (phase locked) and induced power (non-phase locked) 
produces total power. 
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Baseline corrected total power (% change from baseline; baseline period = -700  to -150 
ms relative to stimulus onset) and ITC were calculated for all epoched trials. Subsequent 
analyses focused on the ± 500 ms (relative to the stimulus onset) region as previous 
studies have demonstrated alterations in this region (Gandal et al., 2010; Liao et al., 2012; 
Saunders et al., 2012). Based on a-priori observations (see introduction) the gamma-band 
frequency range was selected for further analyses. Both early gamma-band total power 
and ITC responses (as defined by group-average time-frequency plots; Total power: 30-
100 Hz, 0-120 ms post stimulus; ITC: 30-100 Hz, 0-40 ms post stimulus) as well as later 
(150-470 ms post stimulus) gamma-band total power responses were examined. ITC 
responses were not examined for this later response (150-470 ms post stimulus) due to 
the time-frequency plots demonstrating no activity above baseline in this region. The 
later total power responses were separated into high and low gamma-band frequencies 
(high gamma = 60-100 Hz; low gamma = 30-60 Hz) in accordance with previous 
observations (Carlson et al., 2011). For these spectrotemporal regions of interest (ROI) 
the average power and coherence was calculated for each mouse. 
As mentioned above, the white-noise click paradigm also included a 60 second 
stimuli-free period at the beginning of the paradigm to allow for the collection of 
“resting-state” responses. Data during this period was imported into Fieldtrip and the 
power spectral density (PSD) calculated using fast Fourier transformations. This PSD 
data was then divided into specific spectral sub-regions in accordance with previous 
studies (Gandal et al., 2012b). In addition, examination of the group-level (e.g. male WT) 
PSD showed a potential ROI (28-45 Hz) where a differential pattern resting-state power 
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was selectively occurring. Additional analyses focused on this specific frequency range 
since this ROI was not represented by the a-priori regions above. 
Resting-state data was also combined with the white-click stimulus produced ITC 
response (average ITC for 0-40 ms post stimulus onset) to produce signal to noise ratios 
(SNR) for both high (60-100 Hz) and low (30-60 Hz) frequency regions. In each case the 
resting-period frequency range utilized for this analysis was consistent to the ITC 
frequency range. 
In addition the data from this “resting-period” was analyzed for phase-amplitude 
cross-frequency coupling (CFC) using a previously published analysis pipeline (Berman 
et al., 2015). This CFC analysis pipeline has previously revealed specific alterations to 
alpha to gamma (alpha-gamma) CFC in children with ASD (Berman et al., 2015).  These 
CFC alterations may have been detected due to the variable bandwidth filtering utilized 
by this analysis pipeline, which is more sensitive to CFC involving modulation 
frequencies higher than the theta-band (Berman et al., 2012). In brief, resting-period data 
was again imported into fieldtrip and CFC was calculated utilizing the methodology first 
described by Tort and colleagues (Tort et al., 2010). Modulation frequencies ranged from 
3 to 15 Hz and observed (carrier) frequencies ranged from 20 to100 Hz (both ranges 
using 1 Hz bins) for CFC calculations. Previous literature supports the investigation of 
two separate ROIs for this analysis. First, as previously mentioned, Berman and 
colleagues (2015) observed alterations in alpha-gamma coupling in children with ASD. 
Secondly, theta to high-gamma (theta-high gamma) coupling has been demonstrated in 
recordings from subdural neocortical electrocorticograms of patients with epilepsy 
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(Canolty et al., 2006). As such, both alpha-gamma (“phases” = 8 to 11 Hz; “amplitudes” 
= 35 to 55 Hz) and theta-high gamma (“phases” = 3 to 7 Hz; “amplitudes” = 50 to 100 
Hz) were assessed. For each CFC ROI a subject average modulation index (MI) was 
calculated. 
 
Amplitude-modulated stimuli paradigm analyses 
Similar to the white-noise click analyses, single trial epochs (± 1 second relative to onset 
of the stimuli) were imported into Fieldtrip for each frequency condition. Artifact 
containing epochs were identified and rejected using identical procedures to the white-
noise click paradigm analysis. This artifact rejection resulted in Sex by Genotype groups 
containing on average between 88 to 94 trials remaining. A series of 2 X 2 ANOVAs 
tested each frequency condition for the main effects of Sex, Genotype and their 
interaction on the number of trials remaining. No significant effects of Sex, Genotype or 
their interaction were observed. Baseline corrected total power (% change from baseline; 
the same parameters to the white-noise click paradigm) and ITC were calculated using 
identical Morlet wavelet decomposition as for the white-noise click paradigm. Each 
mouse’s auditory steady state response (ASSR) was quantified by taking the average 
value in the post-stimulus steady state response (Stimulus Frequency ± 5 Hz; 200 – 700 
ms post stimulus). 
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2.5 Statistical analysis of in-vivo electrophysiological response metrics 
For all in-vivo electrophysiological measures a series of 2 (Sex) X 2 (Genotype) 
ANOVAs testing the main effects and their interaction as fixed factors were implemented 
(IBM SPSS, Armonk, New York). Moreover, the specific pairwise comparison of males 
(WT versus Pcdh10+/-) was also examined due to previous observations suggesting that 
only male Pcdh10+/- mice demonstrate altered social interaction (Schoch et al., 2016). Of 
note, if the ANOVA violated Levene’s Test of Equality, then a t-test (assuming unequal 
variance if appropriate) tested for significant differences between males. 
 
2.6 Tissue Collection and HPLC analysis of amino acids 
At least one week after final EEG data collection, mice were humanely euthanized via 
isoflurane sedation followed by decapitation. Brains were dissected over ice to collect 
tissue samples for amino acid analyses. Four regions were harvested during the tissue 
collection - cerebellum, right-hemisphere hippocampus (ipsilateral to the recording site), 
and bilateral posterior cortex (guided by the placement of the recording electrode and the 
corresponding area on the contralateral hemisphere). Tissue samples were immediately 
flash frozen using isopentane and dry ice. All dissections were performed quickly (within 
~ 7 minutes of euthanasia). To prepare samples for HPLC analyses, tissue samples were 
homogenized in 0.8 N perchloric acid buffer (containing 1 mM L-alpha-aminoadipate). 
HPLC analyses were performed at the Children’s Hospital of Philadelphia’s Intellectual 
and Developmental Disabilities Research Center (specifically the Analytical 
Neurochemistry Core) to measure concentrations of aspartate, glutamate, GABA, and 
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glutamine as previously published (Kilpatrick et al., 2010). In short, the samples 
underwent reverse-phase HPLC analysis with o-phthaldialdehyde precolumn 
derivatization. A Model 717 plus Autosampler (Waters, Millipore, Milford, MA, USA) 
automatically derivatized samples with o- phthaldialdehyde and injected said processed 
samples onto a reverse-phase C-18 column. Processed samples were eluted using a 
sodium acetate buffer (50 mM, pH 6.0) with either 20 or 80% methanol using a stepped 
linear gradient. Finally a McPherson Model FL-750 fluorescence detector (Acton, MA, 
USA) with a xenon- mercury lamp set at 316 nm excitation detected concentrations of 
each amino acid (Kilpatrick et al., 2010). Of important note, all HPLC runs were blinded. 
For each amino acid the identity was determined by elution time and reported as nmol/mg 
tissue. Results were tested for group differences using a Linear Mixed Effects Model 
(LMM) (Random intercept, Fixed factors = Sex X Genotype X Brain region (repeated 
measure), Repeated Factor = Subject) (IBM SPSS, Armonk, New York) with both main 
effects and their interactions tested. Additionally statistical differences between male WT 
and male Pcdh10+/- were tested separately using the pairwise comparison for the Sex by 
Genotype interaction derived from the LMM as the within male comparison was of a-
priori interest. 
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3. Results: 
3.1 Pcdh10+/- mice demonstrate unaltered ERPs 
White noise clicks produced stereotypical multicomponent responses as shown in Figure 
4.1A. No significant differences were observed for Sex, Genotype or their interaction for 
AN20 or AN40 response latencies (p > 0.1; data not shown). Similarly, the amplitude of 
the AN20 response demonstrated no significant effect of Sex, Genotype, or their 
interaction (p > 0.1; data not shown). A significant main effect of Sex was observed for 
the AN40 response amplitude, demonstrating larger responses in females than males 
(F(1,24) = 4.29, p < 0.05; Figure 4.1B). The main effect of Genotype and its interaction 
with Sex was not significant for AN40 amplitude (p > 0.1). Although significant Sex by 
Genotype interactions were not observed previous findings have suggested that 
alterations in Pcdh10+/- mice are sex specific (Schoch et al., 2016) and so the within male 
pairwise comparison was also examined. For all ERP-related metrics, this comparison 
was non-significant (p > 0.1; data not shown). 
 
3.2 Pcdh10+/- mice demonstrate select gamma-band activity alterations in response to a 
white noise click 
Group-level total power time frequency plots are presented in Figure 4.2A. Early gamma-
band activity in response to white-noise clicks for both total power and ITC were not 
significantly modulated by Sex, Genotype or their interaction (p > 0.1; data not shown). 
Additionally there was no significant effect of Sex, Genotype or their interaction on late 
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high gamma-band total power (p > 0.1; data not shown). A significant main effect of 
Genotype was observed for late low gamma-band total power (F(1,33) = 4.52, p < 0.05; 
Figure 4.2B), demonstrating reduced power in Pcdh10+/- mice versus WT. No significant 
effect of Sex or its interaction with Genotype was observed for this ROI. The pairwise 
comparison of male mice was examined to test for a-priori specified sex-specific 
alterations in Pcdh10+/- mice. No significant differences between male mice existed at 
any ROI (p > 0.1). 
 
3.3 Male Pcdh10+/- demonstrate selective increases to high frequency resting-state power 
The group-level PSD are presented in Figure 4.3A. For all a-priori ROIs a main effect of 
Sex was either significant (15-25 Hz - F(1,33) = 7.63,  p < 0.01, Figure 4.3C; 60-100 Hz - 
F(1,33) = 5.32, p < 0.05, Figure 4.3E) or trending toward significance (4-12 Hz  -F(1,33) 
= 3.53, p < 0.1 Figure 4.3A; 30-60 Hz - F(1,33) =3.27, p < 0.1, Figure 4.3D), with female 
mice demonstrating greater resting power than males. Of note though, Levene’s Test of 
Equality was violated for the 60-100 Hz ROI (p < 0.01) so care should be taken in 
interpretation of significant observations. Examining the a-posteriori ROI revealed that 
Levene’s Test of Equality was again violated (p < 0.05). Additionally for this a-posteriori 
ROI a significant main effect of Sex was observed (F(1,33) = 4.34, p < 0.05, Figure 4.3F) 
with females demonstrating greater resting power than males. The within male pairwise 
comparison was investigated for those ROI that did not violate Levene’s Test of Equality 
since the male comparison was of a-priori interest. No significant differences existed 
between males for the a-priori ROIs (p < 0.1; data not shown). If Levene’s Test of 
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Equality was violated for a ROI a t-test examined the within male comparison (assuming 
unequal variance if appropriate). No significant difference between males was observed 
for the 60-100 Hz ROI (p < 0.1; data not shown). For the a-posteriori ROI (28-45 Hz) a 
significant increase in resting power for male Pcdh10+/- mice versus male WT was 
observed (t(18) = -2.12, p < 0.05). 
 
 
3.4 Male Pcdh10+/- exhibit reduced signal to noise in the high-gamma band 
Gamma-band SNR was examined for both high and low gamma-band regions. For both 
high and low gamma-band SNR no significant main effect (Sex/Genotype) or their 
interaction was observed (p > 0.1; low gamma - data not shown, high gamma – Figure 
4.4). A-priori hypotheses specified the examination of the within male comparisons. 
While no significant difference was observed for the within male comparison of low-
gamma SNR (p > 0.1; data not shown) pairwise comparisons revealed significantly lower 
SNR in male Pcdh10+/- versus male WT mice (F(1,33) = 4.40, p < 0.05, Figure 4.4). 
 
3.5 Male Pcdh10+/- exhibit subtle deficits in theta-high gamma CFC 
Figure 4.5A show group-average comodulograms. Alpha-gamma CFC demonstrated a 
trend towards significance for the main effect of Sex (F(1,33) = 3.10, p < 0.1; data not 
shown), though again such findings should be treated with caution because Levene’s Test 
of Equality was violated (p < 0.01). The main effect of Genotype and its interaction with 
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Sex was not significant for alpha-gamma CFC. For theta-high gamma CFC Levene’s Test 
of Equality was also violated (p < 0.01). Within the theta-high gamma ROI a near 
significant main effect of Genotype was determined ((F1,33) = 2.91, p < 0.10, Figure 
4.5B). No other effects were significant. T-tests were used to examine the within male 
comparison due to this comparison being of a-priori interest as well as to remove the 
potential issues arising from the violation of Levene’s Test of Equality, While alpha-
gamma CFC demonstrated no significant group differences (p > 0.1; data not shown), 
male Pcdh10+/- mice demonstrated a trend towards significantly decreased theta-high 
gamma CFC versus male WT mice (t(10.1) = 1.88, p < 0.1, Figure 4.5B). 
 
3.6 Male Pcdh10+/- show decreased gamma-band, but not lower frequency, ASSRs 
Group-level 40 Hz ASSR are shown in Figure 4.6A. No significant effect of Sex, 
Genotype or their interaction was observed for the 20 Hz total power ASSR (p > 0.10, 
Figure 4.6B). Levine’s Test of Equality was violated for 40 Hz total power ASSR (p < 
0.05). In addition, a significant Sex by Genotype interaction was observed for the total 
power 40 Hz ASSR (F(1,33) = 4.55, p < 0.05, Figure 4.6C), where male Pcdh10+/- mice 
demonstrated significantly reduced ASSR power than male WT mice (p < 0.05), and a 
trends towards significance for male WT exhibiting greater ASSR power than female WT 
(F(1,33) = 4.45, p < 0.1). No significant effect of Sex, Genotype or their interaction was 
observed for the total power 50 Hz ASSR (p > 0.1, Figure 4.6D). Levene’s Test of 
equality was also violated for the 60 Hz ASSR (p < 0.01). The total power 60 Hz ASSR 
demonstrated a significant main effect of Genotype (F(1,33) 38.2, p < 0.01, Figure 4.6E) 
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with Pchd10+/- exhibiting less ASSR power versus WT mice. A significant main effect of 
Sex was observed for the 80 Hz ASSR total power response (F(1,33)=4.43, p < 0.05, 
Figure 4.6F), demonstrating female mice exhibiting less ASSR power than males. Again, 
pairwise comparisons (if Levene’s Test of Equality was not violated) or t-tests (if 
Levene’s Test of Equality was violated) were utilized since a-priori hypotheses specified 
examination of the within male comparison. Pairwise comparisons of male mice for both 
the 50 Hz and 80 Hz total power ASSR revealed that male Pcdh10+/- demonstrated 
significantly or marginally significant (respectively) less ASSR power versus male WT 
(50 Hz ASSR - F(1,33) = 5.31, p < 0.05, Figure 4.6D; 80 Hz ASSR - F(1,33) = 4.02, p = 
0.053, Figure 4.6F). A similar pattern of male Pchd10+/- mice demonstrating significantly 
less ASSR power than their male WT littermates was also observed for 40 Hz and 60 Hz 
ASSRs (40 Hz - t(13.4) = 3.05, p <0.01, Figure 4.6C; 60 Hz - t(11.5) = 11.5, p <0.05, 
Figure 4.6E). 
ITC was also calculated for the ASSRs to further characterize the ASSR of Pcdh10+/- 
mice. No significant main effect of Sex or Genotype was found at any frequency 
stimulation (p > 0.1; data not shown). Levene’s Test was violated for the 40 Hz ITC 
ASSR (p < 0.05). Additionally the 40 Hz ITC ASSR demonstrated a significant Genotype 
by Sex interaction was observed (F(1,33) = 4.29, p < 0.05, Figure 4.6G). A t-test was 
performed to test a-priori hypotheses about sex specificity and to counteract the violation 
of Levene’s Test of Equality. For the 40 Hz ITC ASSR male Pcdh10+/- mice 
demonstrated significantly less ITC than their male WT littermates (t(18) = 2.30, p <0.05, 
Figure 4.6G). 
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3.7 Pcdh10+/- mice demonstrate selective neurometabolite alterations and possible 
reduced coupling between GABA and gamma-band activity 
Group-level amino acid concentrations are shown in Figures 4.7A-D. The LMM for 
aspartate demonstrated a near significant main effect of Genotype, F(1,95.69) = 3.41, p < 
0.1, with Pcdh10+/- tissue containing higher aspartate concentrations than their WT 
littermates (Figure 4.7A). In addition, a main effect of Region was significant, F(3,72.17) 
= 10.68, p < 0.05, with several pairwise comparisons reaching significance. Right 
hemisphere auditory cortex demonstrated significantly lower aspartate concentrations 
than either left hemisphere auditory cortex or cerebellum (pairwise comparison between 
auditory cortices – p < 0.05; pairwise comparison of right hemisphere to cerebellum – p < 
0.001). Furthermore, hippocampus contained significantly lower aspartate concentrations 
than cerebellum (pairwise comparison – p < 0.05). No other main effect or interaction 
was significant (p > 0.1). 
The LMM for glutamate concentrations demonstrated a significant main effect of Region 
(Figure 4.7B), F(3,.69) = 5.68 p < 0.01,  with again right hemisphere auditory cortex 
demonstrating lower glutamate concentrations than either left hemisphere auditory cortex 
or cerebellum (pairwise comparison between auditory cortices – p < 0.01; pairwise 
comparison of right hemisphere to cerebellum – p < 0.01). No other main effect or 
interactions were significant (p  > 0.1). 
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The LMM for GABA concentrations (Figure 4.7C) demonstrated a significant interaction 
of Sex by Region, F(3,77.56) = 3.19, p <0.05, where females exhibited significantly less 
GABA in left hemisphere auditory cortex as compared to cerebellum and hippocampus 
(female pairwise comparison for  left hemisphere auditory cortex versus cerebellum – p 
<0.01; female pairwise comparison for  left hemisphere auditory cortex versus 
hippocampus – p <0.01). In contrast to these female specific observations, male mice 
demonstrated significantly reduced GABA concentrations in both left and right 
hemisphere auditory cortices versus hippocampus, (male pairwise comparison for left 
hemisphere auditory cortex versus hippocampus – p <0.01; male pairwise comparison for 
right hemisphere auditory cortex versus hippocampus – p <0.001), but no significant 
differences between cerebellum and left or right auditory cortex GABA concentrations  
(p > 0.1). The main effect of Genotype was also significant, F(1,100.73 = 16.98, p < 
0.001, with Pcdh10+/- mice demonstrating significantly higher GABA concentrations than 
their WT littermates. In addition, a main effect of Region was also significant, F(3,77.56) 
= 12.52, p <0.001, with both auditory cortices demonstrating significantly reduced 
GABA concentrations versus hippocampus as well as cerebellum (pairwise comparison 
for  left hemisphere auditory cortex versus hippocampus – p <0.001; pairwise comparison 
for  left hemisphere auditory cortex versus cerebellum – p <0.01; pairwise comparison for  
right hemisphere auditory cortex versus hippocampus – p <0.001; pairwise comparison 
for  right hemisphere auditory cortex versus cerebellum – p <0.05). There were no 
significant differences between auditory cortices or between hippocampus and 
cerebellum (p > 0.1). 
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Lastly, the LMM for glutamine concentrations demonstrated a significant main effect of 
Genotype, F(1,107.59) = 4.30, p < 0.05, demonstrating significantly increased glutamine 
concentrations in Pcdh10+/- mice versus their WT littermates. Additionally, a trend 
towards a significant main effect of Region was observed, F(3,72.827) = 2.33, p < 0.1, 
where right hemisphere auditory cortex demonstrated a trend towards significance for 
reduced glutamine (pairwise comparison for  right hemisphere auditory cortex versus 
cerebellum – p = 0.105). 
The corresponding pairwise comparisons (Sex X Genotype) were investigated since the 
within male comparison was of a-priori interest. GABA was significantly increased for 
male Pcdh10+/ mice versus male WT littermates (pairwise comparison – p < 0.05). No 
other within male pairwise comparison for amino acid concentrations was significant. 
Previous clinical studies have demonstrated significant correlations between relative 
cortical GABA and gamma-band activity in humans (Balz et al., 2015; Gaetz et al., 2011; 
Muthukumaraswamy et al., 2009). In support of this coupling, a recent preclinical study 
demonstrated a significant correlation between parvalbumin immunoreactive cell density 
and corresponding gamma-band ITC (Nakamura et al., 2015). As such, it seems that 
coupling between relative cortical GABA and gamma-band metrics may exist both 
clinically and preclinically. Furthermore, Chapter 3 demonstrated that such coupling 
might be perturbed in ASD. As such, the coupling of underlying GABA concentrations to 
gamma-band activity metrics were investigated in the current data. Only 3 gamma-band 
activity metrics were considered to restrict type 1 statistical error,. The early gamma-band 
ITC observed in response to white-noise clicks (30-100 Hz, 0-40 ms; same ROI as used 
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for above EEG analyses) was investigated to be consistent with Chapter 3. In addition, 
the 40 Hz ASSR responses (both total power and ITC) were probed for correlations to 
underlying GABA concentration since activity around 40 Hz is thought to be reliant on 
GABA for its creation (for review see Whittington et al., 2000). Of note, for subsequent 
analyses groups were collapsed across sex since the main effect of Genotype, but not Sex, 
was significant for GABA concentrations, Early ITC in response to white-noise clicks 
was significantly correlated to auditory cortex GABA in WT (R2 = 0.33, p = 0.01), but 
not Pcdh10+/- mice (Figure 4.7E). Additionally a similar, though only trending towards 
significant, association was determined for auditory cortex GABA concentrations and 40 
Hz ASSR ITC for WT mice (R2 = 0 .18, p < 0.10; Figure 4.7F). Such a coupling was not 
observed in Pcdh10+/- mice (p > 0.1). On the other hand, total power 40 Hz ASSRs failed 
to correlate to right-hemisphere auditory cortex GABA concentrations for either WT or 
Pcdh10+/- mice (p > 0.1). 
Of note, activity from adjacent brain regions may be superimposed on auditory cortex 
activity because the electrodes used in this study were low impedance. In the mouse brain 
the hippocampus lies next to auditory cortex, and volume conduction of the hippocampal 
responses may contaminate cortical recording (Harvey et al., 2012). Therefore, 
hippocampal gamma-band activity probably accounts for part of the variance of the 
recorded electrophysiological signals. As such, white noise click-produced early gamma-
band ITC and 40 Hz ASSRs were also compared to hippocampal GABA concentrations. 
White noise click-produced early gamma-band ITC did not correlate with hippocampal 
GABA in either WT or Pcdh10+/- mice (p > 0.1). On the other hand, 40 Hz total power 
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ASSRs demonstrated near significant coupling to hippocampal GABA (R2 = 0.20, p = 
0.055) in WT mice, which was in direct contrast their Pcdh10+/- counterparts who 
demonstrated no coupling (p > 0.1; Figure 4.7G). 
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4. Discussion: 
The main findings of this study were gamma-band selective alterations to 
electrophysiological activity and altered GABA concentrations in Pcdh10+/- versus WT 
littermates (Figures 4.2-7). This was in direct comparison to the lack of alterations to 
either amplitudes or latencies of ERP components (Figure 4.1). Furthermore, WT mice 
demonstrated a coupling between GABA and the gamma-band activity measure that 
Pcdh10+/- failed to recapitulate (Figure 4.7). 
The present study demonstrated significantly reduced late transient low-gamma band 
activity in Pcdh10+/- mice (Figure 4.2). Moreover, male Pcdh10+/- mice exhibited 
significantly reduced power in gamma-band, but not lower frequency, ASSRs (Figure 
4.6). Male Pcdh10+/- mice additionally demonstrated significantly reduced high gamma-
band SNR (Figure 4.4), which was concurrent to a lack of a significant difference in 
corresponding resting-state power comparison (Figure 4.3). Further examination of 
resting-state PSD demonstrated a frequency region where male Pcdh10+/- mice 
demonstrated significantly increased high frequency (28-45 Hz) resting-state power as 
compared to male WT.  Such gamma-band observations were in clear distinction to the 
lack of any significant alterations to any ERP based metric. 
While gamma-band activity alterations are frequently observed in ASD (Rojas and 
Wilson, 2014), such alterations are not unique to ASD as similar alterations are seen in 
bipolar disorder (Maharajh et al., 2007) and schizophrenia (Leicht et al., 2010). The 
reduced late low gamma-band activity exhibited by Pcdh10+/- mice (Figure 4.2) is in 
direct contrast to the recent observations of increased late high gamma-band activity in a 
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murine model that recreates a key genetic insult of schizophrenia (Carlson et al., 2011). 
While such a discrepancy may be due to the particular murine model studied and so as 
such not generalizable, it may be that this differential response profile could 
separate/classify according to diagnosis (e.g. schizophrenia versus ASD). If so, this 
would resolve the specificity of gamma-band deficits, and could prompt further 
investigation of the biological differences between ASD and schizophrenia that produce 
such differential biomarkers. 
High gamma-band SNR was also reduced in male Pcdh10+/- mice versus male WT 
littermates (Figure 4.4). No such difference existed in the low-gamma band range. While 
previous preclinical studies have demonstrated reduced SNR in ASD and related 
disorders (Billingslea et al., 2014; Gandal et al., 2012b; Tatard-Leitman et al., 2014), to 
the Authors’ knowledge, this is the first study to localize such an alteration to a sub-
section of gamma-band frequencies. Of note, the resting-state power for the 
corresponding high gamma frequency band did not display significant differences for this 
within male comparison (Figure 4.3). As such, it appears that simple alterations to 
resting-state power cannot account for the present findings. A-posteriori examination of 
group-level resting-state activity also revealed a frequency band where male Pcdh10+/- 
mice demonstrated significantly increased power (28-45 Hz; Figure 4.3). As such, the 
current observations support the hypothesis of increased baseline activity, or alternatively 
poor signal to noise, in ASD (Pérez Velázquez and Galán, 2013). 
Gamma-band, but not lower frequency, total power ASSRs were reduced in male 
Pcdh10+/- mice versus their WT counterparts (Figure 4.6). Of note, all mice used in this 
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study were adult mice. An analogous clinical study demonstrated reduced gamma-band 
ASSR in first-degree adult relatives of individuals with ASD (Rojas et al., 2011). This 
study also reported frequency-selective reductions in coherence within the gamma-band 
frequency range of these ASSR of first-degree relatives of ASD (Rojas et al., 2011). Such 
frequency-selective reductions within the gamma-band range were also observed in the 
Pcdh10+/- male mice, though the exact frequency at which the reduced coherence occurs 
was not consistent (clinical = 48 Hz, preclinical = 40 Hz), which may be due related to 
species-specific effects. 
The biological bases for gamma-band activity is relatively understood, with key roles for 
excitatory and inhibitory kinetics (Buzsáki and Wang, 2012). Not only does the GABAA 
receptor’s time constant play a crucial role in the determination of the frequency of such 
activity (Traub et al., 1996), but in addition GABAA receptors have been repeatedly 
found to be critical for activity around 40 Hz (Whittington et al., 2000). GABA’s role in 
gamma-band activity has further been confirmed by optogenetic-based inhibiting or 
driving (exciting) of specific (parvalbumin positive [PV]) interneurons leading to 
decreases (Sohal et al., 2009) or increases (Cardin et al., 2009; Sohal et al., 2009) in 
locally recorded gamma-band activity. These specific alterations to gamma-band activity 
are unique to PV interneuron modulation, with analogous driving of regular-spiking 
neurons causing alterations to low, but not high, frequency activity (Cardin et al., 2009). 
Further support for this GABA to gamma-band activity coupling comes from clinical 
studies where in-vivo GABA levels correlate to attributes of gamma-band activity (Balz 
et al., 2015; Gaetz et al., 2011; Muthukumaraswamy et al., 2009), though these findings 
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have been challenged (Cousijn et al., 2014). 
The lack of significant genotypic differences for ERP-based amplitude and latency 
metrics (Figure 4.1) suggests that alterations to synapse formation/elimination (here due 
to the role of Pcdh10) are not responsible for M100 latency delays in individuals with 
ASD. Alternatively this lack of genotypic differences for the AN40 latency may be due to 
this study only examining adult mice, for whom homeostatic changes have had a longer 
time to allow for recovery. Several studies have found associations between ERP 
component latency and white matter microstructure (Dockstader et al., 2012; Roberts et 
al., 2013, 2009; Stufflebeam et al., 2008). Furthermore, recent studies suggest the 
relationship of middle latency response timing and white-matter microstructure is 
perturbed in ASD (Roberts et al., 2013). Alterations to white-matter pathways are not the 
only plausible cause of ERP-related latency delays. Preclinical studies have also 
demonstrated that alterations to neurotransmitters receptor density (as opposed to the 
current synapse formation/elimination targeted alteration) also produce ERP component 
latency delays (Billingslea et al., 2014; Gandal et al., 2012a). However, these studies 
have used constitutive knock out of receptors and so developmental homeostasis may 
account for the noted middle latency response prolongations. Further studies are needed 
to see if other genetic insults that disrupt synaptic formation and regulation spare ERP 
latencies and/or amplitudes. 
A significant main effect of Sex was observed for the AN40 latency (Figure 4.1). This 
finding replicates previous studies where sex differences have been reported in N40 
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latencies (Amann et al., 2008), and so provides a degree of validation to this current 
study. 
Across Sex by Genotype groups the observed amino acid concentrations were consistent 
with previous studies (Erecińska and Silver, 1990). Noticeably, the main effect of Region 
was consistently significant across amino acids, suggesting that there is regional 
specificity in amino acid concentrations. Previous work supports such findings, though 
additionally observed regional specificity in neurometabolite alterations in a mouse 
model of Fragile X (Gruss and Braun, 2004, 2001). Such regional specificity was not 
observed in the current study, possibly due to the LMM being underpowered to detect 
such significant Genotype or Sex by Region interactions. Additionally, select amino acid 
alterations were observed in Pcdh10+/- mice. GABA, aspartate and glutamine 
concentrations were either significantly, or trending towards significantly, increased in 
Pcdh10+/- versus WT mice. While the exact meaning of such findings is unclear, one 
possible interpretation could be that glutamate might be relatively decreased compared to 
other amino acids in Pcdh10+/- mice. Further studies will need to ascertain whether other 
neurometabolites are increased in Pcdh10+/- mice versus their WT counterparts. Such 
analyses will allow for the determination of whole-scale increases in neurochemical 
concentrations (except for glutamate) in Pcdh10+/- mice. If such global increases in 
neurometabolites are observed then the cellular density in Pcdh10+/- neural tissue should 
be investigated because such increases may be due to increased cell density. 
While the observed increased GABA concentrations contradict observations from clinical 
studies of individuals with ASD (Gaetz et al., 2014; Rojas et al., 2014), these increases 
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still point to altered E/I balance (Rubenstein and Merzenich, 2003) since glutamate 
concentrations were not commensurately altered. A limitation of the current study is that 
the exact interpretation of increased GABA with regards to neurotransmission is unclear. 
In addition to its role as the main inhibitory neurotransmitter, GABA can also enter the 
tricarboxylic acid cycle through the GABA shunt. While initially it was suggested that 
the exact role of GABA could be determined by which isoform of glutamate 
decarboxylase (GAD) the GABA molecule was produced by (GAD65 – 
neurotransmission; GAD67 – GABA shunt) (Martin and Rimvall, 1993) this hypothesis 
has been called into question (Soghomonian and Martin, 1998). Regardless, the tissue 
samples taken in during this study contained both neurotransmitter and metabolic GABA 
pools and there is no method available to separate the functionally different GABA. As 
such, while there may be an increase in GABA in the Pcdh10+/- mice, it is not known how 
this directly relates to neurotransmission. 
An indirect measure of how the observed increased GABA concentrations in Pcdh10+/-  
mice relates to neurotransmission can be identified via the correlation of GABA 
concentrations to gamma-band activity. The early ITC in response to white-noise clicks 
was correlated to electrode site (right hemisphere auditory cortex) GABA concentrations 
in WT, but not Pcdh10+/- , mice. Additionally a trend towards a significant correlation 
was observed between right hemisphere auditory cortex and 40 Hz ASSR ITC in WT, but 
not Pcdh10+/-, mice. Moreover while the hippocampus was not the recording site, 
hippocampal gamma-band activity likely accounted for the part of the recorded gamma-
band signal, due to the combination of volume conduction of the hippocampus responses 
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(Harvey et al., 2012) and the use of low impedance electrodes. In WT mice hippocampal 
GABA near significantly correlated to the total power 40 Hz ASSR. This correlation was 
not observed in Pcdh10+/-. 
Another possible interpretation of the correlation between hippocampal GABA and the 
recorded total power gamma-band ASSRs is that a remote pacemaker is driving the total 
power ASSR activity observed in auditory cortex more than the local GABAergic tone. 
As such, a simple explanation could be the hippocampus and its underlying GABAergic 
concentrations are driving the ASSRs in auditory cortex more than the local GABAergic 
tone. Similar gamma-band pacemaker functions for auditory cortex have been observed 
by high frequency stimulation of the thalamic reticular nucleus (Macdonald et al., 1998). 
Another possibility is that although there is an external pacemaker for auditory cortex, it 
is not the hippocampus. As mentioned above, such a pacemaker could be the thalamus. In 
this scenario, if thalamic GABAergic tone was more strongly correlated to the 
hippocampus inhibitory tone rather than auditory cortex inhibitory tone, a possible 
consequence may be the appearance of a cross-site GABA concentrations to gamma-band 
activity correlation as observed in this study.  Indeed, though by no means correlative, 
results from Gruss and Braun (2001, 2004) demonstrate that group-level GABA 
concentrations were at least qualitatively more similar between thalamus and 
hippocampus than between thalamus and caudal cortex. To resolve such questions future 
studies should A) collect thalamic tissue, B) use high-impedance electrodes in auditory 
cortex to ensure that only auditory cortex activity is recorded or C) high impedance 
electrodes should be placed into potential pacemaker structures in addition to the use of 
162	
low impedance recording electrodes in auditory cortex,. 
When considering the lack of GABA coupling to gamma-band activity in Pcdh10+/ mice 
in conjunction with the increases in GABA concentrations observed in these same mice, 
two possible hypotheses are readily available. First, previous studies have observed that 
increasing GABA concentrations via the administration of tiagabine (hypothesized to 
block synaptic GABA reuptake) results in decreases in gamma-band activity (Nutt et al., 
2015) potentially due to  extra-synaptic GABAB receptors being activated.  Such GABAB 
receptors inhibit both pre- and postsynaptic neurons using long duration inhibitory 
currents that can modulate fast-oscillatory activity (for review see Kohl and Paulsen, 
2010). As such the increased GABA concentrations observed in Pcdh10+/- mice 
ultimately cause less gamma-band activity due to network level inhibition. Second, the 
relative amount of neurotransmission-related GABA in Pcdh10+/- mice is altered with 
possibly a greater proportion of the measured GABA concentrations relating to metabolic 
processes (see above). 
In conclusion this study has demonstrated select gamma-band activity, but not ERP 
component, alterations in Pcdh10+/ mice as compared to their WT littermates. Moreover, 
such gamma-band alterations co-existed with alterations to E/I balance in the Pcdh10+/ 
mice. In addition, the typical coupling of GABA concentrations to gamma-band activity 
seen in WT mice was not exhibited by Pcdh10+/ mice. As such, the current study supports 
the notion of E/I imbalance in ASD leading to gamma-band activity perturbations, though 
questions previous findings of decreased GABAergic concentrations in ASD. 
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Figure Legends: 
Figure 4.1 Pcdh10+/- mice demonstrate unaltered ERPs. (A) Males (blue) and females 
(pink) demonstrate stereotyped auditory event related potentials (ERPs), with a 
negative vertex at ~20 ms (AN20) and ~40 ms (AN40). (B) Females demonstrate 
significantly greater AN40 amplitude than their male counterparts. * p < 0.05 
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Figure 4.2 Pcdh10+/- mice demonstrate select gamma-band activity alterations in 
response to a white noise click. (A) Genotype level total power time frequency plots 
for WT (left) and Pcdh10+/- (right) mice. Black square is region interrogated in B. (B) 
Pcdh10+/- mice demonstrate significantly reduced late low gamma-band activity in 
response to white-noise clicks. * p < 0.05 
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Figure 4.3 Male Pcdh10+/- demonstrate selective increases to high frequency resting-
state power. (A) Group level power spectrum density (PSD) plots (male WT – solid 
black line, female WT – dashed black line, male HET – solid red line, female HET – 
dashed red line) demonstrate the stereotypical decay of power with increased 
frequency. Black dashed box is the a-posterior ROI. A-priori ROIs demonstrated 
either significantly increased (C, E) or trending towards significantly increased (B, D) 
resting-state power in female versus male mice. (F) The a-posteriori ROI demonstrate 
significantly higher resting power in female as compared to male mice. In addition 
the within male comparison demonstrated male Pcdh10+/- exhibiting significantly 
more resting-state power than male WT in this ROI. # p  < 0.10, * p < 0.05, ‡ p(WT 
male versus Pcdh10+/- male) < 0.05 
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Figure 4.4 Male Pcdh10+/- exhibit reduced signal to noise in the high-gamma band. WT 
male mice demonstrate significantly greater SNR than Pcdh10+/- in the high-gamma 
band frequency range. Note, due to high frequency resting-state PSD measures being 
negative (a product of Log-based normalization; see Figure 3), a linear shift 
(arbitrarily chosen to be +5) was incorporated for these values to negate potential 
issue when calculating SNR (SNR = ITC / (Resting PSD + 5)). ‡ p(WT male versus 
Pcdh10+/- male) < 0.05 
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Figure 4.5 Male Pcdh10+/- exhibit subtle deficits in theta-high gamma CFC. (A) Average 
comodulograms for WT (top) and Pcdh10+/- (bottom), additionally split by males 
(left) and females (right). (B) Following a-priori hypotheses the theta-high gamma 
CFC was examined for Pcdh10+/- dependent alterations. A trend towards male 
Pcdh10+/- exhibiting significantly less coupling between theta and high gamma-band 
activity than male WT mice was observed. † p(WT male versus Pcdh10+/- male) < 
0.10 
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Figure 4.6 Male Pcdh10+/- demonstrate decreased gamma-band, but not lower 
frequency, ASSRs. (A) Average ASSR split both by male (left) and female (right), as 
well as WT (top) and Pcdh10+/- (bottom). Gamma-band (C, D, E, F) but not 20 Hz, 
(B) total power ASSRs demonstrate significantly reduced power for male Pcdh10+/- 
versus male WT mice. (G) 40 Hz ITC ASSR demonstrated significantly reduced 
coherence in male Pcdh10+/- versus male WT mice. * p < 0.05, † p(WT male versus 
Pcdh10+/- male) < 0.10, ‡ p(WT male versus Pcdh10+/- male) < 0.05 
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Figure 4.7 Pcdh10+/- mice exhibit selective increases to amino acids and altered 
coupling between GABA and gamma-band activity. Pcdh10+/- mice demonstrate 
significantly increased aspartate (A), GABA (C) and Glutamine (D) compare to WT 
littermates. No significant genotypic alterations to glutamate were observed (B). 
ACxR = right hemisphere auditory cortex; ACxL = left hemisphere auditory cortex; 
HIP = right hemisphere hippocampus; CERE = cerebellum. (E) Early ITC in response 
to white noise clicks significantly correlated to right hemisphere auditory cortex 
GABA concentrations in WT (white diamonds; black line = WT linear regression) but 
not Pcdh10+/- mice (grey squares; grey line = Pcdh10+/- linear regression). (F) 40 Hz 
ASSR ITC near significantly correlates to right hemisphere auditory cortex GABA 
concentrations in WT but not Pcdh10+/- mice. (G) The 40 Hz total power ASSR 
correlates to hippocampal GABA concentrations in WT but not Pcdh10+/- mice. # p 
<0.1, p  < 0.05 
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Figures: 
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Figure 4. 2 
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Figure 4. 4 
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Figure 4. 5 
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Figure 4. 7 
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CHAPTER 5 
Alterations to neurophysiological functioning in OPRM1 A112G SNP 
mice mirrors behavioral phenotypes 
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Abstract: 
The human µ-opioid receptor (MOR) gene single nucleotide polymorphism (SNP) 
OPRM1 A118G has multiple associations with pain sensitivity, addiction, and social 
behavior in primates (including humans). The murine analogue (Oprm1 A112G) causes 
similar behavioral alterations, and these mice also demonstrate reduced MOR sensitivity 
at both the cellular and local circuit levels. To link these findings, in-vivo depth EEG was 
utilized. EEG provides a measure of neuronal function that has been correlated with 
multiple forms of behavior (including sociability). At baseline G/G mice demonstrated 
increased stimulus evoked high gamma-band activity. Previous studies have observed 
that mice with this SNP also demonstrate increased sociability. As such, a juxtaposition 
exists between the pairings of increased post-stimulus gamma-band activity with increase 
sociability, as opposed to the decreases in post-stimulus evoked gamma-band activity and 
sociability seen in several neuropsychiatric disorders. To further probe the effect of G/G 
substitution a morphine challenge was implemented. G/G mice demonstrated reduced 
sensitivity to morphine-related suppression of sensory processing (P1-N1 event related 
potential amplitude) and induced gamma-band responses. These observations mirror 
recent morphine-related behavioral findings in mice with identical SNPs. Furthermore, 
sex by genotype interactions were consistently observed in responses, which again 
parallel previous behavioral findings. Therefore these results may help understand the 
role of the A118G SNP (and MORs in general) in the link between neurophysiological 
activity and behavior. 
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1. Introduction: 
The µ-opioid receptor (MOR) single nucleotide polymorphism (SNP) A118G has 
been repeatedly shown to modulate the analgesic responses to opioids (Chou et al. 2006; 
Sia et al. 2008) and influence the vulnerability for developing opioid addiction (van den 
Wildenberg et al. 2007; Ray & Hutchison 2004; Drakenberg et al. 2006). Furthermore, 
the A118G SNP augments the efficacy of opioid-based alcohol (Anton et al. 2008; Ray & 
Hutchison 2007) and nicotine addiction (Lerman et al. 2004) therapies. This SNP is also 
associated with the pleasure gained from social interactions (Troisi et al. 2012), 
suggesting its role in mediating endogenous opiate responses. 
The A118G MOR SNP may have roles beyond mediating reward. A recent study 
demonstrated an increased risk of schizophrenia with the presence of the G allele (Šerý et 
al. 2010). This increased susceptibility may be due to the specific localization of MOR to 
parvalbumin positive (PV+) interneurons. These PV+ interneurons are thought to be 
critical for proper oscillatory activity (particularly gamma-band activity). Both the 
parvalbumin positive (PV+) interneurons and gamma-band activity are thought to be 
disrupted in schizophrenia (Drake & Milner 1999; Drake & Milner 2002). Moreover, 
gamma-band activity is hypothesized to be involved with basic cortical processing as 
well as higher cognitive functions (for review see (Ainsworth et al. 2012; Herrmann et al. 
2010) respectively). Separately many neuropsychiatric disorders demonstrate altered 
gamma-band activity both at rest and during tasks (for review see (Herrmann & Demiralp 
2005)). Hence, a slight disruption to healthy local circuit function may ultimately 
predispose individuals for psychiatric disorders. Furthermore, the study of a such 
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polymorphism may provide neurophysiological insight to a recent hypothesis that 
multiple separate, yet converging, cellular/circuit alterations can lead to a common a 
neurophysiological outcome (such as those observed in neuropsychiatric disorders) (Port 
et al. 2014). 
Imbalances of excitatory/inhibitory drive (E/I imbalance) have be postulated for 
multiple neuropsychiatric disorders (Rubenstein & Merzenich 2003; Gonzalez-Burgos & 
Lewis 2008). While many rodent models have been used to study E/I imbalance in 
neurodevelopmental psychiatric disorders, mice with an analogous substitution (MOR 
A112G SNP) have not. These mice display a decrease in morphine-related behaviors, and 
decreased MOR expression in several regions (Mague et al. 2009). This study also 
observed sex-specific deficits within G/G homozygous mice for morphine reward. Only 
the G/G female mice failed to find morphine rewarding (Mague et al. 2009). Recent work 
also suggests reduced receptor functionality (Mague et al. 2015) in regions where MOR 
expression is constant between genotypes (i.e. hippocampus) (Mague et al. 2009; Wang 
et al. 2012; Wang et al. 2014). This reduced receptor functionality may be due to altered 
GTPγS binding to the MOR and subsequent intracellular signaling cascades (Wang et al. 
2014). Further linking this murine model to its human analogue, a recent study observed 
that mice with this substitution are more social and resilient to social stress (Briand et al. 
2015). 
As such, precise alterations to circuitry may lead to significant behavioral 
alterations in both human and rodent. To model such a phenomena, we examined the 
effect of the A112G MOR SNP on auditory event related potentials (ERP) and spectral 
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neural activity. Moreover, we evaluated if the previously observed interactions between 
sex and genotype for morphine-related behaviors were recapitulated at the 
neurophysiological level. Intracranial depth EEG was utilized in these studies, as EEG 
can be used to assess the same type of neurophysiological activity in both experimental 
models and clinical disorders. The ultimate goal of the study was to determine if 
behavioral alterations previously described in these mice (such as alterations to 
sociability, and morphine related reward behavior) were reflected at the 
neurophysiological level. 
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2. Materials and Methods: 
2.1 Animals 
 Adult mice (10-20 weeks of age; 20-35 g, male and female) homozygous for the 
A112 (wild-type) or G112 (knock-in) allele were used for these experiments. To generate 
these mice, site-directed mutagenesis of the C57BL/6 mouse Oprm1 was performed in 
bacterial artificial chromosomes to create the aspartic acid substitution of asparagine at 
amino acid position 38 via replacing the adenine at nucleotide position 112 with a 
guanine. This eliminated the equivalent N-linked glycosylation site of the A118G SNP 
found in humans (Mague et al. 2009; Huang et al. 2012)  Mice were bred using A112G 
heterozygous to A112G  heterozygous pairings, and tested for homozygousity via gel 
electrophoresis of DNA PCR products (see (Mague et al. 2009) for further details). Mice 
were group-housed with food and water available ad libitum and maintained on a 12-h 
light/dark cycle in accordance with the University of Pennsylvania Animal Care and Use 
Committee. Mice were generated using C57Bl/6 ES cells (Chemicon) and the colony was 
maintained in this background. The final count for each genotype by sex grouping was 11 
AA females, 10 AA males, 11 GG females, and 8 GG male. All possible effort was taken 
to minimize pain and discomfort in experimental subjects throughout the entire study. 
Furthermore, all protocols were approved by the University of Pennsylvania Institutional 
Animal Care and Use Committees and were conducted in accordance with National 
Institutes of Health guidelines.  
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2.2 Surgery for electroencephalogram (EEG) recordings 
 Adult A112G mice (4-5 months of age, male/female) had intracranial electrodes 
implanted (AP -1.82 mm, ML 1.10 mm, DV -1.9 mm) via stereotaxic surgery. All 
electrodes were tri-polar stainless steel electrodes (200 µm diameter, Plastics One, 
Roanoke VA). These tri-polar electrodes were low impedance electrodes, for which 
similar configurations demonstrate ability to detect auditory brain stem responses, as well 
as later subcortical and cortical responses (P1, N40, P2, P3A) (Siegel et al. 2003; 
Connolly et al. 2003). Previous studies have demonstrated that ERP responses from such 
recordings display a pattern similar to human Cz electrode recordings (Siegel et al. 2003). 
Mice were anaesthetized with isoflurane. Once fully sedated and their scalps cleaned with 
betadine, the skull was exposed (bregma to lambdoid sutures) and electrodes secured in 
the aforementioned coordinates.  
 
2.3 Recording of EEG activity 
 The low-impendence tri-polar electrode configuration utilized in this study 
provides EEG responses very similar to the human clinical responses (see above). In 
addition they have also demonstrated face and predictive validity for genetic, 
developmental and pharmacologic manipulations in mice (Gandal et al. 2010; Saunders, 
Gandal, Roberts, et al. 2012; Gandal, Anderson, et al. 2012). All mice had a minimum of 
two weeks recovery following surgery. Recordings were made following IP injections of 
saline and 1, 2, 7 and 20 mg/kg morphine. Following the 20 mg/kg morphine injection 
and recording session, an IP injection of the specific MOR antagonist naloxone (1 mg/kg) 
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was administered. The purpose of this additional control was to assess if morphine’s 
actions specifically at the MOR was responsible for changes in EEG responses. EEG 
recordings were collected in home cages (between 10AM and 4PM; light phase), which 
were placed within a Faraday cage. Special cage tops were used to accommodate 
stimulus speakers and electrode cables. Electrode cables were connected to a high-
impedance differential AC amplifier (A-M Systems, Carlsborg, Washington, USA). Mice 
were acclimatized to the testing apparatus for 30 min before testing to ensure habituation 
to the environment. Habituation and recordings took place in the presence of background 
white noise of 55 dB. Speakers atop each cage delivered stimuli generated by Micro1401 
hardware and Spike 6 software (Cambridge Electronic Design). Stimuli consisted of 150 
white-noise clicks (10ms duration, 85dB) with a 9 second inter-trial interval. Signals 
were continuously sampled at 1667 Hz and an online bandpass filter (1–500 Hz) was 
applied to all EEG signals.  
 
2.4 EEG data analysis  
 The auditory clicks induced a typical multi-component ERP (Figure 5.1). Latency 
and amplitude changes in these components are associated with psychiatric disorders. As 
such, we measured these components across both dosages and genotype. EEG signals 
were analyzed similar to previously published studies (Gandal et al. 2010), using the 
EEGLab toolbox in MatLab (Delorme & Makeig 2004). In brief, single trials epochs 
(±1000 ms relative to auditory stimuli) were extracted from continuous data. Artifact-
containing epochs (e.g. movement) were then rejected via an activity threshold of >2 SD 
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of the mean. This left between 131 and 140 trials remaining on average per mouse for all 
conditions. This is well above the generally accepted number of required trials to gain 
stable responses. Trials were then baseline corrected to the -400 to -100ms period and 
subsequently averaged together. The amplitudes and latencies for both the P1 and N1 
responses were determined from the resultant waveforms (defined by the most 
positive/negative deflection in the corresponding time window P1: 12.6-27.6ms; N1: 
28.2-49.2ms; previously used in (Saunders et al. 2013)). These components have similar 
morphology (though at 40% of the latency) of analogous human evoked components 
(Siegel et al. 2003). Components (P1 and N1) were verified by visual examination by 
RGP. P1 latency was investigated using a mixed model ANOVA (drug (repeated 
measure) X genotype X sex) (IBM SPSS Statistics, Version 22, IBM Corp, Armonk, 
NY). The amplitude of the N1 peak (negative) was subtracted from the amplitude of the 
P1 peak to account for inter-subject variability. An identical mix model ANOVA was used 
for this relative amplitude change (IBM SPSS Statistics, Version 22, IBM Corp, Armonk, 
NY). 
To further investigate the data, all auditory-evoked response waveforms were 
spectrally decomposed (Morlet Wavelets; 100 linearly spaced frequency bins between 3.0 
and 100 Hz; wavelet cycles increasing from 3 (at low frequencies) to 6 (at high 
frequencies)). There are several forms of spectral activity available for investigation. 
Each of these have differing sensitivity to the characteristics of the underlying oscillatory 
signal. Both evoked power and ITC measure the ability of the brain to align activity over 
trials in response to stimuli and as such it can be seen as a measure of reliability (Port et 
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al. 2014). On the other hand, induced power (or non-phase locked power) is activity that 
occurs after the stimulus but is not aligned (with respects to phase) across trials. Total 
power is the combination of both evoked and induced power. 
Total power (in decibels (dB); baseline period -200 to 0 ms) and inter-trial 
coherence (ITC) were calculated ± 500ms around the stimuli as previous studies have 
found alterations to this region (Gandal et al. 2010; Liao et al. 2012; Saunders, Gandal & 
Siegel 2012). To choose regions of interest (ROI) within the spectral responses, 
EEGLAB’s in-built permutation test (random trials, 200 repetitions) was applied in a 
drug (saline, 20mg/kg morphine and 20mg/kg morphine + 1mg/kg naloxone) and 
genotype/sex (i.e. A/A males, A/A females, G/G males, G/G females) comparison. Such 
a test allows for an unbiased, data-driven, selection of the ROIs from time frequency 
plots. In addition, this approach incorporates controls for multiple comparisons. In short, 
the time-frequency plots were pooled, and then randomly sorted into groups the same size 
as the original groups. One-way/repeated measures ANOVAs were then calculated 
between these randomly chosen groups at each time-frequency bin. The resultant 
maximum F-statistic retained. Repeating this procedure generated a distribution of F-
statistics.  Then the F-statistics from the experimental grouping were compared to this 
distribution. To reduce multiple comparisons, only data from -0.1 to 0.2 seconds were 
included. In addition, all statistical maps resulting from permutation testing were 
corrected using Holm’s multiple comparison correction to ensure that the ROIs identified 
were not due to multiple comparisons Eight ROIs were chosen from this output based on 
either the intersection of the statistical maps or the effect of morphine across 
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genotype/sex. Each region of interest had a binary mask created, and only those time-
frequency bins within the mask were averaged to produce metrics of power. Drug 
condition spectral responses were normalized to the saline trial for each animal (e.g. 
(20mg/kg drug trial – saline trial) / saline trial) when looking at the effect of 
morphine/naloxone to negate baseline differences. Group differences in power/coherence 
(either normalized or raw) were statistically assessed by a two-way ANOVA (genotype X 
sex) at specific drug doses or mixed model ANOVA (genotype X sex X dose (repeated 
measure). Select pairwise comparisons for sex, drug condition, genotype, and their 
interactions were conducted using Sidak corrections for multiple comparisons (IBM 
SPSS Statistics, Version 22, IBM Corp, Armonk, NY). 
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3. Results: 
3.1 Evoked potentials demonstrate sex and genotype differences 
We first measured auditory ERP latencies and amplitudes in responses to 
escalating dosages of morphine (0 – 20 mg/kg), followed by acute naloxone (1 mg/kg). In 
a mixed model ANOVA (drug condition (repeated measure) X sex X genotype), a main 
effect of drug demonstrated that morphine prolonged P1 latencies (Figure 5.1; F(3.525, 
126.915)= 27.742, Greenhouse-Geisser adjusted, p <0.001). We hypothesized that 
morphine’s activation of opioid receptors led to this increased P1 response latency. If so, 
these latency prolongations would be recovered by co-administration of naloxone. A-
priori pairwise comparisons supported this hypothesis with naloxone reversing the 
morphine induced P1 latency prolongation (saline to 20mg/kg morphine - p <0.001, 
saline to naloxone - p>.1). We examined the role of the MOR polymorphism within this 
prominent impact of morphine. A significant genotype X drug condition interactions was 
present (mixed model ANOVA, F(3.525, 126.915)= 3.452, Greenhouse-Geisser adjusted, p 
<0.05), with differences between A/A and G/G suggested at saline and 1 mg/kg morphine 
(post-hoc pairwise comparisons: G/G prolonged latency saline p <0.1, one mg/kg 
Morphine p <0.1). In addition, there was a significant drug condition X genotype X sex 
interaction (mixed model ANOVA, F(3.525, 126.915)= 3.712, Greenhouse-Geisser adjusted, p 
<0.01).  
Morphine also significantly decreased the amplitude of the P1-N1 ERP composite 
responses, which again was partially recovered by naloxone (Figure 5.1; mixed model 
ANOVA, main effect of drug F(3.836, 138.107)= 68.711, p <0.001, saline to 20 mg/kg 
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morphine p <0.001, 20mg/kg morphine to naloxone p <0.001). We additionally 
hypothesized that if the A112G Oprm1 substitution was reducing the sensitivity of the 
MOR receptor, then activating MOR receptors may allow for genotypic differences to be 
seen. Indeed, G/G homozygous mice demonstrating reduced sensitivity to morphine 
during the 20 mg/kg condition (pairwise comparison: Figure 5.1, p <0.05). Previous 
studies have observed sex specific responses to morphine. As such, a-priori pairwise 
comparisons also demonstrated that at 20 mg/kg, males were significantly less sensitive 
than females to morphine (pairwise comparison: Figure 5.1, p <0.05). Moreover, 
previous studies of genetically identical mice demonstrate a genotype X sex interaction 
(females demonstrating greater genotypic differences than male mice). Our results 
reflected this, with G/G female mice less sensitive to morphine than A/A females 
(pairwise comparison: Figure 5.1, p <0.05).  Thus, this sex X genotype interaction for 
morphine’s effect on ERP amplitude and latency appears to parallel previously reported 
behavioral and in vitro findings for the A118G OPRM1 SNP and its murine counterpart. 
 
3.2 Genotype and Sex differences in spectral activity 
Recent clinical and translational work in psychiatric disorders has focused on 
changes in the evoked and baseline spectral responses, particularly with in the gamma-
band (for review see Port et al. 2015; Port et al. 2014). Similar to the ERP’s, we found a 
dose dependent decrease of power/coherence by morphine (largest reductions at 20 
mg/kg) (Supplemental Figure 5.1). We compared the saline, 20 mg/kg morphine and 20 
mg/kg morphine + 1 mg/kg naloxone conditions using permutation testing to assess 
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genotype/sex alterations in spectral activity. Such permutation testing of time–frequency 
plots provides an unbiased selection of ROIs. Saline condition responses were utilized to 
test for genotype and sex differences at baseline. The intersections across each of the 
genotype X sex (e.g. G/G Male) statistical maps were taken to determine ROIs for 
morphine-induced alterations to spectral activity. Four ROIs were identified for 
comparison (Figure 5.2), which correspond to pre-stimulus low frequency, pre-stimulus 
high frequency, post-stimulus gamma frequency, and post-stimulus high gamma 
frequency (Figure 5.2).  
Permutation testing of the individual subject ITC figures (in an identical manner 
to total power), demonstrated 4 ROIs (Figure 5.2). Again, these regions were chosen due 
their intersection of multiple statistical maps. The ROIs represented post stimulus low 
frequencies, post stimulus high gamma, post stimulus beta, and post stimulus gamma/beta 
power. In addition the ITC response within the total power post stimulus gamma ROI 
was calculated to test if phase-locked signals account for the alterations seen in total 
power. 
 
3.3 Genotype differences at baseline (Saline condition) 
Permutation testing of individual time frequency plots revealed significantly 
altered high-gamma frequency post-stimulus activity when comparing between the 
separate genotype/sex combinations (A/A male X A/A female X G/G male X G/G 
female) during the saline condition (p <0.05). G/G mice demonstrated significantly 
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increased mean total power values for this region (Figure 5.3; mixed model ANOVA, F1, 
36=7.936, p <0.01). In addition a trend for a sex X genotype interaction was also present 
(Figure 5.3; mixed model ANOVA, F1, 36= 3.101, p=0.087), with the greatest difference 
in total power was observed in A/A and G/G females (Figure 5.3; F1, 36= 11.724, p 
<.001). 
 
3.4 Morphine decreases relative responses in all time frequency ROIs, which is recovered 
by naloxone 
Morphine suppressed the responses for all total power ROIs regardless of 
genotype or sex (Figure 5.3; Mixed ANOVA (genotype X sex X dose (repeated 
measure); post-stimulus low gamma effect of drug F2, 72= 61.865, p <.001: saline to 
20mg/kg morphine p < 0.001, post stimulus high gamma effect of drug F2, 72= 78.807, p 
<.001: saline to 20mg/kg morphine p < 0.001, pre stimulus high frequencies effect of 
drug F1.929, 69.430= 19.128, p <.001: saline to 20mg/kg morphine p < 0.001, pre stimulus 
low effect of drug F1.948, 70.118= 19.128, p <.001: saline to 20mg/kg morphine p < 
0.001).This effect which was partially reversed by naloxone (Mixed ANOVA (genotype 
X sex X dose (repeated measure); 20mg/kg Morphine to naloxone - post stimulus gamma 
p = 0.001, post stimulus high gamma p = 0.001 , pre stimulus high frequencies p < 0.01, 
pre stimulus low frequencies p < 0.001).  
A similar pattern was seen for ITC, though in contrast naloxone failed to recover 
coherence in the post-stimulus low frequency ROI (Figure 5.4; Mixed ANOVA 
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(genotype X sex X dose (repeated measure); post-stimulus gamma-beta effect of drug F2, 
72= 72.199 p <.001: = saline to 20mg/kg morphine p < 0.001: 20 mg/kg morphine to 
naloxone p < 0.001, post-stimulus high gamma effect of drug F2, 72= 61.404 p <.001: 
saline to 20 mg/kg morphine p < 0.001: 20 mg/kg morphine to naloxone p < 0.001, post 
stimulus beta effect of drug F2, 72= 53.820 p <.001: saline to 20 mg/kg morphine p < 
0.001: 20 mg/kg morphine to naloxone p < .891), post stimulus low frequency effect of 
drug F2, 72= 15.120 p <.001: saline to 20 mg/kg morphine p < 0.001: 20 mg/kg morphine 
to naloxone p < .891). While these naloxone effects point to morphine primarily working 
through MOR, these data also allow for minor non-MOR affects.  
 
3.5 Morphine acts in a genotype dependent manner for low, but not high, frequency total 
power gamma-band responses 
G/G mice demonstrated less sensitivity to morphine’s ability to suppress lower 
frequency gamma-band responses as compared to A/A mice (Figure 5.3, mixed model 
ANOVA, F(1,36) = 4.933,  p <.05). The greatest difference existed again between A/A and 
G/G females (Figure 5.3, mixed model ANOVA, F(1,36) = 3.350, p = 0.076). Naloxone 
abolished any genotypic differences induced by morphine.  Interestingly, this genotypic 
effect may be due to alterations in induced (non-phase locked activity). Supporting this 
hypothesis was that neither the gamma/beta nor the beta ITC ROIs showed an effect of 
genotype or sex for morphine suppression of saline-normalized coherence ((20mg/kg 
coherence – saline trial coherence)  / saline trial coherence). To further investigate the 
role of induced activity in the post-stimulus low gamma ROI, we applied the same post 
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stimulus low gamma ROI from the total power analyses to ITC data. Morphine-induced 
suppression of coherence in this ROI was non-genotype specific. This suggests that the 
induced component of total power had been altered. In comparison, the morphine-
induced effect on power and coherence in post-stimulus high gamma frequencies was not 
significant for either genotype or sex.  
Additional findings of interest are presented in Supplementary Table 5.1. These 
include a trend towards alterations to pre-stimulus power for both high and low 
frequencies either by sex (males demonstrating more power than females), and a sex by 
genotype interaction (G/G males demonstrating greater power than G/G females), (p 
<0.10). In addition there is a trend towards a reduction of morphine-induced suppression 
of post-stimulus low frequency ITC (F(1,40) =3.243, p <0.10). 
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4. Discussion: 
4.1 Perturbations to ERPs and Gamma-band activity at baseline 
 MORs preferentially co-localize to PV+ interneurons in hippocampus (Drake & 
Milner 1999; Drake & Milner 2002). These MORs mediate fast inhibitory responses and 
so contribute to fast circuit activity (including high-frequency oscillations). As such, the 
A112G MOR SNP may be a potential model for observing the effects of a precise 
cellular alteration on the oscillatory activity of large regions of the brain. This is not to 
say that MORs are only located to PV+ interneurons, or are not present in other regions 
of the brain. Instead, this model may demonstrate how a slight molecular alteration that is 
present in multiple regions alters the large-scale brain function (i.e. the recorded gamma-
band activity). Altered gamma-band function has been demonstrated in many 
neuropsychiatric disorders (e.g. schizophrenia (Sun et al. 2011), ASD (Rojas & Wilson 
2014) and even opiate addiction (Wang et al. 2015)). Such alterations have also been seen 
in pre-clinical models that recapitulate key aspects of neuropsychiatric disorders (Amann 
et al. 2010; Port et al. 2014). The most common findings in these pre-clinical studies are 
altered basic sensory processing (ERP component latency/amplitude) and alterations to 
oscillatory activity. In this study we demonstrate both in the A112G MOR SNP mouse 
model.  
At baseline, there were near significant delays for P1 latency in G/G homozygous 
mice. This suggests a subtle level of functional alteration in mice with A112G 
substitutions. Mice homozygous for G/G also demonstrate increased baseline post 
stimulus high gamma-band activity. A potential confound of such a finding could be 
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behavioral (e.g. locomotor) differences during the recording sessions. However, previous 
findings have demonstrated no locomotor differences during baseline/saline treatment in 
these mice, attenuating this potential confound (Mague et al. 2009). Alterations to 
gamma-band auditory responses have been repeatedly observed in clinical (Maharajh et 
al. 2007; Wilson et al. 2007; Kwon et al. 1999) and preclinical studies of 
neuropsychiatric disorders (Amann et al. 2010; Port et al. 2014). Interestingly, contrary to 
our current findings of increased post-stimulus gamma in G/G mice, Autism Spectrum 
Disorders (ASD) demonstrated decreased analogous (post stimulus) gamma-band 
responses (Gandal et al. 2010). Recent findings shed light on this disparity. Mice with 
this A112G SNP are actually more social (Briand et al. 2015), as opposed to individuals 
with ASD. Support for this hypothesis comes from previous animal studies where 
concurrent expression of decreased sociability and decreased post-stimulus gamma-band 
activity have been previously demonstrated in mice (Gandal, Anderson, et al. 2012). 
Moreover, the recovery of gamma-band signal to noise is concurrent to increased 
sociability mice (Gandal, Sisti, et al. 2012). As such, it appears while decreases in post-
stimulus gamma-band responses are associated with decreased sociability (ASD), 
increases in post-stimulus gamma-band activity may relate to increases in sociability. 
Moreover, a recent study suggests no increased risk for ASD by being a carrier for a G 
allele at the A118G SNP. It remains difficult to determine if a protective effect exists for 
being a carrier for homozygous G alleles because only two subjects in this study were 
G/G (though both were non ASD) (Cieślińska et al. 2015).  
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4.2 Morphine-induced alterations to ERP and oscillatory markers: intermediate 
phenotypes allowing for understanding of the neurobiological basis of genotypic effects 
 Clinical studies have shown an effect of the MORP A1118G SNP on a range of 
behaviors and drug responses in humans (for review (Mague & Blendy 2010)). Similar 
findings have been observed in the mouse homolog MOR A112G SNP (Mague et al. 
2009). Morphine challenge masked baseline genotypic differences seen in early sensory 
processing (P1 latency). Moreover, the G/G homozygous mice demonstrated decreased 
sensitivity to opioid activation (as seen in P1-N1 peak amplitude) (Figure 5.1). This 
finding is analogous to recent hippocampal slice findings where G/G homozygous mice 
demonstrated significantly less sensitivity in response to µ-opioid receptor activation (via 
DAMGO challenge) (Mague et al. 2015). The use of supplemental naloxone suggested 
that the effects of morphine on auditory event related potentials were induced by µ opioid 
activation. Naloxone by itself does not affect these early auditory evoked responses 
(Arnsten et al. 1984; Ehlers 1989). Furthermore, consistent with previous studies all 
experiments took place between 10 AM and 4 PM (Gandal et al. 2010; Saunders et al. 
2013; Siegel et al. 2003; Billingslea et al. 2014; Gandal, Anderson, et al. 2012), 
indicating that time of day cannot account for observations in this study. Alternatively, it 
is possible that there could be an effect of multiple injections.  However, the inverted U 
pattern of activity, suggests this was not the reason for increased amplitude over time as 
the administration of naloxone yielded an effect which was opposite to that of the 
previous 4 injections. 
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Morphine’s effects on auditory responses were also tested with regards to sub-
spectral regions derived from permutation testing. These windows each have different 
proposed roles in neuronal activity (e.g. gamma-band activity is involved for local circuit 
activity (Sohal et al. 2009)). Morphine challenge produced genotypic differences within 
these spectral sub-components, such as post stimulus low gamma frequency total power 
and a suggested genotype-dependent low frequency ITC response (see supplement Table 
5.1). Interestingly, G/G were less sensitive than A/A to morphine-induced suppression of 
post stimulus low gamma total power (phase and non phase locked activity) but not ITC 
(phase locked). This indicates that it is not the phase-locked activity that is the mediator 
of genotypic differences, but rather non-phase locked activity (also known as induced 
activity). Moreover, the differences were mainly driven by alterations within females 
(G/G being less sensitive to morphine than A/A), mimicking previous behavioral data of 
A112G mice (Mague et al. 2009).  
Both the morphine-induced decreased P1-N1 amplitude and the post stimulus 
gamma-band activity alterations are occurring in the same time frame. A decrease in P1-
N1 would likely cause a reduction in activity at all frequencies during that time window. 
The current finding suggests that these reductions in activity are only significant for the 
gamma-band activity, mirroring what is found clinically The repeated finding of altered 
spectral activity in this study may be explained by the location of µ opioid receptors 
within specific circuits. As stated above, µ opioid receptors are predominantly located on 
PV+ basket cells in hippocampus. Again, these PV+ cells are key in the production of 
gamma-band activity (Sohal et al. 2009; Cardin et al. 2009). Therefore, MOR A112G 
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substitution may have downstream effects on inhibition that could alter pyramidal cell 
firing synchrony in local circuits, leading to disruption of high frequency activity and 
altering hippocampal/cortical function (Faulkner et al. 1998).  
Theta frequencies were also marginally affected by genotype in this study (a trend 
of genotype; p = 0.08), suggesting a role for mu opioid receptors in the circuits that 
generate these frequencies. This also is consistent with the known cellular mechanisms of 
generating theta rhythms. Theta-generating GABAergic cells are modulated by MOR, 
(Nagode et al. 2014) cholinergic inputs, and cannabinoids (Nagode et al. 2014). Thus, a 
genotype-dependent difference in theta response to MOR activation suggests additional 
complex interactions with other modulatory systems, including nicotinic systems where 
A118G polymorphism has been implicated in addictive behavior.  
 
4.3 Sex differences and sex X genotype interactions are frequently observed in morphine 
responses 
Multiple morphine-related sex-dependent alterations were also observed during 
this study, with such alterations attenuated by naloxone (Supplemental Table 5.1). 
Previously, sex dependent alterations have been observed in response to opioid 
administration (Craft 2008). In both humans and rodents, females are more likely to 
administer opioids and show greater response to rewarding properties of opioids (Cicero 
et al. 2003; Roe et al. 2002). In contrast, males demonstrate greater analgesic response 
when morphine was infused into the periaqueductal gray (Loyd et al. 2008). 
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 Within hippocampus, both the availability of MORs (Torres-Reveron et al. 2009) 
and levels of opioid peptides (Roman et al. 2006; Williams et al. 2011) are influenced by 
ovarian steroid hormones. Interestingly, the most common comparison to 
demonstrate/suggest significance was the A/A females to G/G females. G/G female mice 
demonstrated altered baseline activity and were less sensitive to morphine’s affects than 
the A/A female mice. A comparable lack of response to morphine has been demonstrated 
behaviorally, with G/G mice demonstrating reduced rewarding effects and blunted 
negative effects of withdrawal (Mague et al. 2009). These data indicate the need to 
include female subjects in assessments of genetic factors.  
 
4.4 The A112G Oprm1 substitution allows for both the study of morphine-related 
neurophysiological phenotypes and broader neuropsychiatric disorders related to 
GABAergic disruption 
The results from this study indicate that there are specific alterations due to sex, 
A112G genotype and their interaction for both evoked potentials and spectral sub-
components activity. Mice with the SNP demonstrate increased baseline high gamma 
power. In addition, these mice show reduced sensitivity to morphine suppression of early 
sensory processing and non-phase locked gamma-band activity. Moreover, it was 
common that significant or near significant differences were due to differences between 
A/A and G/G females. Interestingly, our in-vivo electrophysiological results mirror that 
of recent behavioral (both social and morphine-related) results from a cohort of mice with 
the identical SNP (Briand et al. 2015; Mague et al. 2009). This study has multiple 
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significant contributions. First, the direct impact of the A112 MOR substitution on 
behavior at baseline (where increased sociability has been demonstrated) is reflected in 
alterations to neurophysiological activity in-accordance with a-priori hypotheses. Second, 
using the A112 MOR SNP as a model of specific and selective molecular alterations, the 
concept of such precise changes leading to gamma-band perturbations in broader 
neuropsychiatric disorders can be investigated. Lastly, a potential biological basis has 
been determined for the genetic, and sex by genotype, differences observed in behavioral 
studies of these mice previously. Thus this study highlights translational relevance by 
providing physiological insight into the behavioral changes seen across rodents, non-
human primates and people, providing targets for electrophysiological studies in humans.  
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Table Legends: 
Supplemental Table 5.1 Multiple sex or sex by genotype interactions were observed at 
significant or near significant levels during this study, often following the same 
pattern as previously observed with behavioral metrics. 
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Figure Legends: 
Figure 5.1 Auditory evoked-potentials exhibit genotype-based alterations at baseline as 
well as morphine-induced sex and genotype-based differences. A) Grand Average 
(across genotype and sex) evoked potential and locations of P1 and N1. B) Peak-to-
peak measurements between P1 and N1 (P1-N1) exhibit significant alterations in the 
presence of morphine, which was partially recovered by naloxone. Morphine 
challenge also produced genotypic and sex based alterations to evoked responses. C) 
Baseline (saline) P1 latencies suggest a genotypic difference, which are not present 
after morphine challenge. # = p < 0.01 
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Figure 5.2 Permutation test-based dissection of sex and genotype time-frequency 
differences. Using permutation testing for both total power and ITC plots, maps of 
statistical difference regions were computed (for both drug effects within 
genotype/sex combinations and genotype/sex combination effects across drug 
conditions). Regions of interested (ROI) where selected via the intersection of 
statistical maps, or for effects of genotype/sex during the saline condition. A) Total 
power plots were tested for difference during saline (top row) or across drug 
conditions for each sex X genotype combination (columns). Total power ROIs were 
chosen for further study via either an effect during saline or the intersection of the 
drug effect statistical maps with regions representing post stimulus low gamma (red), 
post stimulus high gamma (light blue), pre-stimulus high frequencies (yellow), and 
pre-stimulus low frequencies (orange). B) A similar analysis occurred for ITC plots, 
again with ROIs chosen by the intersection of drug-related statistical maps (no 
differences during the saline condition were observed). Regions represented post 
stimulus gamma/beta (light orange), post stimulus high gamma (pink), post stimulus 
low frequencies (dark red), and post stimulus beta frequencies (white). For all 
regions, binary masks were created and were applied to individual subject’s 
respective plots to derive responses.  
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Figure 5.3 Total power plots reveal sex and genotype and their interaction differences in 
the multiple ROIs. A) The ROIs chosen from statistical permutation testing of time 
frequency plots demonstrate effects of sex, genotype and their interaction during the 
saline condition (left) and 20 mg/kg morphine and naloxone condition (center and 
right; respectively shown as relative change from saline). The four regions span both 
pre-stimulus (top 2 rows), and post-stimulus windows (bottom 2 rows). Morphine 
causes significant relative reductions of power in all ROIs; with naloxone reversing 
these effects (Mixed ANOVA - (genotype X sex X dose (repeated measure)). 
Genotypic differences can be observed both during saline (post-stimulus high 
frequencies), and 20mg/kg morphine (post-stimulus low gamma). A sex X genotype 
interaction was seen during the saline period for post-stimulus high gamma, with 
significant differences between A/A and G/G females. Pre-stimulus high frequency 
power and pre-stimulus low frequency power (trending and significant respectively) 
exhibited sex dependent changes, with males demonstrating a greater power. Based 
on a-priori hypotheses, examining the sex X genotype interaction showed that G/G 
homozygous mice, but not A/A, demonstrated differences in pre-stimulus high 
(trending) and low (significant) power. B) Radar plots of spectral responses relative 
to saline condition demonstrate specific sex, genotype and sex by genotype 
interactions. Each genotype by sex (A/A male - bottom quadrant, A/A female - left 
quadrant, G/G male - top quadrant, G/G female - right quadrant) shows a differing 
profile of spectral activity in response to saline (blue), 20 mg/kg morphine (red) and 
supplemental naloxone (green). All data is shown as relative change from saline 
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(hence saline always equals 0). Again morphine is seen to decrease responses in all 
time frequency ROIs, which is recovered by naloxone. Interestingly, morphine-
induced suppression of power was attenuated in G/G mice for low gamma-band 
response (left most), with the greatest difference between females. A similar trend 
was seen for low frequency pre-stimulus power (middle left). No such effects were 
seen for pre-stimulus high frequencies (middle right) or post-stimulus high gamma. * 
= p < 0.05, Mixed model ANOVA genotype X sex X dose (repeated measure), with 
Sidak correction for multiple comparisons. 
  
206	
Figure 5.4 ITC plots reveal sex, genotype and their interaction differences in the multiple 
ROIs. Morphine significantly reduces relative coherence in all ROIs, with naloxone 
reversing these effects in all ROIs except low frequency    (Mixed ANOVA - 
(genotype X sex X dose (repeated measure)). A) Unlike total power, ITC was not 
affected by sex at baseline A genotype by sex interaction occurred at the gamma/beta 
ROI (second row, left), demonstrating significant pairwise differences between 
females. This divergence between females was also seen in the beta (top tow, left) 
ROI. B) Radar plots of coherence relative to saline condition. Each genotype by sex 
combination (A/A male - bottom quadrant, A/A female - left quadrant, G/G male - 
top quadrant, G/G female - right quadrant) shows a differing profile of coherence in 
response to saline (blue), 20 mg/kg morphine (red) and supplemental naloxone 
(green). All data is shown as relative change from saline (hence saline always equals 
0). Again, morphine decreased responses in all time frequency ROIs. A/A mice 
demonstrated near significant increases of this morphine-induced suppression of post 
stimulus low frequencies coherence as compared to G/G mice. The beta (top left) and 
the gamma/beta (top middle) ITC ROIs showed no effect of genotype or sex for 
morphine suppression of coherence. Separately, the low gamma ROI for total power 
was applied to the plots (third row) to determine if genotypic alterations seen in total 
power where due to phase-locked signals. Contrary to total power, morphine’s 
suppression of coherence in the total power low gamma ROI was non-genotype 
specific. Morphine’s suppression is recovered by naloxone, except for the low 
frequency ROI (bottom right). Naloxone’s ability to reverse morphine suppression of 
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coherence in the beta ROI was genotype specific.  In addition, a genotype by sex 
interaction for naloxone’s effect was significant in the total power low gamma ROI 
(Fig. 5; F(1,36) = 5.051, p <0.05) with A/A males and G/G females demonstrating 
increased coherence.  . * = p < 0.05, Mixed model ANOVA genotype X sex X dose 
(repeated measure), with Sidak correction for multiple comparisons. 
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Supplemental Figure 5.1 Morphine causes a dose dependent decrease in auditory 
stimulus related potentials and power. A. As quantified by the voltage difference 
between P1 and N1 components, grand averages of responses to single tones are 
decreased by 20mg morphine This change is for the most part reversed by the MOR 
antagonist naloxone (Nal), (*) show significant reductions from saline, (+) points to 
significant increase of potentials in NAL from 20mg/kg morphine. When the 
individual evoked responses are wavelet transformed and averaged to generate the 
time-frequency plots (B) for each dosage of morphine. These plots show a wide-band 
increase in power (yellow to red) often followed by a strong suppression in the beta-
band shown in blue. There is also a reduction in activity with increasing levels of 
morphine that is reversed by naloxone. Similarly, there is an increase in inter-trial 
coherence (ITC) (black to yellow). 
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Tables: 
Supplemental Table 5. 1 
Condition Period Frequency 
Range 
Power/ITC Effect F p 
Saline  Pre 
stimulus 
High 
Frequency 
Total Power Male>Female  F1, 36= 
4.128 
0.05 
Saline Pre-
stimulus 
Low 
Frequency 
Total Power Male>Female  F1, 36= 
3.147 
0.085 
Saline Pre-
stimulus 
Low 
Frequency 
Total Power G/G 
Male>G/G 
Females 
 0.07 
Naloxone Post-
stimulus 
Beta ITC GG show less 
recovery 
F(1,36) = 
4.251 
<0.05 
Naloxone Post-
stimulus 
Beta ITC A/A females 
> G/G 
females 
recovery 
F(1,36) 
4.892 
<0.05 
Naloxone Post-
stimulus 
Total Power 
Low 
Gamma 
ROI 
ITC A/A males and 
G/G females 
have increased 
coherence 
F(1,36) = 
5.051 
<0.05 
20 mg/kg Pre- Low Total Power Females > F(1,40) = 0.057 
210	
Morphine stimulus Frequencies Male 
suppression 
3.874, 
20 mg/kg 
Morphine 
Post-
stimulus 
Low 
frequency   
ITC A/A > G/G 
suppression 
F(1,40) 
=3.243 
0.080 
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Figures: 
Figure 5. 1 
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Figure 5. 2 
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Figure 5. 3 
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Figure 5. 4 
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Supplemental Figure 5. 1 	
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Abstract: 
 A single nucleotide polymorphism (SNP) in the human µ-opioid receptor gene 
(OPRM1 A118G) has been widely studied for its association in a variety of drug 
addiction and pain sensitivity phenotypes; however, the extent of these adaptations and 
the mechanisms underlying these associations remain elusive. To clarify the functional 
mechanisms linking the OPRM1 A118G SNP to altered phenotypes, we used a mouse 
model possessing the equivalent nucleotide/amino acid substitution in the Oprm1 gene. In 
order to investigate the impact of this SNP on circuit function, we used voltage-sensitive 
dye imaging in hippocampal slices and in vivo electroencephalogram recordings of the 
hippocampus following MOPR activation. As the hippocampus contains excitatory 
pyramidal cells whose activity is highly regulated by a dense network of inhibitory 
neurons, it serves as an ideal structure to evaluate how putative receptor function 
abnormalities may influence circuit activity. We found that MOPR activation increased 
excitatory responses in wild-type animals, an effect that was significantly reduced in 
animals possessing the Oprm1 SNP. Furthermore, in order to assess the in vivo effects of 
this SNP during MOPR activation, EEG recordings of hippocampal activity following 
morphine administration corroborated a loss-of-function phenotype. In conclusion, as 
these mice have been shown to have similar MOPR expression in the hippocampus 
between genotypes, these data suggest that the MOPR A118G SNP results in a loss of 
receptor function. 
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1. Introduction: 
Mu-opioid receptors (MOPR) modulate several pathways including pain and 
pleasure. The A118G single nucleotide polymorphism (SNP) in the µ-opioid receptor 
gene (OPRM1) has been associated with an altered vulnerability to opioid addiction 
(Drakenberg et al. 2006; Ray & Hutchison 2004; van den Wildenberg et al. 2007), a 
decreased response to opioid-induced analgesia (Chou et al. 2006; Sia et al. 2008), and an 
enhanced response to therapies for alcohol (Anton et al. 2008; Ray & Hutchison 2007) 
and nicotine addiction (Lerman et al. 2004). Mice possessing the equivalent SNP 
(A112G) have decreased MOPR expression and morphine-evoked behaviors, altered 
GTPγS binding to the MOPR and downstream intracellular signaling cascades, and sex-
specific deficits in morphine reward (Knapman et al. 2014; Mague et al. 2009; Wang et 
al. 2014; Wang et al. 2012)Additionally, recent studies in humans possessing the A118G 
SNP (Troisi et al. 2012; Way et al. 2010; Way et al. 2009) and in this mouse model of the 
A118G SNP (Briand et al. 2015) have shown in parallel that this SNP may have 
important ramifications for more complex behaviors, such as stress resiliency, which 
would also impact relapse behaviors in addiction.  However, it has not been determined 
whether these effects result from decreased receptor availability or altered receptor 
function. For instance, male and female mice homozygous for the G112 allele (G/G) 
show equivalent MOPR expression decreases in reward-related brain regions; however, 
only the females show decreased morphine reward (Mague et al. 2009; Wang et al. 2014; 
Wang et al. 2012). 
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In order to address if alterations in receptor function were responsible for these 
changes, we evaluated circuit function in the hippocampus, a region displaying similar 
MOPR expression between genotypes and sexes (Mague et al. 2009; Wang et al. 2014; 
Wang et al. 2012). In CA1, MOPRs are predominantly found on somatodendritic and 
axonal aspects of fast-spiking, parvalbumin (PV)-containing GABAergic basket cells. 
Activation of MOPRs hyperpolarizes these cells and decreases GABAergic 
neurotransmission, thereby disinhibiting glutamatergic neurons and providing net 
excitatory activity (Glickfeld et al. 2008; Neumaier et al. 1988); for visual, see Figure 
6.1. As perisomatic GABAergic inhibition can induce fast changes in neuronal polarity 
and gate cell firing at high frequencies (Csicsvari et al. 2003; Uhlhaas & Singer 2010), 
regulation of excitatory output by PV neurons may underlie network synchrony and 
gamma-band oscillatory activity (Whittington & Traub 2003) and influence memory 
storage/retrieval (Montgomery & Buzsáki 2007; Montgomery et al. 2009). Indeed, loss of 
GABAergic modulation induced by MOPR activation has been shown to reduce high-
frequency oscillations in the hippocampus (Whittington et al. 1998) and cortex (Sun et al. 
2006; Zuo et al. 2007) and mediate conditioned effects of morphine (Rezayof et al. 
2007). 
In order to better understand the synaptic and circuit-level alterations conferred by 
the A112G SNP, we employed voltage-sensitive dye imaging (VSDi) techniques in 
hippocampal slice preparations to evaluate opioid-stimulated responses. CA1 pyramidal 
cells supply a clear view of inhibition because they do not generate recurrent excitation; 
accordingly, excitatory postsynaptic potentials (EPSPs) induced by afferents are followed 
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almost exclusively by locally-induced inhibitory postsynaptic potentials (IPSPs). As a 
result, CA1 IPSPs form a temporally distinct and measurable VSDi component (Ang et 
al. 2005; Carlson & Coulter 2008). In these studies, we found that while baseline net 
circuit activity elicited by a single excitatory stimulus was similar between wild-type A/A 
and G/G mice, DAMGO-mediated increases in circuit activity were significantly 
attenuated in G/G mice, suggesting a loss-of-function of the MOPR. Furthermore, in vivo 
hippocampal EEG recordings showed a MOPR loss-of-function in G/G mice following a 
systemic injection of morphine. These data, which support clinical findings of decreased 
responses to opioidergic modulation, demonstrate both ex vivo and in vivo functional 
receptor deficits resulting from this SNP.  
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2 Materials and Methods: 
2.1 Animals 
 All experiments utilized adult male and female mice (3–5 months of age; 20–35 
g). Estrous cycle for female mice was not determined. Mice used in these experiments 
were either homozygous for the A112 (wild-type) or G112 (knock-in) allele [for detailed 
description of generation of Oprm1tm1Jabl mice, see (Mague et al. 2009)]. Briefly, an 
equivalent N-linked glycosylation site to the A118G SNP found in humans was 
eliminated using site-directed mutagenesis in a bacterial artificial chromosome containing 
the C57BL/6 mouse oprm1. This was accomplished by replacing the adenine at 
nucleotide position 112 with a guanine, resulting in an aspartic acid substitution of 
asparagine at amino acid position 38. These mice were maintained on a C57BL/6 
background and were bred, group housed, and maintained on a 12 h light/dark cycle with 
food and water available ad libitum in accordance with the University of Pennsylvania 
Animal Care and Use Committee. 
 
2.2 Voltage-sensitive dye imaging (VSDi) 
 VSDi experiments were performed according to previous studies [(Ang et al. 
2005; Ang et al. 2006); for detailed methodology, see (Carlson & Coulter 2008)]. Briefly, 
mice were decapitated following isoflurane anesthesia. The brain was removed and 
horizontal hippocampal slices (350 µm) were cut using an Integraslice 7550 PSDS 
vibrating microtome (Campden Instruments, Lafayette, IN) in ice-cold sucrose artificial 
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cerebrospinal fluid (ACSF), in which NaCl was replaced with an equiosmolar 
concentration of sucrose.  ACSF consisted of 130 mM NaCl, 3 mM KCl, 1.25 mM 
NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 1 mM MgCl2, 2 mM CaCl2 (pH 7.2-7.4 
when saturated with 95% O2/5% CO2). Slices were then transferred to a static interface 
chamber (34°C) for 30 min and kept at 22-25°C thereafter. The osmolarity of all 
solutions was 305-315 mOsm.  
 Slices were stained for 20 min with 0.125 mg/ml (in ACSF) of the voltage-
sensitive dye di-3-ANEPPDHQ (D36801, Invitogen), and imaged in an oxygenated 
interface chamber using an 80 x 80 CCD camera recording at a 1 kHz frame rate 
(NeuroCCD: RedShirtImaging, Decatur, GA). Epi-illumination was provided by a 
custom LED illuminator. Compared to the more commonly used photodiode array, the 
CCD chip well size (215,000 electrons) requires use of relatively low light-intensities, 
thereby minimizing photodynamic damage. The structures and regions of the slice were 
identified thusly: SO – stratum oriens, SR – stratum radiatum, SLM – stratum lacunosum 
moleculare, CTX – cortex, DG – dentate gyrus. Schaffer collateral stimulation using a 
single 20-µA, 200-µs pulse was administered with the electrode placed in SR near the 
CA3/CA1 border (Figure 6.2a,b). This stimulation protocol was utilized to highlight 
influences of PV interneurons, as these cells have been shown to respond with high 
reliability to initial, but not repeated, afferent input (Pouille & Scanziani 2004; Spruston 
2008). A field-recording electrode was also placed in SR to monitor population responses 
following stimulation; these data, however, were not analyzed or included in this 
manuscript. After initial electrode-placement and evaluation of population responses, the 
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slice was allowed to recover for at least 5 min prior to testing. Baseline responses elicited 
by 12 single-stimulus trials, each separated by 20s, were recorded during bath application 
of ACSF. Following these recordings, the control ACSF was replaced by ACSF 
containing the selective MOPR agonist [d-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin 
[DAMGO; 1 µM (Sigma-Aldrich)], which bathed the slice for at least 10 min prior to the 
presentation of 12 single-stimulus trials of 20-µA, 200-µs pulses.  
 
2.3 VSDi data analyses 
 VSD data was analyzed in IGOR (Wavemetrics, Lake Oswego, OR) on 12-trial-
averages as previously described (Ang et al. 2005; Ang et al. 2006). Briefly, 
fluorescence-changes were calculated as the percent change in fluorescence divided by 
the resting fluorescence (%ΔF/F0). Fitted double exponentials were subtracted from the 
normalized fluorescence to compensate for photobleaching. Raster Plot Quantification: 
Raster plots were generated by plotting the fluorescence signals across an imaginary line 
drawn through the peak of the response from SO to the SLM over the slice image and 
plotting the fluorescence signal from those pixels that fall under the line for all sampling 
points in time (Figure 6.2c). To determine net excitatory changes resulting from DAMGO 
administration, we employed a raster plot subtraction method that compared pixel-
changes before and after DAMGO administration. Specifically, we subtracted the 
DAMGO raster plot (Figure 6.4aii) from the basal raster plot (Figure 6.4ai), resulting in a 
representation of the alteration in inhibitory regulation as a result of MOPR stimulation 
(Figure 6.4aiii). From 2D traces corresponding to average subtracted pixel-changes for 
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SO, SR, and SLM, we determined 1) the peak amplitude of disinhibition, determined by 
the greatest change in fluorescence (%ΔF/F0), 2) the duration of disinhibition, measured 
as time (ms) that the loss of inhibition remained elevated, and 3) the area under the curve 
(AUC), which summed the subtracted changes in fluorescence for a 50-ms window 
following the stimulation (Figure 6.4biii). Statistical analyses were performed with 
GraphPad Prism 5.0 software package (GraphPad Software, San Diego, CA). Differences 
between groups (genotype and sex) were assessed using two-way ANOVAs.  
 
2.4 Surgery for electroencephalogram (EEG) recordings 
 Male and female A112G mice underwent stereotaxic implantation of bipolar, 
twisted, stainless steel electrodes into region CA1 of the hippocampus (200 µm diameter, 
Plastics One, Roanoke VA). All surgeries used aseptic techniques and were performed 
with sterile gloves and full gown. The surgical field, table and stereotaxic frame were 
disinfected prior to surgery. Animals were anaesthetized with isoflurane and then placed 
in a stereotaxic frame for hippocampal depth electrode placement with continuous 
isoflurane inhalation by facemask. The scalp was cleaned with betadine and a midline 
incision was made, exposing the bregma and lambdoid sutures. Hippocampal depth 
electrodes (stainless steel) were placed using stereotaxic coordinates (AP -1.82 mm, ML 
1.10 mm, DV -1.9 mm). The electrodes were cemented in place and the animals were 
kept under a warming light and carefully observed until fully awake and mobile. 
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2.5 Recording of EEG activity 
  Recording of EEG activity was performed between 10AM and 4PM, after a 
minimum of two weeks recovery from surgery. The mice were tested in their home cages, 
which were fitted with special tops to accommodate speakers and electrode cables, and 
placed inside a Faraday cage. The mice were acclimatized to the testing apparatus for 30 
min before the first stimulus onset. Following a baseline trial, animals were injected with 
increasing doses (0, 1, 2, 7, and 20 mg/kg; i.p.) of morphine sulfate (NIDA) dissolved in 
saline. Subsequently, in order to demonstrate that the effects of morphine were mediated 
by MOPRs, naloxone (1 mg/kg; i.p.) was co-administered with a second 20 mg/kg 
injection of morphine. The head stage was connected to a three-channel electrode cable, 
which was connected to a high-impedance differential AC amplifier (A-M Systems, 
Carlsborg, Washington, USA). Auditory stimuli were generated by Micro1401 hardware 
and Spike 6 software (Cambridge Electronic Design) and delivered through speakers 
attached to the cage top. All experiments were done in the presence of background white 
noise of 55 dB. For gating experiments, 150 white-noise clicks pairs (S1, S2) were 
presented with a 500 msec inter-stimulus interval and a 9 second inter-trial interval. EEG 
signal was bandpass filtered online between 1 and 500 Hz, and grand average waveforms 
were created from -500 ms to 1000 ms relative to the auditory stimulus. To remove 
movement artifacts, trials containing activity over 2 SD of the mean were rejected. Initial 
peak analysis was performed in Microsoft Excel (Redmond, WA) or Igor (Wavemetrics, 
OR) on the remaining averaged trials. The baseline was corrected at stimulus onset of S1 
and S2 independently.  
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2.6 EEG data analysis 
 Spectral decomposition of auditory-evoked response waveforms were performed 
using the EEGLab toolbox in MatLab (Delorme & Makeig 2004), as published 
previously (Gandal et al. 2010). Single-trial epochs between -0.1 and 0.2 seconds relative 
to the first stimulus (S1) were extracted from the continuous EEG data sampled at 1667 
Hz. For each epoch, total power (i.e., event-related spectral perturbation, ERSP) was 
calculated using Morlet wavelets in 100 linearly spaced frequency bins between 2.0 and 
100 Hz, with wavelet cycles increasing from 3 (at low frequencies) to 6 (at high 
frequencies). Total power was calculated in decibels (dB) relative to baseline power (-
100 to 0 ms) in each frequency band. Data from specific time and frequency windows 
were extracted as the average power for each window. For comparisons of group level 
data, only saline, 20mg/kg morphine, and 20mg/kg morphine + Naloxone were 
considered. Since the differential effect of genotype on morphine’s ability to modulate 
responses was of primary interest and total power at baseline (saline condition) was not 
different between A/A and G/G mice, results for the 20mg/kg morphine condition and 
20mg/kg morphine + Naloxone conditions were normalized to the saline condition. A 
repeated measures mixed-model (genotype x condition) ANOVA assessed significance of 
power changes (IBM SPSS Statistics, Version 22, IBM Corp, Armonk, NY); pairwise 
comparisons were deduced using least squares differences. 
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3 Results: 
3.1 Quantification of baseline responses 
To evaluate differences in circuit responses to afferent activity, compound 
population responses in CA1 were induced with a single 20-µA, 200-µs pulse delivered 
to Schaffer collateral axons passing through SR of CA1. VSDi of area CA1 recorded an 
evoked fast depolarization followed by a rapid repolarization (Figure 6.2), reflecting 
responses at the single-cell level (Ang et al. 2005; Ang et al. 2006; Carlson & Coulter 
2008). As previously validated, these alterations in fluorescence depict net functional 
changes in neuronal activity, which have been shown to be comparable to 
AMPA/NMDA-mediated EPSPs and GABA-mediated IPSPs measured by intracellular 
electrophysiological techniques (Ang et al. 2005; Ang et al. 2006; Carlson & Coulter 
2008). The initial depolarization, which directly activated CA1 dendrites and local 
interneurons, propagated to distal regions of SR and outwards towards SLM and SO and 
was followed by a longer hyperpolarization. This can be visualized spatially in snapshots 
of the averaged peak excitatory (Figure 6.2bi) or inhibitory (Figure 6.2bii) responses and 
temporally as 2D traces of fluorescence changes over time (Figure 6.2d) or raster plots of 
activity, which show changes in fluorescence across space and time (Figure 6.2c).  
A112 and G112 animals, both male and female, displayed similar VSDi responses 
to Schaffer collateral stimulation under basal conditions (Figure 6.3). However, in SR, 
there was a significant reduction in the peak amplitude of the response in G112 animals 
regardless of sex (main effect of genotype, F1,19 = 5.26, p < 0.05; Figure 6.3c). While a 
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trend was observed in the SO peak amplitude in response to Schaffer collateral 
stimulation in females (Figure 6.3a), this effect was not significant. 
 
3.2 Analysis of DAMGO-mediated response-changes 
 To determine if the A112G SNP alters hippocampal circuit activity during MOPR 
stimulation, we first examined responses following application of the highly specific 
MOPR agonist DAMGO (1 µM) and normalized these to each animal’s basal response. 
In accordance with previous studies (Mcquiston 2007; McQuiston & Saggau 2003) and 
expectations for agents that inhibit GABAergic release, we found increases in neuronal 
activation following DAMGO administration in wild-type mice (Figure 6.4a).  
In order to compare baseline and DAMGO-mediated responses, we subtracted the 
raster plot pixel-changes following DAMGO application from the raster plot responses 
observed under basal conditions in order to highlight the loss of inhibition due to MOPR-
stimulated GABA inactivation. Since MOPR stimulation with DAMGO effectively 
decreases GABA transmission, any increase in excitatory events must have occurred due 
to this reduction in inhibitory modulation; the subtracted raster plots illustrate this 
MOPR-mediated loss of inhibition. An advantage of this approach is that it allowed us to 
more reliably compare drug treatment effects across genotypes and sexes. By subtracting 
the actual pixel responses between sessions, we eliminated the requirement for excessive 
numerical transformations and were able to analyze 2D traces quantified directly from the 
subtracted plot.  
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 Comparing the subtracted raster plots between genotypes and sexes showed that 
while all groups showed an initial decrease in inhibitory modulation following DAMGO 
application, the wild-type animals had an elevated and prolonged response compared to 
the G/G mice (Figure 6.4c). Indeed, these observations were supported by quantification 
of raster plots for each of the regions within CA1. In order to identify differences 
between groups, we used a 2D trace of the subtracted pixel-changes over time for each 
region of CA1 and measured the peak amplitude and duration of the response in addition 
to the area under the curve (AUC) (Figure 6.5). In the SO, there were significant 
reductions in the ability of DAMGO to disinhibit excitatory responses both in G/G 
animals and in females, without an interaction between these effects. The G/G genotype 
and the females showed reduced disinhibition compared to their respective counterparts 
for the peak amplitude (main effects of genotype, F1,19 = 7.45, p < 0.05 and sex, F1,19 = 
6.30, p < 0.05; Figure 6.5a), duration (main effects of genotype, F1,19 = 22.58, p < 0.001 
and sex, F1,19 = 6.05, p < 0.05; Figure 6.5b), and the AUC (main effects of genotype, F1,19 
= 20.68, p < 0.001 and sex, F1,19 = 9.94, p < 0.01; Figure 6.5c). 
We found a similar pattern in the SR, in which there was a significant reduction in 
the ability of DAMGO to disinhibit excitatory responses in G/G animals, as demonstrated 
by decreases in the peak amplitude (main effect of genotype, F1,19 = 13.76, p < 0.01; 
Figure 6.5d), duration (main effect of genotype, F1,19 = 47.12, p < 0.0001; Figure 6.5e), 
and the AUC (main effect of genotype, F1,19 = 22.37, p < 0.001; Figure 6.5f). There was 
also a main effect of sex for the duration of response, in which the females of both 
genotypes showed reduced disinhibition compared to their male counterparts (main effect 
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of sex, F1,19 = 10.67, p < 0.01; Figure 6.5e); there was not, however, an interaction 
between genotype and sex main effects. Another advantage of this analysis was that it 
allowed us to evaluate differences in SLM, a region that, due to its lower basal responses, 
we could not otherwise have analyzed. Though the responses for all groups were lower in 
this region compared to the SR and SO, there was still a significantly reduced 
disinhibition in the SLM for the G/G animals for the peak (main effect of genotype, F1,19 
= 6.30, p < 0.05; Figure 6.5g), duration (main effect of genotype, F1,19 = 8.42, p < 0.05; 
Figure 6.5h), and AUC (main effect of genotype, F1,19 = 18.76, p < 0.001; Figure 6.5i). 
 
3.3 EEG 
 MOPRs located on terminals of PV interneurons can strongly modulate 
oscillatory activity of the hippocampus (Gulyás et al. 2010). Indeed, recent work has 
demonstrated that PV cells are critical for the generation of gamma oscillations in the 
hippocampus and neocortex (Fuchs et al. 2007; Lodge et al. 2009). In order to test if 
CA1-specific A118G differences in MOPR modulation of inhibition examined in vitro 
are reflected in gamma-band brain activity recorded in vivo, mice were implanted with 
low impedance hippocampal depth electrodes to measure EEG activity. Using an auditory 
stimulus protocol, tone-evoked gamma-band power was evaluated before and after an 
acute injection of morphine. At baseline (saline condition), total gamma power did not 
differ between genotypes (A/A vs. G/G; T36.31=0.9552, p = 0.34). In order to investigate 
the change in responses following MOPR activation, EEG power following morphine 
injection and morphine + Naloxone injection were normalized to the baseline data. 
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Similar to prior work in rats (Zuo et al. 2007), we found that morphine (20 mg/kg, i.p.) 
reduced auditory-evoked gamma activity in the range of 31 to 51 Hz in all mice. 
However, this response was significantly reduced in G/G animals (genotype × condition 
interaction: F1,38 = 4.49, p < 0.05; Figure 6.6a,b). Co-administration of naloxone (1 
mg/kg; i.p.) reversed the effect of morphine similarly in all animals (Figure 6.6c). As 
such, EEG recordings demonstrate a differential reduction in Gamma activity in after 
MOPR activation dependent on A112G substitution. This specific reduction in gamma 
activity after MOPR activation is consistent with the cell-type specific localization of 
these receptors (Drake & Milner 1999; Drake & Milner 2002), and previous in vivo 
findings (Zuo et al. 2007).  The reduced effect of morphine in G/G mice is consistent 
with the loss-of-function phenotype identified in the hippocampal slice preparation. 
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4. Discussion: 
  MOPR stimulation in the hippocampus increases net excitatory activity by 
decreasing GABAergic inhibition from local interneurons, resulting in the disruption of 
pyramidal cell firing synchrony and an alteration in hippocampal function (Faulkner et al. 
1998). A common SNP in the gene encoding the MOPR has been shown to alter a variety 
of behaviors and drug responses in clinical populations [for review, (Mague & Blendy 
2010)] and in animal models (Barr & Goldman 2006; Mague et al. 2009; Ramchandani et 
al. 2011; Y. Zhang et al. 2014). Neither the extent of these changes nor the mechanisms 
mediating the effects are completely understood. We used VSDi techniques to investigate 
circuit changes in the hippocampus in order to determine if functional alterations 
resulting from this SNP could better inform results from previous clinical and preclinical 
studies. Additionally, we utilized in vivo EEG recordings to evaluate changes in 
oscillatory activity in the hippocampus in awake animals that were acutely administered 
opiates. Overall, we found that the augmentation of excitatory responses elicited by 
opiate administration in wild-type animals was reduced in animals homozygous for the 
G112 allele. This reduction was particularly striking in raster plot subtraction analyses in 
which DAMGO-mediated responses of individual pixels were subtracted from basal 
responses, revealing the loss of inhibition caused by the MOPR activation. Similar results 
were found when evaluating hippocampal circuitry in vivo: reductions in gamma band 
activity caused by MOPR activation were decreased in G/G mice.   Furthermore, our data 
suggests that the A112G SNP results in the reduced functionality of the receptor, as it has 
been shown that MOPR expression levels in the hippocampus are similar between 
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genotypes and sexes in A112G mice (Mague et al. 2009; Wang et al. 2014; Wang et al. 
2012; Y. Zhang et al. 2014). 
.  
4.1 Ex Vivo VSDi Recordings Demonstrate that the MOPR A112G SNP Results in a Loss 
of MOPR Functionality and Altered Hippocampal Circuitry Evoked Responses 
 While baseline responses were similar between genotypes and sexes, there was a 
significantly lower peak response in the SR in the G/G animals. This could result from 
enhanced tonic GABAergic activity, possibly suggesting either a reduction in efficacy of 
endogenous MOPR modulation of GABA activity or, alternatively, a reduction in 
endogenous opioidergic tone in G/G animals. However, this effect was not seen for other 
measures of responses in the SR or SO, suggesting only a subtle consequence of these 
potential baseline alterations. Similarly, previous behavioral work with these mice did not 
uncover robust baseline differences, but only reductions in morphine-mediated behaviors 
(Mague et al. 2009).  
 Despite similar basal responses, there was a pronounced difference between 
genotypes following application of DAMGO. Raster plot subtraction analysis revealed 
robust MOPR deficits in the G/G animals in all CA1 regions tested. Though both 
genotypes showed an initial peak disinhibitory effect of DAMGO, this response was 
more intense and prolonged in A/A animals. Since the extent and duration of responses 
seem to be most affected, these data suggest that there could potentially be alterations in 
the desensitization or trafficking of the receptor. 
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In these experiments, we also found significant reductions in the female responses 
to MOPR activation compared to males, regardless of genotype. This was not surprising 
given the frequency of reported sex-differences in response to opioid administration 
(Craft 2008). Opioids have been shown to be more efficacious in males compared to 
females in both rodent (Kepler et al. 1989) and human (Cepeda & Carr 2003) studies 
investigating sex-differences in the analgesic properties of opioids. In contrast, female 
rats respond more robustly to the rewarding properties of opioids (Cicero et al. 2003) and 
women are more likely to abuse prescription opioid analgesics (Roe et al. 2002). 
Specifically in the hippocampus, ovarian steroid hormones have been shown to influence 
levels of opioid peptides (Roman et al. 2006; Williams et al. 2011) and the availability of 
MOPRs on the surface of PV cells (Torres-Reveron et al. 2009). In contrast to our 
previous studies, however, we did not demonstrate interactions between genotype and 
sex. This could suggest that differences in CA1 responses to MOPR activation may not 
directly underlie the sex-specific reduction in morphine-conditioned place-preference 
studies (Mague et al. 2009).  
 Since VSDi responses show net activity of entire circuits, we were unable to 
isolate responses of specific subpopulations of interneurons and, thus, cannot 
unequivocally ascribe our findings to MOPR modulation of PV basket cells. However, 
previous studies have shown that MOPRs are found predominantly on these interneurons 
(Drake & Milner 1999; Drake & Milner 2002) and that stimulation of these cells 
disinhibits glutamatergic dendrites (Glickfeld et al. 2008). This is supported by the 
findings provided by the stimulation protocol utilized in these studies, in which a single 
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200-µs pulse was administered, as the PV interneurons have been shown to respond with 
high reliability to initial, but not repeated, afferent input (Pouille & Scanziani 2004; 
Spruston 2008). Also, GABAA receptors located opposite PV cell terminals produce 
IPSPs that rise and decay very rapidly (Klausberger et al. 2002; Lavoie et al. 1997). 
Indeed, other studies evaluating MOPR-mediated elevations of CA1 responses to Shaffer 
collateral stimulation found that paired current pulses, similar to the single pulses utilized 
in the present studies, were mediated by GABAA receptors (McQuiston & Saggau 2003), 
while DAMGO-induced augmentations of CA1 responses following prolonged 
stimulation were mediated by GABAB receptors (Mcquiston 2007). These features of PV-
containing, fast-spiking interneurons enable them to induce a reliable and brief, yet 
intense, somatic shunting of postsynaptic conductance (Bartos et al. 2007; Vida et al. 
2006). Thus, reduced PV interneuron inhibition is a plausible explanation for the 
augmentation of CA1 responses following DAMGO administration in these current 
experiments. The reduced disinhibition demonstrated by the G/G animals following 
DAMGO administration suggests a disruption in MOPR modulation of these PV 
interneurons resulting from the A112G SNP.  
 
4.2 In Vivo EEG Electrophysiological Recordings Also Demonstrate that the MOPR 
A112G SNP Results in Altered Hippocampal Responses 
A consequence of the increase in excitatory responses demonstrated in wild-type 
mice could be a reduction in both neuronal synchrony and the formation of high-
frequency oscillatory activity. Indeed, PV interneurons have been shown to be important 
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in generating gamma-band oscillations in the hippocampus (Bartos et al. 2007; Fuchs et 
al. 2007). Given the reduced MOPR-mediated augmentation of responses in the G/G 
animals, we would predict that reductions in gamma-activity resulting from MOPR 
activation (Sun et al. 2006; Zuo et al. 2007) would be decreased in these animals. Our 
findings support this prediction. Gamma-band power was decreased in all mice after 
administration of morphine, though blunted in G/G mice. Naloxone blocked all gamma 
frequency-related effects of morphine for both genotypes, suggesting that the reductions 
in gamma were mediated by actions at the MOPR. It should be noted, however, that as 
we did not measure the effects of naloxone alone, we cannot conclude unequivocally that 
the reversal in gamma responses results from the blockade of morphine action and not 
some other mechanism, such as inhibition of endogenous opioids. However, while one 
study did find significant effects of naloxone alone in monkeys on EEG measures (Ehlers 
1989), similar studies have found no effect of naloxone alone in vitro (Lynch et al. 1981), 
in conscious rats (Coltro Campi & Clarke 1995; Tortella et al. 1978), or in children 
(Nalin et al. 1988), suggesting that naloxone’s effects in the EEG studies were most 
likely due to blockade of the exogenously administered morphine. 
Clinical studies, as well as those in rodents and non-human primates, have shown 
that reductions in evoked gamma power are an intermediate phenotype with broad 
relevance to neuropsychiatric disorders, pain sensitivity and, in the hippocampus, 
cognition (Carlson et al. 2011; Uhlhaas & Singer 2011). Thus, these EEG data provide 
initial evidence those differences in sensitivity shown in vitro may act via PV-cells to 
mediate some of the behavioral phenotypes associated with the A118G allele. 
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Additionally, because similar EEG studies can be performed in humans, the EEG 
phenotype provides a framework for translating neurophysiological and behavioral 
correlates from the A118G mouse model to identifying functional neural substrates 
underlying the A118G genotype and behavior interaction identified humans. 
 
4.3 Conclusions 
 We observe an alteration in hippocampal function as a result of the Mu Opioid 
Receptor SNP, A112G, and the reduced effect of DAMGO and morphine in G/G animals 
further supports a loss-of-function of the MOPR as a consequence of this SNP. Previous 
work with this mouse line has provided evidence for reduced MOPR expression and 
decreased behavioral responses to acute morphine administration; likewise, clinical 
findings have demonstrated a reduced response to the analgesic properties of opioids 
(Chou et al. 2006; Sia et al. 2008). In support of these findings, authors often cite in vitro 
studies showing decreases in MOPR expression (Befort et al. 2001; Zhang et al. 2005). 
However, the present data were derived from evaluation of MOPR function in the 
hippocampus, which possesses equivalent MOPR expression between genotypes and 
sexes as demonstrated using RT-PCR (Mague et al. 2009) and quantitative in vitro 
autoradiography (Wang et al. 2014; Wang et al. 2012). From our data, it appears that the 
strong disinhibition controlled by MOPRs on interneurons of the hippocampus is absent, 
therefore leading us to conclude that this polymorphism represents a “loss of function” 
phenotype in the context of hippocampal microcircuitry (Figure 6.1).  While others have 
observed that MOPRs in cultured cells perhaps follow a gain of function phenotype 
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(Bond et al. 1998; Margas et al. 2007), these models do not possess well-organized 
circuits and therefore do not accurately reflect complex brain structures. In contrast, our 
ex vivo slices maintain microcircuitry and are representative of a “loss of function” 
phenotype at the circuitry level, which is closely paralleled by our in vivo EEG 
hippocampal findings following systemic administration of opiates.  We posit that the 
loss of function in our microcircuitry model occurs due to the reduced inhibitory drive 
onto pyramidal cells (Figure 6.1). However, the mechanism underlying changes in 
receptor function remains unknown. Attempts to identify changes in agonist binding, 
protein coupling, downstream signaling, and receptor trafficking have not produced 
conclusive evidence for the specific deficit [for review, see (Knapman & Connor 2015)]. 
For instance, in whole-cell patch-clamp studies using a mouse line possessing humanized 
A/A or G/G alleles, Mahmoud and colleagues found a functional reduction of voltage-
gated Ca2+ activation following morphine administration in isolated sensory neurons 
from G/G animals (Mahmoud et al. 2011), consistent with a loss of function of the 
receptor. In separate experiments using this A112G mouse line, a reduction in GTPγS 
binding was detected in several brain regions (Wang et al. 2014). In addition, human 
positron emission topography studies have demonstrated a decreased binding potential of 
[11C]carfentanil, indicating a reduced MOPR availability, in those with the G allele (Ray 
et al. 2011; Weerts et al. 2012). Together, these results suggest deficits in the early stages 
of binding and signal transduction and would be consistent with the immediate changes 
seen after acute MOPR agonist administration. However, these data do not rule out other 
changes to protein binding, downstream signaling, internalization, or dimerization. Future 
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studies specifically aimed at these characteristics will help elucidate the mechanisms 
whereby this polymorphism disrupts MOPR function. In summary, the modeling of this 
SNP in mice identified reduced function in the absence of reduced expression and 
suggests that human SNPs may have more complex consequences on phenotypes than 
previously appreciated. 
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Figure Legends: 
Figure 6.1 Schematic highlighting MOPR role in hippocampal circuit. (A, B) Shaffer 
Collateral projections (represented by dotted line) from pyramidal cells in CA3 
synapse with dendrites of CA1 pyramidal cells as well as local inhibitory interneurons 
(shown in blue).  A) Thus, stimulating CA3 axons (1) will produce direct activation 
of CA1 dendrites (2) as well as indirect (i.e., feed-forward) inhibition of these 
dendrites/cell bodies through GABAergic interneuron activation (3). B) MOPR 
activation (e.g., with DAMGO or morphine) during CA3 axonal firing (1) will 
decrease GABA release from the interneuron (3), resulting in a net increase in 
excitatory influences on CA1 pyramidal cells (2).   
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Figure 6.2 VSDi procedure, quantification, and analysis: (a) A diagram of hippocampus 
circuitry illustrates the stimulus protocol utilized in this study. A stimulating electrode 
was placed in the Shaffer collateral axons from CA3 pyramidal cells and a recording 
electrode was placed in the distal end of SR in CA1. The light gray line represents the 
pyramidal cell layer and the dotted black line delineates the path of the Shaffer 
collateral axons. The dark gray box depicts the area visualized in b. (b) Horizontal 
slices containing the hippocampus were visualized under a 10x lens. The black 
triangles show the stimulating electrode placement and the white triangle shows the 
placement of the recording electrode. The structures and regions are labeled thusly: 
SO – stratum oriens, SR – stratum radiatum, SLM – stratum lacunosum moleculare, 
CTX – cortex, DG – dentate gyrus. The average normalized pixel-changes for the 
duration indicated following stimulation demonstrates the peak excitatory (bi) and 
inhibitory (bii) responses for a representative wild-type animal. Changes in membrane 
voltage are illustrated in red (excitation) or blue (inhibition). The black line 
corresponds to the raster plot shown in c. (c) Raster plots corresponding to the pixels 
along the black line drawn in figure 6.2b show the average pixel-changes over time 
for the SO, SR, and SLM during baseline. Changes in membrane voltage are 
illustrated in red (excitation) or blue (inhibition). (d) A 2D trace of the SR region 
from c.  
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 Figure 6.3 Baseline responses:  There were no differences between genotypes or sexes 
in the SO for amplitude (a) or tau (b). In the SR, there was a significant reduction in 
the peak excitation for G/G mice (c) but not for the tau (d). All data are presented as 
mean ± SEM, n = 5; * p < 0.05 compared to A/A. 
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Figure 6.4 Raster plot subtraction analyses: (a) Raster plots corresponding to the pixels 
along the black line drawn in figure 6.2b show the average pixel-changes over time 
for the SO, SR, and SLM during baseline (ai) or DAMGO application (aii). 
Subtraction of the baseline plots from the DAMGO plots shows the net disinhibition 
resulting from MOPR activation (ciii). Changes in membrane voltage are illustrated in 
red (excitation) or blue (inhibition). (b) A 2D trace of the SR region shows the 
quantification of subtracted raster plots. The amplitude was determined by the peak 
disinhibitory response. The duration, shown as the horizontal dashed red line, 
measured the time (ms) during which disinhibition was elevated above noise. The 
area under the curve (AUC; diagonal red lines) was calculated for a 50-ms window 
following stimulation. For all 2D plots, the scales of response amplitudes correspond 
to the numerical axis of the color scales drawn to the left of each trace. (c) 
Representative subtracted raster plots for A/A male (ci), A/A female (cii), G/G male 
(ciii), and G/G female (civ) show the loss of inhibition resulting from DAMGO 
administration. 
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Figure 6.5 DAMGO-mediated inhibition is reduced in G/G animals.  (a) Analysis of 2D 
traces from each strata of CA1 reveals alterations in genotype or sex responses to 
DAMGO administration. In the SO, both the G/G animals and females, each 
compared to their respective counterparts, showed decreases in the amplitude (a), 
duration (b) and AUC (c). In the SR, G/G animals showed reductions in amplitude 
(d), duration (e), and AUC (f); additionally, there was a significant reduction in 
females compared to males for duration only (e). In the SLM, levels of disinhibition 
were lower compared to the other CA1 regions; however, G/G animals still showed a 
decreased response to DAMGO administration measured by the amplitude (g), 
duration (h), and AUC (i). All data are presented as mean ± SEM, n = 5; * p < 0.05, 
** p < 0.01, *** p < 0.001, † p < 0.0001 compared to A/A; + p < 0.05 compared to 
males. 
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Figure 6.6 G/G mice exhibit reduced gamma-related responses to MORP activation. A) 
Total power response for representative A/A (top) and G/G (bottom) mice, for Saline 
(left), 20 mg/kg Morphine (center), and 20 mg/kg Morphine + 1mg/kg Naloxone 
(Nal)  (right). Note the decrease in high frequency (gamma) activity (box 1). This did 
not occur at lower frequencies (box 2). B) Group average results for gamma activity 
(31–51 Hz), * = p < 0.05 compared to A/A C) Group Average results for low 
frequency 6–11 Hz, demonstrate no significant group differences. B and C are 
presented as mean ± SEM, n = 8–11. 
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Figure 6. 6 
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CHAPTER 7 
Summary & Conclusion 
1. Summary 
 The purpose of this dissertation was to uncover the underlying neurobiological 
mechanisms of auditory electrophysiological biomarkers for Autism Spectrum Disorder 
(ASD), particularly gamma-band oscillatory activity alterations. To do so a multimodal 
translational approach was undertaken that spanned both preclinical (in-vitro and in-vivo) 
and clinical settings. Moreover, multiple methodologies were implemented within each 
setting. The auditory electrophysiological biomarkers of interest in this thesis (M100 
latency delays and gamma-band perturbations) allows for the direct study of analogous 
constructs between clinical and preclinical settings. As such, the traditional T1 to T4 
translational processes (Szilagyi 2009) has been expanded on, with an iterative process 
that cycles concepts and hypotheses between preclinical settings and clinical settings. 
Figure 7.1 demonstrates a methodological benefit to such a translational approach; where 
spectral decomposition is adapted from the clinical research environment into in-vitro 
experiment analyses using identical core time-frequency analyses. Without this explicit 
and concerted effort for translational research such a methodological leap would be 
unlikely. Furthermore, Figure 7.1 suggests that the gamma-band activity perturbations 
seen in ASD and their underlying neurobiology may be available for direct in-vitro study. 
As such, it may be possible to localize ASD-related electrophysiological biomarkers to 
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within structural laminar or cell types, which is currently impossible for MEG or EEG 
based studies to resolve. 
 This dissertation contains the first longitudinal study of auditory 
magnetoencephalography (MEG) biomarkers for ASD. This study demonstrated the 
persistence (from childhood into adolescence) of auditory gamma-band activity 
alterations in individuals with ASD. The auditory phase-locked gamma-band activity in 
response to simple tones was decreased in ASD individuals versus to typically 
developing (TD) age-matched controls. Moreover, while non-significant, evoked gamma-
band power matured four times slower in ASD. An interesting, though preliminary, 
additional result from this study was that individuals with ASD who subsequently 
demonstrated “optimal outcome” (i.e. who did nit meet diagnostic criteria at follow-up) 
had intermediate gamma-band activity responses as compared to TD controls and ASD 
individuals. 
 This dissertation also demonstrated that gamma-band activity was coupled to 
underlying neurochemistry in TD controls in the Superior Temporal Gyrus. Gamma-band 
inter-trial coherence (ITC) and relative cortical γ-Aminobutyric acid (GABA) 
concentrations were correlated in TD controls. In addition, gamma-band ITC and relative 
cortical GABA concentrations were both decreased in individuals with ASD. 
Additionally there was weaker coupling between these two metrics in our cohort of 
individuals with ASD. It is not immediately clear if the weaker coupling seen in our 
cohort of individuals with ASD between gamma-band coherence and relative cortical 
GABA is due to increased variance from biological variability, or distinct sub-
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populations for whom coupling is differentially intact or not. Of note, we propose 
potential metric of gamma-band activity normalized by relative cortical GABA was 
suggested and could denote a “functional to neurochemical coupling” or “GABA 
efficiency” index. Future studies will evaluate whether this metric is able to stratify the 
ASD population into treatment paths or demonstrate early efficacy of treatment.  
 Additionally, this dissertation demonstrated that Pcdh10 heterozygous  (Pcdh10+/-
) mice, who mimic a key range of genetic insult in familial ASD, demonstrate in-vivo 
gamma-band electrophysiological perturbations. Both stimulus-related and resting-state 
gamma-band oscillatory activity perturbations were observed in these mice as compared 
to their wild-type littermates. This was in contrast to the lack of latency perturbations for 
event related potential (ERP) components. In addition, these Pcdh10+/- mice 
demonstrated increased GABA concentrations, and perturbed coupling of GABA 
concentrations to gamma-band activity. As such, this study characterized how a key 
genetic insult of ASD affects electrophysiological activity (both at rest and in response to 
auditory stimuli), and presented a possible mechanism for such alterations.  
 Moreover this dissertation demonstrated that the A112G Oprm1 single nucleotide 
polymorphism (SNP) caused subtle in-vitro response alteration due to reduced µ opioid 
functionality in mice. Furthermore such subtle alterations may be the underlying cause of 
the increased gamma-band activity observed in response to simple white-noise clicks 
seen in these murine SNP (compare to the decreased gamma-band activity in Pcdh10+/-). 
This observation coexists with increased sociability in mice with A112G Oprm1 SNPs 
(Briand et al. 2015). While not conclusive, this suggests that increases in sociability may 
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occur with increase in gamma-band activity responses, the opposite of what occurs in 
ASD. Table 7.2 highlights main findings of this dissertation. 
 
2. Conclusion and future directions 
 In conclusion, this dissertation demonstrated several underlying neurobiological 
alterations that relate to the auditory electrophysiological perturbations seen in ASD. By 
utilizing both clinical and preclinical studies observations were made that would have 
been unlikely in isolation.  
 This work observed that reduced auditory gamma-band activity is a persistent 
perturbation from childhood into adolescence in individuals with ASD. Such 
observations support studies by Rojas and colleagues which demonstrated that auditory 
gamma-band activity perturbations in adults (Rojas et al. 2008) to similar tones. 
Syntheses of current and previous observations (Rojas et al. 2008) therefore suggest that 
gamma-band activity alterations are persistent phenotypes present through the life span of 
an individual with ASD. Furthermore such gamma-band activity perturbations are 
observed in first degree relative of individuals with ASD, and so may constitute an 
endophenotype (Rojas et al. 2008; Rojas et al. 2011). Corresponding alterations to 
gamma-band activity in adults with ASD have also been demonstrated in the visual 
system (Grice et al. 2001; Sun et al. 2012) and so suggest that such gamma-band 
alterations may be a core feature of ASD.  
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 Moreover, this dissertation demonstrated that gamma-band activity alterations 
may relate to underlying neurochemistry. While there are multiple models for the 
generation of gamma-band activity, a consistent feature in several schema is the crucial 
role for GABA (Whittington et al. 2000). Importantly in such systems, the GABAA 
receptor’s time constant (~25ms) is thought to set the oscillation frequency of the 
recorded activity (Traub et al. 1996). Indeed, support for such models comes from 
multiple studies and points towards specific cells, parvalbumin positive basket cells, as 
the pacemakers (Buzsáki & Wang 2012). Recent clinical studies support such hypotheses 
with GABAergic pharmaceutical administration in healthy adults altering gamma-band 
activity (Hall et al. 2010; Muthukumaraswamy et al. 2013; Muthukumaraswamy 2014). 
Furthermore, correlations between relative cortical GABA concentrations and 
corresponding gamma-band activity have been observed in neurotypical adults for 
multiple systems (Muthukumaraswamy et al. 2009; Gaetz et al. 2011; Balz et al. 2015). 
However, it was unknown if this relationship existed within the auditory system and how 
ASD impacted to such a correlation. While both decreased relative cortical GABA (Rojas 
et al. 2014; Gaetz et al. 2014) and gamma-band activity (Wilson et al. 2007; Rojas et al. 
2008; Gandal et al. 2010; J Christopher Edgar et al. 2015) in ASD had been repeatedly 
demonstrated separately, their relationship was unknown. This dissertation demonstrates 
whereas this coupling does occur in TD controls, it is weakened for our ASD cohort. 
Further work is needed to determine if the “functional to neurochemical coupling” or 
“GABA efficiency” index suggested in this study has clinical relevance. This clinical 
relevance is crucial knowledge because several emerging treatments for ASD focus on 
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the manipulation of the GABA system, though show only partial efficacy (Erickson et al. 
2014; Lemonnier et al. 2012) akin to a subpopulation based differential coupling. 
Promisingly these compounds have efficacy in murine models for recovering both 
behavioral (Gandal, Sisti, et al. 2012; Tyzio et al. 2014; Silverman et al. 2015) and neural 
activity (Gandal, Sisti, et al. 2012; Tyzio et al. 2014) phenotypes with particular 
relevance to ASD. Moreover, MEG-derived gamma-band activity measures have the 
potential to be utilized as a proxy measure for relative cortical GABA in the individuals 
that demonstrate such “functional to neurochemical coupling”, which is of significance 
because oscillatory activity is simpler to measure than neurochemistry in humans, which 
is of practical and clinical significance. 
 In addition, this dissertation’s preclinical research demonstrates that a genetic 
manipulation mimicking a key genetic insult in familial ASD (Pcdh10+/- mice) produced 
both increased GABA concentrations as well as perturbations to gamma-band activity, 
but had no effect on ERP component latencies or amplitudes. This is contrary to clinical 
ASD where both auditory gamma-band activity perturbations (Wilson et al. 2007; Rojas 
et al. 2008; Gandal et al. 2010; J Christopher Edgar et al. 2015) as well as M100 latency 
delays (Gage, Siegel & Roberts 2003; Roberts et al. 2010; J Christopher Edgar et al. 
2015; Edgar, Lanza, et al. 2014) have been repeatedly observe.  As such the findings 
from this dissertation suggest that gamma-band activity alterations and M100 delays in 
ASD may not be redundant. Instead they may potentially appear in difference cohorts, or 
at least may vary independently in the degree of their impairment. Indeed, Gandal and 
colleagues (2010)  demonstrated that only about 15% of the variance in auditory gamma-
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band ITC is accounted for by auditory M100 latencies. Additionally, how such alterations 
to M100 latency or gamma-band activity differentially relate to symptomatology in ASD 
is unclear. 
 Gamma-band response alterations were also observed in the A112G Oprm1 SNP 
mouse model. These mice demonstrate increased gamma-band activity as compared to 
their wild type littermates, and in addition were previously observed to exhibit increased 
sociability (Briand et al. 2015). Moreover, in-vitro experiments demonstrated that these 
mice exhibit reduced µ opioid functionality. While not conclusive, this work 
demonstrates how increases in sociability may be concurrent with increased gamma-band 
activity, a crucial positive control for the implementation of gamma-band activity as a 
biomarker for ASD. Williams syndrome (which is marked by increased sociability) also 
demonstrates increases in gamma-band activity in response to social stimuli (Bernardino 
et al. 2013), however such findings are confounded by comorbid cognitive disabilities. 
 Future studies should focus on the dissociation of gamma-band activity alterations 
and M100 latency delays on clinical symptoms and preclinical behavior. In addition, 
notably absent form this dissertation, the underlying biological mechanisms of M100 
latency delays requires further investigation. Clinical studies suggest that middle 
response latencies are associated with relevant white matter microstructural properties 
(Stufflebeam et al. 2008; Roberts et al. 2009; Dockstader et al. 2012; Roberts et al. 2013). 
Moreover, the relationship of white matter microstructure to evoked electrophysiological 
responses may be perturbed in ASD (Roberts et al. 2013) Separately, preclinical studies 
have repeatedly demonstrated delayed middle latency responses in animal models that 
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recapitulate key aspects of ASD (Gandal et al. 2010; Gandal, Anderson, et al. 2012; 
Billingslea et al. 2014). Frequently these studies utilized genetically based manipulations 
to neurotransmitter signaling. While it may be that middle latency response delays are 
due to signal transduction impairments (i.e. decreased/absent NMDA receptors), the 
signal transmission (e.g. white matter microstructure) of these mice is still unknown.  
 This thesis also did not address the effect of current interventions, or biologically 
targeted novel interventions. For instance a recent study observed that effective 
behavioral therapy, quantified as improved clinical scores, was concurrent to normalized 
gamma-band activity (Van Hecke et al. 2013). Subsequently initial rodent studies have 
demonstrated that behavioral training can recover cortical response latencies (Crystal T. 
Engineer et al. 2014).  It remains unclear what neurobiological changes are occurring 
with effective behavioral therapies. An outcome of the present study examining the 
coupling of GABA and gamma-band activity in individuals with ASD suggests that 
interventions that either increase this coupling, or enhance GABA-related signaling may 
be of use. Indeed as mentioned above, several GABA-related interventions show efficacy 
in treating certain ASD symptoms (Berry-Kravis et al. 2012; Lemonnier et al. 2012). To 
effectively implement such GABA-related treatments in ASD, the source of the increased 
variance in the GABA to gamma-band activity coupling in ASD needs to be determined 
(e.g. whether the variance is due to intrinsic heterogeneity of ASD or the existence of 2 
(or more) sub-populations within the ASD population). Such future studies would 
enhance our understanding not only of the biological basis of ASD, but also possible 
interventions for ASD and related neurodevelopmental disorders.  
260	
 As such, although there are questions that remain to be answered, this dissertation 
has characterized key auditory biomarkers for ASD and provided insight into their 
neurobiological etiology. Moreover, significant progress has been made in extending the 
traditional sphere of translational research and this work has demonstrated how a cross-
species multimodal approach allows for the development of novel techniques and 
analyses, allowing insight into neurobiological mechanisms of ASD with clinical and 
therapeutic implications. 
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Table Legend: 
Table 1: Overview of this dissertation. Each chapter (1st column), with the system (2nd 
left), major question (3rd column) and major observation (4th column) for this 
dissertation. Synthesis of observations are present in last row. MEG = 
magnetoencephalography; MRS – magnetic resonance spectroscopy; EEG – 
electroencephalography; HPLC = High Performance Liquid Chromatography; VSDi 
– Voltage Sensitive Dye Imaging 
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Figure Legend: 
Figure 7.1 Application of a translational approach to analyses allows for the 
measurement of similar constructs from clinical to preclinical studies. (A) A clinical 
evoked power auditory steady state response (ASSR) to a 40Hz amplitude modulated 
tone as recorded by magnetoencephalography (MEG) (B) An analogous ASSR as 
recorded by scalp electroencephalography (EEG; approximately Cz electrode) (C) 
The corresponding in-vivo murine ASSR in response to a 40Hz white-noise 
amplitude modulated square wave as recorded by depth EEG (D) An in-vitro steady 
state response from auditory cortex in response to 40Hz white-matter stimulation as 
recorded by voltage sensitive dye imaging (VSDi). 
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Tables: 
Table 7. 1 
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Figures: 
Figure 7. 1 	
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